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Abbreviations 
APMA  p-amino-phenyl-mercuric acetate 
ARMS  Amplification refractory mutational system 
BIA  Bio-immuno activity assay 
CD  Crohn’s disease 
CI  Confidence interval 
CRC  Colorectal carcinoma 
DSS  Dextran sodium sulphate 
ECM  Extracellular matrix 
ELISA  Enzyme-linked immunosorbent assay 
HR  Hazard ratio 
IBD  Inflammatory bowel disease 
IFN  Interferon 
IL  Interleukin 
HRP  Horse radish peroxidase 
kDa  Kilo Dalton 
LPS  Lipopolysaccharide 
MMP  Matrix metalloproteinase 
MPO  Myeloperoxidase 
NS  Not significant 
PMNL  Polymorphonuclear leukocyte 
PWM  Pokeweed mitogen 
RFLP  Restriction fragment length polymorphism 
RT-PCR Reverse transcription polymerase chain reaction 
SEM  Standard error of the mean 
SNP  Single nucleotide polymorphism 
TGF  Transforming growth factor 
TIMP  Tissue inhibitor of metalloproteinases 
TNF  Tumor necrosis factor 
































10 - Chapter 1 
 
Inflammatory Bowel Disease - a major health problem  
Inflammatory bowel disease (IBD), i.e., Crohn’s disease (CD) and ulcerative colitis 
(UC), are characterized by an idiopathic, chronic and recurrent inflammation of the 
gastrointestinal tract. In CD, inflammation is segmental and transmural, often 
localized in (but not confined to) the ileocaecal area, while UC is limited to the 
mucosal lining of the colon, often starting in the rectum and extending in proximal 
direction through the years. In both CD and UC, inflammation may result in severe 
tissue damage, i.e., discontinuation of the epithelial border, ulcera, fissures, loss of 
circular folding, cobblestone appearance, fibrosis, stenosis and in CD also the 
formation of entero-entero, entero-viscero or entero-cutaneous fistulae. Abdominal 
pain, increased defecation frequency, bloody diarrhea, nausea, significant body 
weight loss and anemia related fatigue all contribute to the general malaise IBD 
patients often experience. Disease course may be complicated by osteoporosis, 
arthritis, ankylosing spondylitis, iritis, uveitis, erythema nodosom and primary 
sclerosing cholangitis (UC). Patients are at increased risk for developing colorectal 
carcinoma
1,2
 and recently, IBD was associated with a higher incidence of adverse 
pregnancy outcomes.
3
 First line of treatment consists of 5-ASA containing 
mesalasine/sulphasalazine or corticosteroid budesonide/prednisolone tablets, 
enema or suppository. In corticosteroid refractory patients disease modifying drugs 
azathioprine, cyclosporin, methotrexate or mycophenolate mofetil are administered. 
The therapeutic arsenal for CD patients has been expanded recently with biological 
agents specifically targeting TNF-α in the immune cascade. Chimeric (75% 
human/25% murine) infliximab and humanised adalumimab anti TNF-α antibodies 
have proven to be effective in the clinical setting for steroid dependent/refractory 
CD patients.
4-6
 Disadvantages include the large placebo effect requiring further 
optimalization, host antibody response to infliximab and high medical costs.
7,8
 
Biological agents against IL-12, adhesion molecules and IL-6 receptors are 
promising new candidates but are not expected to enter the market soon.
9,10
 
Despite advances in treatment protocols, the natural history of the disease appears 
unmodified.
11,12
 Cumulative 10 year surgical resection probability rates vary from 
25-60 % in CD and 25% in UC patients and these percentages have remained 
similar for 4 decades although surgical resection rates within the first year of 
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diagnosis might be decreasing.
13-16
 The socioeconomic burden remains high: in the 
United States total costs of IBD related healthcare are approximately 1 billion US 
dollar per year.
17
 When work-productivity losses due to chronic disability are taken 
into account, total costs of IBD in the USA were estimated $ 5 billion in 2000.
18
 
Therefore, much effort is spent in research aimed at identifying the epidemiology, 
etiology and pathogenic mechanisms underlying IBD. 
 
Inflammatory Bowel Disease - epidemiology & etiology 
Annual incidence rates of CD in white residents of Western countries vary between 
4-9 per 100,000, whereas the incidence of UC appears somewhat higher (9-14 per 
100,000), with concordant prevalence rates of 130-175 (CD) and 240-275 (UC) per 
100,000 persons.
16,19-22
 Studies from Canada and New Zealand, however, reported 
higher incidence figures for CD compared to UC (14.6 versus 14.3 and 16.5 versus 
7.6 per 100,000, respectively).
23,24
 In both CD and UC, distribution of age at onset 
of disease is skewed, with an incidence peak between 20-30 years. Incidence and 
prevalence rates have risen after the Second World War, reaching the current 
plateau in the 1970s, affecting more people in urban versus rural areas.
25,26
 People 
in white collar occupations appear more at risk compared to other groups in the 
population.
27
 A north-south gradient has been postulated,
28
 but in industrializing 
countries, incidence and prevalence of IBD are also increasing,
29
 as are disease 
rates among Asian immigrants in Western countries.
30
 Although disease 
concordance rates in monozygotic twins are high (CD: 60, UC: 20 %), pointing to a 
genetic influence, these sub maximum figures also suggest the involvement of one 
or several environmental factor(s) in the etiology of IBD.
31
 Smoking was 





 Other studies have suggested an association of CD and/or UC 
with infectious agents such as Mycobacterium avium sp. Paratuberculosis,
34
 
invasive Escherichia coli strains
35,36
 and measles virus infection or vaccination.
37-39
 
In case of Helicobacter pylori, a protective effect was suggested.
40
 Married couples 
are at greater risk of sequentially contracting the disease after cohabitation.
41
 
Persons born in the winter months were more at risk for IBD
42
 and onset of 
symptoms was also especially observed during this period, thus arguing for the 
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rationale of an infectious agent involved in the etiology of IBD,
43
 although this 
remains to be confirmed.
44
 Other studies have focused on an association with 
dietary food intake, such as breastfeeding, fast food, coca cola beverages and 
chocolate consumption.
45-47







 have also been implicated, again with inconclusive or even 
contradictory results.
52
 Probably, the rise in incidence of IBD after the Second 
World War in Western and industrializing countries might be attributed to the 
introduction of better sanitary conditions, thus improving survival of susceptible 
individuals and/or shifting the development of the immune system towards 
hypersensitivity.
53-55
 It should be noted that incidence and prevalence of asthma 
and diabetes type I have also increased, pointing to a more general promoting 
effect of western lifestyle on auto-immune disease.
56
  
Several studies indicate genetic susceptibility in the etiology of IBD as well. For 
instance, IBD concordance rates are higher in monozygotic versus dizygotic 
twins,
31
 IBD affecting multiple family members is frequently seen,
57
 and incidence 
rate of IBD appears to be associated with ethnicity and religion group, as 
demonstrated by the increased prevalence in white Caucasian subjects and 
Ashkenazi Jews compared to blacks, Asians and Hispanics.58-60 Early genome-
wide association studies have identified (potential) IBD loci on chromosomes 1, 3, 
4, 5, 6, 7, 10, 12, 14, 16, 19, 22 and X.
61-66
 Subsequent fine-mapping has revealed 
the involvement of the nucleotide-binding oligomerisation protein 2 (NOD2)/ 
caspase activation and recruitment domain 15 (CARD15) gene on chromosome 
16q12 in CD susceptibility,
67,68
 which was confirmed in other studies.
69,70
 
Interestingly, single nucleotide polymorphisms (SNPs) within this gene were also 




 increased mortality 
following sepsis
73
 and allogeneic stem cell transplantation.
74,75
 This landmark 
success and the increasing availability of high density SNP arrays led to a surge in 
genome wide research and to the identification of other loci strongly implicated in 
the pathogenesis of CD and/or UC, including the gene encoding a subunit for the 
IL-23 receptor (IL-23R) on chromosome 1p31,
76,77
 genes involved in 
autophagy/breakdown of intracellular pathogens (autophagy related 16-like 1 gene 
(ATG16L1) on 2q37 and immunity related p47 guanosine triphosphatase murine 
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orholog (IRGM) on 5q33,
78-82
 a gene desert on 5p13 regulating expression of the 
prostaglandin receptor EP4 (PTGER4) (83), the nel-like 1 precursor (NELL1) gene 
on 11p15
84
 and just recently 3p21.31, NKX2-3, CCNY (CD and UC) and PTPN2, 
HERC2 and STAT3 (UC).
85
 Importantly, these studies were conducted in 
Caucasian  populations and not replicated in Asian IBD patients, reinforcing the 
pivotal role of ethnicity in this matter.
86,87
 Other genes potentially involved in the 
susceptibility and/or phenotype of CD and/or UC are derived from candidate gene 
approach and include those encoding interleukin-1 receptor antagonist (IL-1RA), 
IL-2, IL-4, IL-10, IL-11, tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B 
(NFκB), Toll like receptors (TLR), discs large homolog 5 (DLG-5), mucins, organic 
cation transporter-1 and -2 (OCTN-1, -2), mannan binding lectin (MBL), multidrug 
resistance 1 protein (MDR) and pregnane X receptor (PXR).
88-102
 Occasionally, 
conflicting data were generated, probably due to the relatively small sample size 
often used, especially in the early studies.
103-106
 Also, because of the nature of this 
approach, significant results might indicate the association of an adjacent 
predisposing gene in linkage disequilibrium with the examined gene, complicating 
this matter. However, it appears that, in cooperation with selected environmental 
stimuli, different sets of predisposing genes might give rise to essentially the same 
clinical disease manifestation, collectively called IBD. This is corroborated by the 
large number of mouse models, where targeting (i.e., IL-10) or overexpressing (i.e.,  
TNF-α) of different genes leads to similar IBD like disease.
107-112
    
 
Inflammatory Bowel Disease - pathogenic mechanisms 
A widely accepted hypothesis states that IBD is an exaggerated immune response 
towards commensal bacteria in genetically susceptible individuals.
113
 The recent 
rise in incidence of both forms of IBD might be attributed to increased exposure to 
so-called psychrotrophic bacteria by introduction of refrigerated food (cold chain 
hypothesis).
114
 The concept of commensal bacteria playing a pathogenic role is 
corroborated by the increased frequency of anti-Escherichia coli outer membrane 
porin C, anti-flagellin and autoreactive mycobacterial HSP65 antibodies in CD 
and/or UC.
115-117
 Flagellin specific T cells were able to cause fulminant colitis in an 
adoptive mouse transfer model.
118
 Moreover, murine models for IBD do not 
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develop enteritis given a pathogen-free environment, although this was just 
recently challenged by the development of chronic ileitis in germ/free SAMP1/YitFc 
mice, suggesting that bacteria exacerbate disease but are not required for 
induction.
119
 In CD patients, expression of anti-bacterial α-defensins HD5 and HD6 
by ileal Paneth cells is reduced, especially in NOD-2 mutation carriers.
120
 The 
levels of mucus forming proteins mucin3, 4, 5B and of sealing tight junction 
proteins claudin 5 and -8 are downregulated, whereas expression of pore-forming 
claudin 2 and rate of epithelial cell apoptosis are increased, resulting in impaired 
mucosal barrier function.
121,122
 After epithelial injury, in CD patients an abnormally 
low neutrophil accumulation was observed compared to healthy controls, 
suggesting an impaired innate immune response.
123
 The impaired mucosal barrier 
and/or the impaired innate immunity might result in overexposure to commensal 
bacteria, initiating and/or propagating the uncontrolled adaptive immune response 
seen in IBD. Importantly, IBD T-lymphocytes and neutrophils demonstrate 
increased resistance to apoptosis, thus sustaining the immune response.
124-127
 
Also, T cell regulatory (Treg) function might be insufficient to dampen the 
inflammatory reaction.
128
 Both diseases are characterized by upregulation of pro-
inflammatory cytokines (i.e., IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-15, -16, -17, -32,  
TNF-α, IFN-γ), chemokines (MIP1α, MIP1β, MIP3α, MCP1, MCP2, RANTES), 
neuropeptide substance P, growth factors (bFGF, VEGF, KGF), eicosanoid PGE2, 
corresponding receptors (TNF-R2, neurokinin-1/substance P receptor) and 
endothelial/leucocyte adhesion molecules (ICAM-1, selectins, LFA-1, α4β7 
integrin/MAdCAM) in the (inflamed) intestinal mucosa, not compensated for by anti-
inflammatory cytokines, soluble receptors and/or receptor antagonists (i.e., IL-10, 
TGF-β1, sTNFR, sIL1-RII, sgp130, IL-1RA).
129-156
 However, some important 
differences are observed in the cytokine profile between CD and UC (upregulation 
of IL-12, IL-23 versus IL-13, respectively), reflecting the Th1 versus Th2 nature of 
the corresponding disease.
157-160
 The cytokine expression in IBD is different in 
chronic versus early lesions, thus complicating this issue.
161,162
 The upregulation of 
cytokines, chemokines, neuropeptides, growth factors, receptors and adhesion 
molecules chronically activates resident mesenchymal, epithelial and immune cells 
and continuously attracts new leucocytes from the peripheral circulation. In the 
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battle against their unknown targets, these cells may damage the intestinal tissue 
in various ways. T cell activated neutrophils and macrophages release massive 
amounts of harmful reactive oxygen metabolites by NADPH-dependent oxidative 
burst, targeting membrane lipids, protein and DNA, thus disrupting cellular 
structure at the molecular level and promoting malignancy.
163-166
 An imbalanced 
anti-oxidant response in IBD patients may exacerbate disease.
167-169
 Cytotoxic 
CD8+ T cells release pore forming perforin, proteolytic granzymes and/or express 
Fas ligand, triggering apoptosis in epithelial cells and disrupting mucosal barrier 
function.
170-172
 Cytotoxic perforin releasing CD4+ T cells were demonstrated in 
CD
173,174
 and activated complement in conjunction with IgG1 auto antibodies 
against tropomyosin isoform 5 may target epithelial cells in UC.175,176 Increased 
expression of tissue remodeling neutrophil elastase by neutrophils and of chymase 
and tryptase by mast cells is associated with IBD.
177-179
 Synthetic elastase and 
tryptase inhibitors were found beneficial in experimental colitis.
180,181
 Concurrent 
attenuated induction of serine anti-proteases might exacerbate disease.
182
 All 
activated cells also release specific members of the tissue remodeling Matrix 
Metalloproteinases (MMP), which are described below.    
 
Matrix metalloproteinases - classification 
Based on the catalytic group at the active center, five classes of proteases are 
recognized, i.e., serine-, threonine-, cysteine-, aspartic- and metallo-proteases, 
divided into clans and families based on protein folding and sequence similarity, 
see also http://merops.sanger.ac.uk/.
183
 Clan MA of the metalloproteases is divided 
into subclans MA (M) and MA(E). Proteases designated to subclan M all contain a 
conserved methionine residue to the carboxy side of the active center, thus forming 
a characteristic loop or “Met turn” in the protein secondary structure, providing the 
base of the active cleft and are therefore called metzincins.
184
 The metzincins are 
currently categorized into 12 families, each split into a variable number of 
subfamilies. Subfamily M12B contains the ADAMs (A Disintegrin And 
Metalloproteinase) and ADAMTSs (A Disintegrin-like And Metalloproteinase with 
Thrombospondin type 1 motifS).
185,186
 It includes TACE (TNF-α Converting 
Enzyme, ADAM-17), which is important in releasing membrane-bound TNF-α and 
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TNF-R from the cell membrane
187
 and ADAMTS-4 and -5, which cleave aggrecan 
in cartilage and might contribute to the structural damage seen in human 
arthritis.
188-190
 Subfamily M10A, also called the matrixins, contains the matrix 
metalloproteinases (MMP). The human genome currently comprises 23 different 
MMPs, according to substrate specificity and protein structure subdivided into the 
collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT) MMPs, 
and a rest group (Table 1, page 24-26).  
 
Matrix metalloproteinases - structure  
All MMPs consist of a pre-, pro- and catalytic domain and, apart from MMP-7, -23 
and -26, also contain a hinge region of varying length connecting a hemopexin 
domain (Table 1).
191,192
 All MMPs except MMP-23 have a conserved sequence 
around cysteine in the propeptide (PRCGXPD), which is also found in the ADAMs 
and ADAMTSs. The cystein in this motif maintains the latency of the MMP. Limited 
proteolysis of the pro-peptide, treatment with chaotropic agents or 
organomercurials (APMA: p-amino-phenyl-mercuric acetate is widely used in in 
vitro experiments) disrupts the cystein-zinc bond and actives the enzyme.
193
 A furin 
recognition motif (RX(R/K)R) is present on the carboxy terminus of the cysteine 
switch motif in several MMPs, allowing intracellular activation by furin-like pro-
protein convertases in the Golgi apparatus. Recently, furin mediated inactivation of 
MMP-2 was observed and it appears other MMPs previously not recognized as 
furin substrates may also be targets.
194
 The catalytic domain contains a conserved 
active site sequence: HEXXHXXGXXH with three histidine residues depicted in 
bold binding the zinc atom. The conserved sequence is shared with all other 
members of the metzincin group. MMP molecules contain additional non-catalytic 
zinc and calcium ions, which are involved in stabilizing the tertiary structure of the 
enzyme.
195,196
 In the catalytic domain of MMP-2 and -9 three fibronectin type II 
repeats are inserted which bind gelatin and collagen thus facilitating the breakdown 
of these substrates. The flexible O-glycosylated proline-rich linker of MMP-9 is 
exceptionally large and facilitates binding of the enzyme to TIMP and cargo 
transporters.
197
 The hemopexin domain co-determines substrate specificity and 
affinity. It binds Tissue Inhibitor of Metalloproteinases (TIMP, natural inhibitors of 
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MMPs) and docking molecules on cell surface membranes, for instance integrins 
and CD44. The hemopexin domain is also involved in MMP di-/oligomerization and 
CD97 mediated MMP uptake and internal degradation.
198
 The MT-MMPs are 
connected to the cell by a short hydrophobic transmembrane segment or 
alternatively are glycosylphoshatidylinositol (GPI) anchored, focusing the cell’s 
proteolytic capacity. However, cleavage at the stem region by other MMPs or 
ADAMs may release an active ectodomain.
199,200
 The cysteine array and 
immunoglobulin-like domain in MMP-23 are of unknown function. The structural 
organization of the MMPs is also observed in the ADAMs and ADAMTSs, but these 
enzymes lack the hemopexin domain and possess other C-terminal extensions 
instead.
186
      
 
Matrix metalloproteinases - expression 
The expression of MMPs is tightly controlled at the transcriptional, translational 
and/or secretory level. Pro-inflammatory cytokines, chemokines, growth factors and 
oxidants including IL-1α, IL-1β, IL-6, IL-12, TNF-α, bFGF, MCP-1 and manganese 
superoxide dismutase (Mn-SOD) generated H2O2 upregulate the expression of 
several members of the MMP family including but not limited to MMP-1, -2, -3, -9,  
-12 and/or -13 in a variety of cells encompassing fibroblasts, enterocytes, T cells, 
chondrocytes, osteoblasts, endothelium and/or macrophages, sometimes in a 
synergistic manner.
201-211
 Anti-inflammatory (TGF-β), pleiotropic (IFN-γ) cytokines 
and steroid sex hormones (estradiol) may downregulate MMP, whereas other 
members of the MMP family (i.e., MMP-2) display a rather constitutive expression 
rate in distinct cell types.
212-215
 Importantly, results for a given combination of 
cytokine and MMP are not only dependent on cell type but also at what time point 
in their development and under what (experimental) conditions these cells are 
studied. Expression is also regulated by cell contact with the surrounding matrix, 
neighboring cells and pathogens. For instance: collagen I is able to induce MMP-1 
in migrating keratinocytes thus promoting its own degradation and ligation of the 
fibronectin receptor α4/5β1, CD40 and TLR-2 may induce MMP-9.
216-220
 The 
extrinsic signals are relayed to the MMP promoter by one or more intracellular 
signaling pathways, including NFκβ, SMAD, STAT, MAPK kinase pathways and 
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are integrated at cis-acting elements in the promoter, resulting in altered mRNA 
transcription rate.
221
 Promoter activity is also dependent on DNA and histone 
methylation, acetylation and/or phosphorylation status.
222,223
 Also, single nucleotide 
polymorphisms may result in the loss or gain of suppressor/enhancer DNA 
elements, affecting mRNA transcription. For instance, the replacement of cytosine 
with thymidine at -1306 in the MMP-2 promoter disrupts an Sp1 binding site, 
resulting in significantly decreased promoter activity.
224
 A single guanine insertion 
at -1607 of the MMP-1 promoter creates an Ets binding site, elevating the 
transcriptional level of MMP-1.
225
 The 3’UTR may contain ARE elements binding 
Hu and KH type splicing regulatory protein (KSFP) proteins increasing or 
decreasing mRNA stability, respectively, a mechanism shared with TNF-α and 
other pro-inflammatory cytokines.
226
 The 3’UTR of MMP-9 mRNA is involved in 
binding cytoplasmic nucleolin, promoting transport to polyribosomes and enhancing 
protein translation efficiency.
227
 Neutrophils and eosinophils store MMP-8, -9 
and/or MT6-MMP in secretory granules which are released upon stimulation with 
pro-inflammatory cytokines such as IL-8 and TNF-α.
228-230
 MT-1 MMP is stored in 
trans-golgi network/endosomes and may be expressed on the cell surface within 
minutes following Concanavalin A treatment of HT1080 cells.
231
 Vesicular 
trafficking from the Golgi apparatus to the plasma membrane is dependent on actin 
and tubulin polymerization and can be suppressed by exposure to hypoxia, with 




Matrix metalloproteinases - activation, inhibition and 
degradation 
Except for furin-like pro-protein convertase-activated MT-MMPs and MMP-11, all 
other MMPs are secreted as inactive zymogens. Limited proteolysis by plasmin, 
thrombin, trypsin and other proteinases removes part of the propeptide region, 
inducing a conformational change in the MMP molecule disrupting the bond 
between the protective cysteine and catalytic zinc residue. Autocatalysis 
subsequently removes the entire propeptide region after which the enzyme 
becomes fully active.
233
 The cysteine switch dogma is challenged by observations 
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of mutant MMP-3 with the cysteine replaced by serine or histidine. These 
molecules retained latency and could be activated with APMA, results not 
consistent with cysteine as primary regulator of MMP latency.
234
 The final MMP 
activity is dependent on the activating proteinase, i.e., MMP-3-activated MMP-1 
displays a higher conversion rate of collagen substrate compared to plasmin- 
activated MMP-1.
235
 Contact with substrate or even non-functional protease may 
induce conformational change and activation of MMP without loss of the pro-
peptide.
236,237
 Oxidative activation and inactivation may play an important role 
during inflammation.
238
 MMP-2 can be activated as described above, but the 
activation pathway in a complex with MT-MMPs and TIMP-2 is believed to be the 
most important physiologically.
238
 MMP stability can be enhanced by MMP- binding 
proteins. For instance, neutrophil-derived lipocalin protects MMP-9 and may 
worsen prognosis in breast and gastric cancer.
239,240
 MMP activity is inhibited by 
the endogenous inhibitors TIMPs, but glycosylation status co-determines affinity for 
TIMP and activity of the MMP.
241
 General antiproteinases such as  
α2-macroglobulin also inhibit MMPs and the resulting inhibitor-MMP complex is 
subsequently removed from the circulation by scavenger receptors on 
macrophages. MMPs undergo further autocatalysis, inactivating themselves. 
Uptake of soluble MMPs by cells is mediated by the LRP receptor followed by 
degradation in lysosomal vesicles.
198
 MT-MMPs are internalized by dynamin- 




Matrix metalloproteinases - substrate specificity 
A whole array of structural matrix proteins including, but not limited to, collagen  
I-XI, proteoglycans, elastin, laminin, vitronectin, tenascin, entactin and fibronectin 
can be cleaved by one or more members of the MMP family. In addition, non-
structural proteins such as cytokines, growth hormones and binding proteins (for 
instance: IL-8, TGF-β and IGFBP-3) are cleaved as well (Table 1).
244
 MMPs may 
also act intracellularly, targeting myosin light chain and troponin in cardiac 
myocytes.
245,246
 Although overlapping, every MMP is characterized by its own 
substrate specificity, determined by the size and shape of the substrate-binding 
pocket. For instance, the gelatinases preferentially cleave collagen IV and gelatin, 
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whereas MMP-1 and -8 preferentially convert collagen I and III. Importantly, most 
substrate specificities have been determined in vitro and remain to be confirmed  
in vivo. In addition, MMPs may act using a non-proteolytic mechanism. For 
example, binding of TIMP-2 to MMP-14 upregulates cell migration and proliferation 
by activation of ERK1/-2, a process mediated by the cytoplasmic tail of MMP-14 




Tissue inhibitors of metalloproteinases 
The four different TIMPs currently known in humans inhibit activated MMPs by 
forming non-covalent 1:1 stoichiometric complexes that are resistant to heat-
denaturation and proteolytic degradation. TIMP-1 and TIMP-3 also inhibit members 
of the ADAM and/or ADAMTS family.
248
 TIMPs also bind to the proform of MMP-2 
and MMP-9, thus regulating the activation process of these MMP members. 
Different TIMPs have different MMP binding specificities, for instance, TIMP-1 
binds preferentially (pro-) MMP-9 but not MMP-2 while TIMP-2 binds (pro-) MMP-2 
and not MMP-9. TIMPs are expressed by a variety of cell types including 
fibroblasts, enterocytes and leucocytes. Expression may be regulated by several 
cytokines, growth factors, hormones, etc., or is constitutive instead, dependent on 
TIMP and cell type studied, similar to the regulation of MMP expression. Of note, 
cytokines (i.e., TGF-β) that repress MMP expression, may enhance levels of TIMP 
and collagen, promoting a fibrotic phenotype.
249
 Expression is also dependent on 
DNA-methylation and histone-acetylation status.
250
 Hypomethylation of the TIMP-1 
promoter may result in TIMP-1 expression from the otherwise inactive X 
chromosome in females, resulting in an overall increase of TIMP-1 levels.
251,252
 
Conversely, hypermethylation of a TIMP-2 CpG island upstream of the transcription 
start site is associated with diminished TIMP-2 expression in cervical carcinoma.
253
 
TIMP-1 and -2 were originally identified as erythroid potentiating factors and it now 
appears TIMPs are more generally involved in cell growth and/or apoptosis. The 
TIMP effect may be anti-apoptotic through ligation of the CD63/integrin-β1 complex 
but also pro-apoptotic via inhibition of MMP-mediated degradation of cell death 
receptor.
254
 Several mutations in the TIMP-3 gene introducing an extra cysteine-
residue and promoting dimerization, are associated with Sorsby’s fundus dystrophy 
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Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases - expression in IBD 
MMPs are involved in normal physiological processes where matrix turnover is 
important, such as wound healing, embryogenesis, angiogenesis, etc. They are 
also implicated in several disease pathologies such as arthritis, dental disease and 
cancer metastasis. In IBD, high levels of proinflammatory cytokines in inflamed 
ulcerated tissue are associated with aberrant expression of MMPs and also TIMPs, 
but the balance between MMPs and TIMPs appears shifted to a more proteolytic 
phenotype.
256-262
 The increased MMP/TIMP ratio in IBD may result in excessive 
tissue breakdown and facilitate leucocyte extravasation and migration, although 
MMP-specific substrate cleavages in IBD mucosa have not been detected so far.
263
 
Excessive expression of MMPs may also enhance fibroblast trans migration, 
promoting fibrosis and stenosis, especially in CD.
264-266
 Alternatively, the MMP over 
TIMP ratio may not be sufficiently enhanced to compensate for the increased 
collagen production by IBD fibroblasts, again resulting in fibrosis.
267
 Targeting 
TIMP-1 with non-functional MMP-9 mutants inhibited liver fibrogenesis, in favor of 
the second hypothesis.
268
 MMPs may also generate new epitopes by cleaving 
substrates, thus perpetuating the immune response.
269
 In several IBD models, 
administration of synthetic MMP inhibitors improved disease course and DSS-
induced colitis was attenuated significantly in MMP-9 deficient mice.
270-272
 
However, ablation of MMP-2 was observed to aggravate experimental colitis, 
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Outline of the studies described in this thesis 
Inflammatory bowel disease is of major concern in industrialized countries. Health 
and economical costs have prompted the initiation of studies aimed at revealing the 
epidemiology, etiology and pathogenesis of IBD. Both CD and UC are 
characterized by excessive tissue breakdown during inflammation. The matrix 
metalloproteinases are important in normal physiological and pathological tissue 
remodeling and repair processes, including IBD. A short overview of IBD and 
MMPs is given in chapter 1. 
Several studies have documented on the altered expression of MMPs in IBD 
tissue. Chapter 2 reports on the expression of MMP-2 and MMP-9 in IBD inflamed 
versus non-inflamed IBD and control intestinal mucosa. MMP levels were 
measured by enzyme linked immunosorbent assay (ELISA), zymography, activity 
assay and reverse transcription polymerase (RT-PCR) assay. The cellular 
localization of MMP expression was determined by immunohistochemistry. 
Infliximab is administered to steroid refractory CD patients and targets TNF-α, 
disrupting proinflammatory communication and promoting apoptosis in leucocytes 
via reverse signaling. The effect of infliximab on MMP-1, -2, -3, -9 and TIMP-1, -2 
protein expression is described in chapter 3. Intestinal explants were cultured ex 
vivo with/without (w/wo) infliximab and relative expression of MMP, TIMP, TNF-α 
was measured by ELISA, activity assay and/or RT-PCR. In addition, explants were 
cultured w/wo pokeweed mitogen (PWM), to study the expression profiles under 
inflammatory conditions.  
Chapter 4 describes the MMP-2 and MMP-9 serological and mucosal expression 
profile after the administration of infliximab to CD patients with fistulizing or active 
disease. Whole blood cultures w/wo infliximab and/or lipopolysaccharide (LPS) 
were performed to study in vitro the contribution of TNF-α in the regulation of  
MMP-2 and MMP-9 mRNA and protein expression. 
In chapter 5 expression of MMP-1, -2, -3, -9 and TIMP-1, -2 as measured by 
ELISA and/or activity assays in a large collection of IBD and control intestinal 
mucosa and related to CD phenotype is reported. The net MMP activity was 
compared to MMP over TIMP ratio and correlated with myeloperoxidase (MPO) 
content.         
Introduction - 23 
 
Single nucleotide polymorphisms (SNP) in genes may affect mRNA transcription, 
stability and/or protein function, thus enhancing disease susceptibility and/or 
phenotype. Chapter 6 documents the distribution of (functional) SNPs in the genes 
encoding MMP-1, -2, -3 and -9, TIMP-1, -2 and TNF-α in a large cohort of IBD 
patients versus control subjects. Results were correlated with protein expression 
and clinical course, i.e., development of fistulae, stenotic complications and organ 
involvement.          
After surgical resection, CD patients often experience recurrence of disease. 
Numerous studies have attempted to identify causal factors and smoking has been 
established as a bad prognostic factor. In chapter 7 the clinical course of a large 
cohort of fully documented CD patients was related to MMP and TIMP genotypes 
and protein levels in surgically resected intestinal mucosa. In addition, several 
clinical and demographic variables such as smoking habits, sex and age at 
resection were retrospectively collected and related to the clinical outcome as well. 
The different studies are finally compiled as a summarizing discussion in  






Table 1 (next pages). MMPs and TIMPs, adapted from references.
191,192,244,274
  
Pre = prepeptide signal sequence, pro = propeptide, catalytic = catalytic domain, 
Zn = catalytic zinc, F = fibronectin type II repeat, Fu = furin pro-protein convertase 
cleavage site, TM = transmembrane region, cyt = cytoplasmic tail, GPI= 
glycosylphosphatidylinositol anchor, CA = cysteine array, Ig = immunoglobulin, V= 
vitronectin insert. Note: substrate specificities were determined in vitro and remain 
to be confirmed in vivo. MMPs may digest other substrates not mentioned in this 
overview. *Cellular expression is dependent on stimulation by cytokines, 
extracellular matrix, DNA-methylation and acetylation, oncogenic transformation, 
etc., and expression should not be viewed as limited to those cells or tissues 
mentioned. References indicated between brackets.  






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Introduction - 27 
 
References 
1. Herszenyi L, Miheller P, Tulassay Z. Carcinogenesis in inflammatory bowel 
disease. Dig Dis. 2007;25:267-69. 
2. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in 
Crohn's disease: a meta-analysis of population-based cohort studies. Am J 
Gastroenterol. 2005;100:2724-29. 
3. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of 
inflammatory bowel disease on pregnancy. Gut. 2007;56:830-837. 
4. Osterman MT, Lichtenstein GR. Infliximab in fistulizing Crohn's disease. 
Gastroenterol Clin North Am. 2006;35:795-820. 
5. Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. 
BioDrugs. 2007;21:125-32. 
6. Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. 
Gastroenterol Clin North Am. 2006;35:775-93. 
7. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact 
on health care resources in the UK. Eur J Gastroenterol Hepatol. 
2005;17:1047-52. 
8. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with 
Crohn's disease in a commercially-insured setting. Am J Ther. 2006;13:502-6. 
9. D'haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and 
Crohn's disease. Curr Gastroenterol Rep. 2006;8:506-12. 
10. Van Assche G. Emerging drugs to treat Crohn's disease. Expert Opin Emerg 
Drugs. 2007;12:49-59. 
11. Vermeire S, Van Assche G, Rutgeerts P. Review article: Altering the natural 
history of Crohn's disease--evidence for and against current therapies. Aliment 
Pharmacol Ther. 2007;25:3-12. 
12. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease 
outcome in Crohn's disease changed during the last four decades? Aliment 
Pharmacol Ther. 2004;20:483-96. 
13. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in 
pediatric patients with Crohn's disease. Gastroenterology. 2006;130:1069-77. 
28 - Chapter 1 
 
14. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and 
prognosis of inflammatory bowel disease during the last 5 decades: a 
population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 
2007;13:481-89. 
15. Loftus EV, Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural 
history of Crohn's disease in population-based patient cohorts from North 
America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60. 
16. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel 
disease and decreasing surgery rates in Copenhagen City and County, 2003-
2005: a population-based study from the Danish Crohn colitis database. Am J 
Gastroenterol. 2006;101:1274-82. 
17. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive 
diseases in the United States. Gastroenterology. 2002;122:1500-1511. 
18. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory 
bowel disease in the United States: results from the National Health Interview 
Survey. Am J Gastroenterol. 2003;98:1064-72. 
19. Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn's disease 
and ulcerative colitis in Denmark. A study based on the National Registry of 
Patients, 1981-1992. Int J Epidemiol. 1997;26:1003-8. 
20. Loftus CG, Loftus EV, Jr., Harmsen WS, et al. Update on the incidence and 
prevalence of Crohn's disease and ulcerative colitis in Olmsted County, 
Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-61. 
21. Russel MG, Dorant E, Volovics A, et al. High incidence of inflammatory bowel 
disease in The Netherlands: results of a prospective study. The South 
Limburg IBD Study Group. Dis Colon Rectum. 1998;41:33-40. 
22. Stone MA, Mayberry JF, Baker R. Prevalence and management of 
inflammatory bowel disease: a cross-sectional study from central England. Eur 
J Gastroenterol Hepatol. 2003;15:1275-80. 
23. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's 
disease and ulcerative colitis in a central Canadian province: a population-
based study. Am J Epidemiol. 1999;149:916-24. 
Introduction - 29 
 
24. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's 
disease in Canterbury, New Zealand: results of an epidemiologic study. 
Inflamm Bowel Dis. 2006;12:936-43. 
25. Loftus EV, Jr., Silverstein MD, Sandborn WJ, et al. Crohn's disease in 
Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. 
Gastroenterology. 1998;114:1161-68. 
26. Loftus EV, Jr., Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in 
Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. 
Gut. 2000;46:336-43. 
27. Sonnenberg A. Occupational distribution of inflammatory bowel disease 
among German employees. Gut. 1990;31:1037-40. 
28. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory 
bowel disease across Europe: is there a difference between north and south? 
Results of the European Collaborative Study on Inflammatory Bowel Disease 
(EC-IBD). Gut. 1996;39:690-697. 
29. Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel 
disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408-13. 
30. Tsironi E, Feakins RM, Probert CS, et al. Incidence of inflammatory bowel 
disease is rising and abdominal tuberculosis is falling in Bangladeshis in East 
London, United Kingdom. Am J Gastroenterol. 2004;99:1749-55. 
31. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel 
disease among Danish twins. Results of a nationwide study. Scand J 
Gastroenterol. 2000;35:1075-81. 
32. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. 
World J Gastroenterol. 2005;11:3971-79. 
33. Hoie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may 
predict 10-yr disease recurrence in a European-wide population-based cohort. 
Am J Gastroenterol. 2007;102:1692-701. 
34. Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies 
paratuberculosis and Crohn's disease: a systematic review and meta-analysis. 
Lancet Infect Dis. 2007;7:607-13. 
30 - Chapter 1 
 
35. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of 
adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's 
disease. Gastroenterology. 2004;127:412-21. 
36. Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a 
feature of Crohn's disease. Lab Invest. 2007;87:1042-54. 
37. Morris DL, Montgomery SM, Thompson NP, et al. Measles vaccination and 
inflammatory bowel disease: a national British Cohort Study. Am J 
Gastroenterol. 2000;95:3507-12. 
38. Pardi DS, Tremaine WJ, Sandborn WJ, et al. Early measles virus infection is 
associated with the development of inflammatory bowel disease. Am J 
Gastroenterol. 2000;95:1480-1485. 
39. Thompson NP, Montgomery SM, Pounder RE, et al. Is measles vaccination a 
risk factor for inflammatory bowel disease? Lancet. 1995;345:1071-74. 
40. Vare PO, Heikius B, Silvennoinen JA, et al. Seroprevalence of Helicobacter 
pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a 
protective factor? Scand J Gastroenterol. 2001;36:1295-300. 
41. Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in 
spouses and their offspring. Gastroenterology. 2001;120:816-19. 
42. Chowers Y, Odes S, Bujanover Y, et al. The month of birth is linked to the risk 
of Crohn's disease in the Israeli population. Am J Gastroenterol. 
2004;99:1974-76. 
43. Moum B, Aadland E, Ekbom A, et al. Seasonal variations in the onset of 
ulcerative colitis. Gut. 1996;38:376-78. 
44. Card TR, Sawczenko A, Sandhu BK, et al. No seasonality in month of birth of 
inflammatory bowel disease cases: a prospective population based study of 
British under 20 year olds. Gut. 2002;51:814-15. 
45. Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease 
attributable to smoking, oral contraception and breastfeeding in Italy: a 
nationwide case-control study. Cooperative Investigators of the Italian Group 
for the Study of the Colon and the Rectum (GISC). Int J Epidemiol. 
1998;27:397-404. 
Introduction - 31 
 
46. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a 
case-control study. Epidemiology. 1992;3:47-52. 
47. Russel MG, Engels LG, Muris JW, et al. Modern life' in the epidemiology of 
inflammatory bowel disease: a case-control study with special emphasis on 
nutritional factors. Eur J Gastroenterol Hepatol. 1998;10:243-49. 
48. Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, et al. Risk factors for 
inflammatory bowel disease in the general population. Aliment Pharmacol 
Ther. 2005;22:309-15. 
49. Persson PG, Leijonmarck CE, Bernell O, et al. Risk indicators for inflammatory 
bowel disease. Int J Epidemiol. 1993;22:268-72. 
50. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on 
inflammatory bowel disease and irritable bowel syndrome: a prevalence study. 
Am J Gastroenterol. 1998;93:1867-72. 
51. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on 
relapse in patients with inflammatory bowel disease: a prospective 18-month 
follow-up study. Psychosom Med. 2004;66:79-84. 
52. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Controversies 
surrounding the comorbidity of depression and anxiety in inflammatory bowel 
disease patients: a literature review. Inflamm Bowel Dis. 2007;13:225-34. 
53. Delco F, Sonnenberg A. Military history of patients with inflammatory bowel 
disease: an epidemiological study among U.S. veterans. Am J Gastroenterol. 
1998;93:1457-62. 
54. Gent AE, Hellier MD, Grace RH, et al. Inflammatory bowel disease and 
domestic hygiene in infancy. Lancet. 1994;343:766-67. 
55. Green C, Elliott L, Beaudoin C, et al. A population-based ecologic study of 
inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol. 
2006;164:615-23. 
56. Tedeschi A, Airaghi L. Is affluence a risk factor for bronchial asthma and type 
1 diabetes? Pediatr Allergy Immunol. 2006;17:533-37. 
57. Binder V, Orholm M. Familial occurrence and inheritance studies in 
inflammatory bowel disease. Neth J Med. 1996;48:53-56. 
32 - Chapter 1 
 
58. Kurata JH, Kantor-Fish S, Frankl H, et al. Crohn's disease among ethnic 
groups in a large health maintenance organization. Gastroenterology. 
1992;102:1940-1948. 
59. Roth MP, Petersen GM, McElree C, et al. Geographic origins of Jewish 
patients with inflammatory bowel disease. Gastroenterology. 1989;97:900-
904. 
60. Sonnenberg A, Wasserman IH. Epidemiology of inflammatory bowel disease 
among U.S. military veterans. Gastroenterology. 1991;101:122-30. 
61. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides 
evidence for novel linkages in inflammatory bowel disease in a large 
European cohort. Am J Hum Genet. 1999;64:808-16. 
62. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a 
susceptibility locus for Crohn's disease on chromosome 16. Nature. 
1996;379:821-23. 
63. Ma Y, Ohmen JD, Li Z, et al. A genome-wide search identifies potential new 
susceptibility loci for Crohn's disease. Inflamm Bowel Dis. 1999;5:271-78. 
64. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian 
families with inflammatory bowel disease reveals two novel susceptibility loci. 
Am J Hum Genet. 2000;66:1863-70. 
65. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in 
inflammatory bowel disease provides evidence for susceptibility loci on 
chromosomes 3, 7 and 12. Nat Genet. 1996;14:199-202. 
66. Vermeire S, Satsangi J, Peeters M, et al. Evidence for inflammatory bowel 
disease of a susceptibility locus on the X chromosome. Gastroenterology. 
2001;120:834-40. 
67. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich 
repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-
603. 
68. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 
associated with susceptibility to Crohn's disease. Nature. 2001;411:603-6. 
Introduction - 33 
 
69. Brant SR, Wang MH, Rawsthorne P, et al. A population-based case-control 
study of CARD15 and other risk factors in Crohn's disease and ulcerative 
colitis. Am J Gastroenterol. 2007;102:313-23. 
70. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene 
mutations to the risk and site of disease in inflammatory bowel disease. 
Gastroenterology. 2002;122:867-74. 
71. Weidinger S, Klopp N, Rummler L, et al. Association of CARD15 
polymorphisms with atopy-related traits in a population-based cohort of 
Caucasian adults. Clin Exp Allergy. 2005;35:866-72. 
72. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau 
syndrome. Nat Genet. 2001;29:19-20. 
73. Brenmoehl J, Herfarth H, Gluck T, et al. Genetic variants in the 
NOD2/CARD15 gene are associated with early mortality in sepsis patients. 
Intensive Care Med. 2007;33:1541-48. 
74. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 
mutations associate with transplant-related mortality and GvHD following 
allogeneic stem cell transplantation. Blood. 2004;104:889-94. 
75. Mayor NP, Shaw BE, Hughes DA, et al. Single nucleotide polymorphisms in 
the NOD2/CARD15 gene are associated with an increased risk of relapse and 
death for patients with acute leukemia after hematopoietic stem-cell 
transplantation with unrelated donors. J Clin Oncol. 2007;25:4262-69. 
76. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study 
identifies IL23R as an inflammatory bowel disease gene. Science. 
2006;314:1461-63. 
77. Tremelling M, Cummings F, Fisher SA, et al. IL23R variation determines 
susceptibility but not disease phenotype in inflammatory bowel disease. 
Gastroenterology. 2007;132:1657-64. 
78. Genome-wide association study of 14,000 cases of seven common diseases 
and 3,000 shared controls. Nature. 2007;447:661-78. 
79. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of 
nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in 
ATG16L1. Nat Genet. 2007;39:207-11. 
34 - Chapter 1 
 
80. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy 
gene IRGM and multiple other replicating loci contribute to Crohn's disease 
susceptibility. Nat Genet. 2007;39:830-832. 
81. Prescott NJ, Fisher SA, Franke A, et al. A nonsynonymous SNP in ATG16L1 
predisposes to ileal Crohn's disease and is independent of CARD15 and 
IBD5. Gastroenterology. 2007;132:1665-71. 
82. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study 
identifies new susceptibility loci for Crohn disease and implicates autophagy in 
disease pathogenesis. Nat Genet. 2007;39:596-604. 
83. Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by 
genome-wide association maps to a gene desert on 5p13.1 and modulates 
expression of PTGER4. PLoS Genet. 2007;3:e58. 
84. Franke A, Hampe J, Rosenstiel P, et al. Systematic association mapping 
identifies NELL1 as a novel IBD disease gene. PLoS ONE. 2007;2:e691. 
85. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent 
studies of Crohn's disease identifies previously unknown disease loci for 
ulcerative colitis. Nat Genet. 2008;40:713-15. 
86. Roberts RL, Gearry RB, Hollis-Moffatt JE, et al. IL23R R381Q and ATG16L1 
T300A Are Strongly Associated With Crohn's Disease in a Study of New 
Zealand Caucasians With Inflammatory Bowel Disease. Am J Gastroenterol. 
2007. 
87. Yamazaki K, Onouchi Y, Takazoe M, et al. Association analysis of genetic 
variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese 
patients. J Hum Genet. 2007;52:575-83. 
88. Aithal GP, Day CP, Leathart J, et al. Association of single nucleotide 
polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with 
Crohn's disease in a British population. Genes Immun. 2001;2:44-47. 
89. Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is 
associated with susceptibility to inflammatory bowel disease. 
Gastroenterology. 2006;130:341-48. 
90. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria 
interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 
Introduction - 35 
 
Asp299gly polymorphism is associated with Crohn's disease and ulcerative 
colitis. Gut. 2004;53:987-92. 
91. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug 
resistance gene determine susceptibility and disease behavior in ulcerative 
colitis. Gastroenterology. 2005;128:288-96. 
92. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel 
NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum 
Mol Genet. 2004;13:35-45. 
93. Klein W, Tromm A, Griga T, et al. Interleukin-4 and interleukin-4 receptor gene 
polymorphisms in inflammatory bowel diseases. Genes Immun. 2001;2:287-
89. 
94. Klein W, Tromm A, Griga T, et al. A polymorphism in the IL11 gene is 
associated with ulcerative colitis. Genes Immun. 2002;3:494-96. 
95. Kyo K, Parkes M, Takei Y, et al. Association of ulcerative colitis with rare 
VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet. 
1999;8:307-11. 
96. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between 
ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor 
antagonist. Gastroenterology. 1994;106:637-42. 
97. Moehle C, Ackermann N, Langmann T, et al. Aberrant intestinal expression 
and allelic variants of mucin genes associated with inflammatory bowel 
disease. J Mol Med. 2006;84:1055-66. 
98. Parkes M, Satsangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to 
inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol. 
1998;113:28-32. 
99. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation 
transporter genes are associated with Crohn disease. Nat Genet. 
2004;36:471-75. 
100. Pierik M, Joossens S, Van Steen K, et al. Toll-like receptor-1, -2, and -6 
polymorphisms influence disease extension in inflammatory bowel diseases. 
Inflamm Bowel Dis. 2006;12:1-8. 
36 - Chapter 1 
 
101. Rector A, Lemey P, Laffut W, et al. Mannan-binding lectin (MBL) gene 
polymorphisms in ulcerative colitis and Crohn's disease. Genes Immun. 
2001;2:323-28. 
102. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is 
associated with inflammatory bowel disease. Nat Genet. 2004;36:476-80. 
103. Hacker UT, Gomolka M, Keller E, et al. Lack of association between an 
interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. 
Gut. 1997;40:623-27. 
104. Noble CL, Nimmo ER, Drummond H, et al. DLG5 variants do not influence 
susceptibility to inflammatory bowel disease in the Scottish population. Gut. 
2005;54:1416-20. 
105. Oostenbrug LE, Dijkstra G, Nolte IM, et al. Absence of association between 
the multidrug resistance (MDR1) gene and inflammatory bowel disease. 
Scand J Gastroenterol. 2006;41:1174-82. 
106. Zipperlen K, Peddle L, Melay B, et al. Association of TNF-alpha 
polymorphisms in Crohn disease. Hum Immunol. 2005;66:56-59. 
107. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of 
TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint 
and gut-associated immunopathologies. Immunity. 1999;10:387-98. 
108. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop 
chronic enterocolitis. Cell. 1993;75:263-74. 
109. Mombaerts P, Mizoguchi E, Grusby MJ, et al. Spontaneous development of 
inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75:274-
82. 
110. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel 
disease: mice deficient for the multiple drug resistance gene, mdr1a, 
spontaneously develop colitis. J Immunol. 1998;161:5733-44. 
111. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with 
a disrupted interleukin-2 gene. Cell. 1993;75:253-61. 
112. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse 
transforming growth factor-beta 1 gene results in multifocal inflammatory 
disease. Nature. 1992;359:693-99. 
Introduction - 37 
 
113. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel 
disease. J Clin Invest. 2007;117:514-21. 
114. Hugot JP, Alberti C, Berrebi D, et al. Crohn's disease: the cold chain 
hypothesis. Lancet. 2003;362:2012-15. 
115. Mei L, Targan SR, Landers CJ, et al. Familial expression of anti-Escherichia 
coli outer membrane porin C in relatives of patients with Crohn's disease. 
Gastroenterology. 2006;130:1078-85. 
116. Stevens TR, Winrow VR, Blake DR, et al. Circulating antibodies to heat-shock 
protein 60 in Crohn's disease and ulcerative colitis. Clin Exp Immunol. 
1992;90:271-74. 
117. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a 
unique response that is associated independently with complicated Crohn's 
disease. Gastroenterology. 2005;128:2020-2028. 
118. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in 
Crohn disease. J Clin Invest. 2004;113:1296-306. 
119. Bamias G, Okazawa A, Rivera-Nieves J, et al. Commensal bacteria 
exacerbate intestinal inflammation but are not essential for the development of 
murine ileitis. J Immunol. 2007;178:1809-18. 
120. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in 
Crohn's disease are associated with diminished mucosal alpha-defensin 
expression. Gut. 2004;53:1658-64. 
121. Buisine MP, Desreumaux P, Debailleul V, et al. Abnormalities in mucin gene 
expression in Crohn's disease. Inflamm Bowel Dis. 1999;5:24-32. 
122. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of 
claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction 
in active Crohn's disease. Gut. 2007;56:61-72. 
123. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in 
Crohn's disease: a clinical investigation. Lancet. 2006;367:668-78. 
124. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's 
disease and other gastrointestinal inflammation show defective CD2 pathway-
induced apoptosis. Gastroenterology. 1999;116:557-65. 
38 - Chapter 1 
 
125. Brannigan AE, O'Connell PR, Hurley H, et al. Neutrophil apoptosis is delayed 
in patients with inflammatory bowel disease. Shock. 2000;13:361-66. 
126. Fayad R, Brand MI, Stone D, et al. Apoptosis resistance in ulcerative colitis: 
high expression of decoy receptors by lamina propria T cells. Eur J Immunol. 
2006;36:2215-22. 
127. Itoh J, de La MC, Strong SA, et al. Decreased Bax expression by mucosal T 
cells favours resistance to apoptosis in Crohn's disease. Gut. 2001;49:35-41. 
128. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory 
CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 
2005;128:1868-78. 
129. Andus T, Daig R, Vogl D, et al. Imbalance of the interleukin 1 system in 
colonic mucosa--association with intestinal inflammation and interleukin 1 
receptor antagonist [corrected] genotype 2. Gut. 1997;41:651-57. 
130. Autschbach F, Schurmann G, Qiao L, et al. Cytokine messenger RNA 
expression and proliferation status of intestinal mononuclear cells in 
noninflamed gut and Crohn's disease. Virchows Arch. 1995;426:51-60. 
131. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal 
chemokine expression is unselectively increased in both ulcerative colitis and 
Crohn's disease. J Pathol. 2003;199:28-35. 
132. Bernstein CN, Sargent M, Rector E. Alteration in expression of beta 2 
integrins on lamina propria lymphocytes in ulcerative colitis and Crohn's 
disease. Clin Immunol. 2002;104:67-72. 
133. Brauchle M, Madlener M, Wagner AD, et al. Keratinocyte growth factor is 
highly overexpressed in inflammatory bowel disease. Am J Pathol. 
1996;149:521-29. 
134. Brynskov J, Tvede N, Andersen CB, et al. Increased concentrations of 
interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in 
endoscopical mucosal biopsy specimens with active inflammatory bowel 
disease. Gut. 1992;33:55-58. 
135. Cui G, Olsen T, Christiansen I, et al. Improvement of real-time polymerase 
chain reaction for quantifying TNF-alpha mRNA expression in inflamed 
Introduction - 39 
 
colorectal mucosa: an approach to optimize procedures for clinical use. Scand 
J Clin Lab Invest. 2006;66:249-59. 
136. Daig R, Andus T, Aschenbrenner E, et al. Increased interleukin 8 expression 
in the colon mucosa of patients with inflammatory bowel disease. Gut. 
1996;38:216-22. 
137. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in 
inflammatory bowel disease. Gut. 2003;52:65-70. 
138. Griga T, May B, Pfisterer O, et al. Immunohistochemical localization of 
vascular endothelial growth factor in colonic mucosa of patients with 
inflammatory bowel disease. Hepatogastroenterology. 2002;49:116-23. 
139. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in 
Crohn's disease. Gut. 2005;54:488-95. 
140. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in 
Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal 
inflammation. Am J Gastroenterol. 2001;96:822-28. 
141. Kaser A, Ludwiczek O, Holzmann S, et al. Increased expression of CCL20 in 
human inflammatory bowel disease. J Clin Immunol. 2004;24:74-85. 
142. McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and 
interleukin 1 beta converting enzyme by intestinal macrophages in health and 
inflammatory bowel disease. Gut. 1998;42:214-19. 
143. McCormack G, Moriarty D, O'Donoghue DP, et al. Tissue cytokine and 
chemokine expression in inflammatory bowel disease. Inflamm Res. 
2001;50:491-95. 
144. Monteleone G, Mann J, Monteleone I, et al. A failure of transforming growth 
factor-beta1 negative regulation maintains sustained NF-kappaB activation in 
gut inflammation. J Biol Chem. 2004;279:3925-32. 
145. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell 
adhesion molecules in inflammatory bowel disease. Evidence of immunologic 
activation of vascular endothelial cells. Lab Invest. 1993;69:77-85. 
146. Noguchi M, Hiwatashi N, Liu Z, et al. Secretion imbalance between tumour 
necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 
1998;43:203-9. 
40 - Chapter 1 
 
147. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour 
necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically 
normal intestinal biopsies from patients with Crohn's disease. Gut. 
1996;39:684-89. 
148. Sakai T, Kusugami K, Nishimura H, et al. Interleukin 15 activity in the rectal 
mucosa of inflammatory bowel disease. Gastroenterology. 1998;114:1237-43. 
149. Schmidt C, Baumeister B, Kipnowski J, et al. Alteration of prostaglandin E2 
and leukotriene B4 synthesis in chronic inflammatory bowel disease. 
Hepatogastroenterology. 1996;43:1508-12. 
150. Schreiber S, Heinig T, Thiele HG, et al. Immunoregulatory role of interleukin 
10 in patients with inflammatory bowel disease. Gastroenterology. 
1995;108:1434-44. 
151. Seegert D, Rosenstiel P, Pfahler H, et al. Increased expression of IL-16 in 
inflammatory bowel disease. Gut. 2001;48:326-32. 
152. Shioya M, Nishida A, Yagi Y, et al. Epithelial overexpression of interleukin-
32alpha in inflammatory bowel disease. Clin Exp Immunol. 2007;149:480-486. 
153. Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial 
receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the 
colon and jejunum of patients with inflammatory bowel disease. Gut. 
1999;45:856-63. 
154. ter Beek WP, Biemond I, Muller ES, et al. Substance P receptor expression in 
patients with inflammatory bowel disease. Determination by three different 
techniques, i.e., storage phosphor autoradiography, RT-PCR and 
immunohistochemistry. Neuropeptides. 2007;41:301-6. 
155. Woywodt A, Ludwig D, Neustock P, et al. Mucosal cytokine expression, 
cellular markers and adhesion molecules in inflammatory bowel disease. Eur J 
Gastroenterol Hepatol. 1999;11:267-76. 
156. Holtmann MH, Douni E, Schutz M, et al. Tumor necrosis factor-receptor 2 is 
up-regulated on lamina propria T cells in Crohn's disease and promotes 
experimental colitis in vivo. Eur J Immunol. 2002;32:3142-51. 
Introduction - 41 
 
157. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 
cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, 
and cell restitution. Gastroenterology. 2005;129:550-564. 
158. McClane SJ, Rombeau JL. Cytokines and inflammatory bowel disease: a 
review. JPEN J Parenter Enteral Nutr. 1999;23:S20-S24. 
159. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and 
actively released by Crohn's disease intestinal lamina propria mononuclear 
cells. Gastroenterology. 1997;112:1169-78. 
160. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 
2007;13:26-28. 
161. Brandt E, Colombel JF, Ectors N, et al. Enhanced production of IL-8 in chronic 
but not in early ileal lesions of Crohn's disease (CD). Clin Exp Immunol. 
2000;122:180-185. 
162. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early 
and chronic ileal lesions of Crohn's disease. Gastroenterology. 1997;113:118-
26. 
163. D'Inca R, Cardin R, Benazzato L, et al. Oxidative DNA damage in the mucosa 
of ulcerative colitis increases with disease duration and dysplasia. Inflamm 
Bowel Dis. 2004;10:23-27. 
164. Keshavarzian A, Banan A, Farhadi A, et al. Increases in free radicals and 
cytoskeletal protein oxidation and nitration in the colon of patients with 
inflammatory bowel disease. Gut. 2003;52:720-728. 
165. Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in 
inflammatory bowel disease: semi-quantification, localization, and association 
with mucosal antioxidants. J Pathol. 2003;201:28-36. 
166. Nair J, Gansauge F, Beger H, et al. Increased etheno-DNA adducts in 
affected tissues of patients suffering from Crohn's disease, ulcerative colitis, 
and chronic pancreatitis. Antioxid Redox Signal. 2006;8:1003-10. 
167. Kruidenier L, Kuiper I, van Duijn W, et al. Imbalanced secondary mucosal 
antioxidant response in inflammatory bowel disease. J Pathol. 2003;201:17-
27. 
42 - Chapter 1 
 
168. Kruidenier L, Kuiper I, van Duijn W, et al. Differential mucosal expression of 
three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol. 
2003;201:7-16. 
169. Tamaki H, Nakamura H, Nishio A, et al. Human thioredoxin-1 ameliorates 
experimental murine colitis in association with suppressed macrophage 
inhibitory factor production. Gastroenterology. 2006;131:1110-1121. 
170. Jenkins D, Seth R, Kummer JA, et al. Differential levels of granzyme B, 
regulatory cytokines, and apoptosis in Crohn's disease and ulcerative colitis at 
first presentation. J Pathol. 2000;190:184-89. 
171. Souza HS, Tortori CJ, Castelo-Branco MT, et al. Apoptosis in the intestinal 
mucosa of patients with inflammatory bowel disease: evidence of altered 
expression of FasL and perforin cytotoxic pathways. Int J Colorectal Dis. 
2005;20:277-86. 
172. Ueyama H, Kiyohara T, Sawada N, et al. High Fas ligand expression on 
lymphocytes in lesions of ulcerative colitis. Gut. 1998;43:48-55. 
173. Allez M, Tieng V, Nakazawa A, et al. CD4+NKG2D+ T cells in Crohn's disease 
mediate inflammatory and cytotoxic responses through MICA interactions. 
Gastroenterology. 2007;132:2346-58. 
174. Muller S, Lory J, Corazza N, et al. Activated CD4+ and CD8+ cytotoxic cells 
are present in increased numbers in the intestinal mucosa from patients with 
active inflammatory bowel disease. Am J Pathol. 1998;152:261-68. 
175. Ebert EC, Geng X, Lin J, et al. Autoantibodies against human tropomyosin 
isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody 
and complement-mediated lysis. Cell Immunol. 2006;244:43-49. 
176. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin 
G1 and activated complement colocalise with the M(r) 40 kD putative 
autoantigen in ulcerative colitis. Gut. 1993;34:650-657. 
177. Andoh A, Deguchi Y, Inatomi O, et al. Immunohistochemical study of 
chymase-positive mast cells in inflammatory bowel disease. Oncol Rep. 
2006;16:103-7. 
Introduction - 43 
 
178. Raithel M, Winterkamp S, Pacurar A, et al. Release of mast cell tryptase from 
human colorectal mucosa in inflammatory bowel disease. Scand J 
Gastroenterol. 2001;36:174-79. 
179. Saitoh O, Sugi K, Matsuse R, et al. The forms and the levels of fecal PMN-
elastase in patients with colorectal diseases. Am J Gastroenterol. 
1995;90:388-93. 
180. Isozaki Y, Yoshida N, Kuroda M, et al. Anti-tryptase treatment using 
nafamostat mesilate has a therapeutic effect on experimental colitis. Scand J 
Gastroenterol. 2006;41:944-53. 
181. Morohoshi Y, Matsuoka K, Chinen H, et al. Inhibition of neutrophil elastase 
prevents the development of murine dextran sulfate sodium-induced colitis. J 
Gastroenterol. 2006;41:318-24. 
182. Schmid M, Fellermann K, Fritz P, et al. Attenuated induction of epithelial and 
leukocyte serine antiproteases elafin and secretory leukocyte protease 
inhibitor in Crohn's disease. J Leukoc Biol. 2007;81:907-15. 
183. Rawlings ND, Morton FR, Barrett AJ. MEROPS: the peptidase database. 
Nucleic Acids Res. 2006;34:D270-D272. 
184. Bode W, Gomis-Ruth FX, Stockler W. Astacins, serralysins, snake venom and 
matrix metalloproteinases exhibit identical zinc-binding environments 
(HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a 
common family, the 'metzincins'. FEBS Lett. 1993;331:134-40. 
185. Blobel CP. ADAMs: key components in EGFR signalling and development. 
Nat Rev Mol Cell Biol. 2005;6:32-43. 
186. Jones GC, Riley GP. ADAMTS proteinases: a multi-domain, multi-functional 
family with roles in extracellular matrix turnover and arthritis. Arthritis Res 
Ther. 2005;7:160-169. 
187. Bell JH, Herrera AH, Li Y, et al. Role of ADAM17 in the ectodomain shedding 
of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc 
Biol. 2007;82:173-76. 
188. Gendron C, Kashiwagi M, Lim NH, et al. Proteolytic activities of human 
ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem. 
2007;282:18294-306. 
44 - Chapter 1 
 
189. Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human 
articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. 
Arthritis Rheum. 2007;56:575-85. 
190. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase 
in mouse cartilage in vivo and in vitro. Nature. 2005;434:648-52. 
191. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes 
and their inhibitors in development and disease. Best Pract Res Clin 
Rheumatol. 2006;20:983-1002. 
192. Nagase H, Visse R, Murphy G. Structure and function of matrix 
metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-73. 
193. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of 
regulation of metalloproteinase activity with potential applicability to the entire 
matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 1990; 
87:5578-82. 
194. Cao J, Rehemtulla A, Pavlaki M, et al. Furin directly cleaves proMMP-2 in the 
trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem. 
2005;280:10974-80. 
195. Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of 
fibroblast collagenase complexed with an inhibitor. Science. 1994;263:375-77. 
196. Zhang Y, Dean WL, Gray RD. Cooperative binding of Ca2+ to human 
interstitial collagenase assessed by circular dichroism, fluorescence, and 
catalytic activity. J Biol Chem. 1997;272:1444-47. 
197. Rosenblum G, Van den Steen PE, Cohen SR, et al. Insights into the structure 
and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase 
B. Structure. 2007;15:1227-36. 
198. Piccard H, Van den Steen PE, Opdenakker G. Hemopexin domains as 
multifunctional liganding modules in matrix metalloproteinases and other 
proteins. J Leukoc Biol. 2007;81:870-892. 
199. Toth M, Osenkowski P, Hesek D, et al. Cleavage at the stem region releases 
an active ectodomain of the membrane type 1 matrix metalloproteinase. 
Biochem J. 2005;387:497-506. 
Introduction - 45 
 
200. Toth M, Sohail A, Mobashery S, et al. MT1-MMP shedding involves an ADAM 
and is independent of its localization in lipid rafts. Biochem Biophys Res 
Commun. 2006;350:377-84. 
201. Abraham M, Shapiro S, Lahat N, et al. The role of IL-18 and IL-12 in the 
modulation of matrix metalloproteinases and their tissue inhibitors in 
monocytic cells. Int Immunol. 2002;14:1449-57. 
202. Fujisaki K, Tanabe N, Suzuki N, et al. The effect of IL-1alpha on the 
expression of matrix metalloproteinases, plasminogen activators, and their 
inhibitors in osteoblastic ROS 17/2.8 cells. Life Sci. 2006;78:1975-82. 
203. Im HJ, Muddasani P, Natarajan V, et al. Basic fibroblast growth factor 
stimulates matrix metalloproteinase-13 via the molecular cross-talk between 
the mitogen-activated protein kinases and protein kinase Cdelta pathways in 
human adult articular chondrocytes. J Biol Chem. 2007;282:11110-11121. 
204. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation 
of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. 
J Immunol. 1997;158:2327-33. 
205. Kelley MJ, Rose AY, Song K, et al. Synergism of TNF and IL-1 in the induction 
of matrix metalloproteinase-3 in trabecular meshwork. Invest Ophthalmol Vis 
Sci. 2007;48:2634-43. 
206. Nelson KK, Ranganathan AC, Mansouri J, et al. Elevated sod2 activity 
augments matrix metalloproteinase expression: evidence for the involvement 
of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res. 
2003;9:424-32. 
207. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte 
matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol. 
2002;32:404-12. 
208. Rutter JL, Benbow U, Coon CI, et al. Cell-type specific regulation of human 
interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in 
human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem. 
1997;66:322-36. 
46 - Chapter 1 
 
209. Solis-Herruzo JA, Rippe RA, Schrum LW, et al. Interleukin-6 increases rat 
metalloproteinase-13 gene expression through stimulation of activator protein 
1 transcription factor in cultured fibroblasts. J Biol Chem. 1999;274:30919-26. 
210. Werle M, Schmal U, Hanna K, et al. MCP-1 induces activation of MAP-kinases 
ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res. 
2002;56:284-92. 
211. Xie S, Issa R, Sukkar MB, et al. Induction and regulation of matrix 
metalloproteinase-12 in human airway smooth muscle cells. Respir Res. 
2005;6:148. 
212. Liao EY, Luo XH. Effects of 17beta-estradiol on the expression of matrix 
metalloproteinase-1, -2 and tissue inhibitor of metalloproteinase-1 in human 
osteoblast-like cell cultures. Endocrine. 2001;15:291-95. 
213. Ma Z, Chang MJ, Shah RC, et al. Interferon-gamma-activated STAT-1alpha 
suppresses MMP-9 gene transcription by sequestration of the coactivators 
CBP/p300. J Leukoc Biol. 2005;78:515-23. 
214. Mackay AR, Ballin M, Pelina MD, et al. Effect of phorbol ester and cytokines 
on matrix metalloproteinase and tissue inhibitor of metalloproteinase 
expression in tumor and normal cell lines. Invasion Metastasis. 1992;12:168-
84. 
215. Yuan W, Varga J. Transforming growth factor-beta repression of matrix 
metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem. 
2001;276:38502-10. 
216. Gebbia JA, Coleman JL, Benach JL. Selective induction of matrix 
metalloproteinases by Borrelia burgdorferi via toll-like receptor 2 in 
monocytes. J Infect Dis. 2004;189:113-19. 
217. Malik N, Greenfield BW, Wahl AF, et al. Activation of human monocytes 
through CD40 induces matrix metalloproteinases. J Immunol. 1996;156:3952-
60. 
218. Moore C, Shen XD, Gao F, et al. Fibronectin-alpha4beta1 integrin interactions 
regulate metalloproteinase-9 expression in steatotic liver ischemia and 
reperfusion injury. Am J Pathol. 2007;170:567-77. 
Introduction - 47 
 
219. Sudbeck BD, Pilcher BK, Welgus HG, et al. Induction and repression of 
collagenase-1 by keratinocytes is controlled by distinct components of 
different extracellular matrix compartments. J Biol Chem. 1997;272:22103-10. 
220. Xie B, Laouar A, Huberman E. Fibronectin-mediated cell adhesion is required 
for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene 
expression during macrophage differentiation. The signaling role of protein 
kinase C-beta. J Biol Chem. 1998;273:11576-82. 
221. Vincenti MP, Brinckerhoff CE. Signal transduction and cell-type specific 
regulation of matrix metalloproteinase gene expression: can MMPs be good 
for you? J Cell Physiol. 2007;213:355-64. 
222. Couillard J, Demers M, Lavoie G, et al. The role of DNA hypomethylation in 
the control of stromelysin gene expression. Biochem Biophys Res Commun. 
2006;342:1233-39. 
223. Martens JH, Verlaan M, Kalkhoven E, et al. Cascade of distinct histone 
modifications during collagenase gene activation. Mol Cell Biol. 2003;23:1808-
16. 
224. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic 
variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-
specific transcriptional regulation. J Biol Chem. 2001;276:7549-58. 
225. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the 
matrix metalloproteinase-1 promoter creates an Ets binding site and augments 
transcription. Cancer Res. 1998;58:5321-25. 
226. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J 
Cell Physiol. 2007;211:19-26. 
227. Fahling M, Steege A, Perlewitz A, et al. Role of nucleolin in posttranscriptional 
control of MMP-9 expression. Biochim Biophys Acta. 2005;1731:32-40. 
228. Chakrabarti S, Zee JM, Patel KD. Regulation of matrix metalloproteinase-9 
(MMP-9) in TNF-stimulated neutrophils: novel pathways for tertiary granule 
release. J Leukoc Biol. 2006;79:214-22. 
229. Kang T, Yi J, Guo A, et al. Subcellular distribution and cytokine- and 
chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in 
neutrophils. J Biol Chem. 2001;276:21960-21968. 
48 - Chapter 1 
 
230. Wiehler S, Cuvelier SL, Chakrabarti S, et al. p38 MAP kinase regulates rapid 
matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res 
Commun. 2004;315:463-70. 
231. Zucker S, Hymowitz M, Conner CE, et al. Rapid trafficking of membrane type 
1-matrix metalloproteinase to the cell surface regulates progelatinase a 
activation. Lab Invest. 2002;82:1673-84. 
232. Rahat MA, Marom B, Bitterman H, et al. Hypoxia reduces the output of matrix 
metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and 
elevating membranal association. J Leukoc Biol. 2006;79:706-18. 
233. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry. Circ Res. 
2003;92:827-39. 
234. Galazka G, Windsor LJ, Birkedal-Hansen H, et al. APMA (4-
aminophenylmercuric acetate) activation of stromelysin-1 involves protein 
interactions in addition to those with cysteine-75 in the propeptide. 
Biochemistry. 1996;35:11221-27. 
235. Suzuki K, Enghild JJ, Morodomi T, et al. Mechanisms of activation of tissue 
procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 
1990;29:10261-70. 
236. Bannikov GA, Karelina TV, Collier IE, et al. Substrate binding of gelatinase B 
induces its enzymatic activity in the presence of intact propeptide. J Biol 
Chem. 2002;277:16022-27. 
237. Rosenblum G, Meroueh S, Toth M, et al. Molecular Structures and Dynamics 
of the Stepwise Activation Mechanism of a Matrix Metalloproteinase Zymogen: 
Challenging the Cysteine Switch Dogma. J Am Chem Soc. 2007;129:13566-
74. 
238. Fu X, Parks WC, Heinecke JW. Activation and silencing of matrix 
metalloproteinases. Semin Cell Dev Biol. 2007. 
239. Fernandez CA, Yan L, Louis G, et al. The matrix metalloproteinase-
9/neutrophil gelatinase-associated lipocalin complex plays a role in breast 
tumor growth and is present in the urine of breast cancer patients. Clin Cancer 
Res. 2005;11:5390-5395. 
Introduction - 49 
 
240. Kubben FJ, Sier CF, Hawinkels LJ, et al. Clinical evidence for a protective role 
of lipocalin-2 against MMP-9 autodegradation and the impact for gastric 
cancer. Eur J Cancer. 2007;43:1869-76. 
241. Van den Steen PE, Opdenakker G, Wormald MR, et al. Matrix remodelling 
enzymes, the protease cascade and glycosylation. Biochim Biophys Acta. 
2001;1528:61-73. 
242. Jiang A, Lehti K, Wang X, et al. Regulation of membrane-type matrix 
metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad 
Sci U S A. 2001;98:13693-98. 
243. Lafleur MA, Mercuri FA, Ruangpanit N, et al. Type I collagen abrogates the 
clathrin-mediated internalization of membrane type 1 matrix metalloproteinase 
(MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem. 
2006;281:6826-40. 
244. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for 
matrix anymore! Curr Opin Cell Biol. 2001;13:534-40. 
245. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in 
isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular 
target for matrix metalloproteinase-2. Circulation. 2005;112:544-52. 
246. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix 
metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion 
injury. Circulation. 2002;106:1543-49. 
247. D'Alessio S, Ferrari G, Cinnante K, et al. Tissue inhibitor of 
metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase 
induces MAPK activation and cell growth by a non-proteolytic mechanism. J 
Biol Chem. 2008;283:87-99. 
248. Lambert E, Dasse E, Haye B, et al. TIMPs as multifacial proteins. Crit Rev 
Oncol Hematol. 2004;49:187-98. 
249. Eickelberg O, Kohler E, Reichenberger F, et al. Extracellular matrix deposition 
by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. 
Am J Physiol. 1999;276:L814-L824. 
50 - Chapter 1 
 
250. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and 
histone deacetylase inhibition in the re-expression of genes silenced in 
cancer. Nat Genet. 1999;21:103-7. 
251. Anderson CL, Brown CJ. Polymorphic X-chromosome inactivation of the 
human TIMP1 gene. Am J Hum Genet. 1999;65:699-708. 
252. Anderson CL, Brown CJ. Variability of X chromosome inactivation: effect on 
levels of TIMP1 RNA and role of DNA methylation. Hum Genet. 
2002;110:271-78. 
253. Ivanova T, Vinokurova S, Petrenko A, et al. Frequent hypermethylation of 5' 
flanking region of TIMP-2 gene in cervical cancer. Int J Cancer. 2004;108:882-
86. 
254. Chirco R, Liu XW, Jung KK, et al. Novel functions of TIMPs in cell signaling. 
Cancer Metastasis Rev. 2006;25:99-113. 
255. Langton KP, McKie N, Curtis A, et al. A novel tissue inhibitor of 
metalloproteinases-3 mutation reveals a common molecular phenotype in 
Sorsby's fundus dystrophy. J Biol Chem. 2000;275:27027-31. 
256. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are 
elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-22. 
257. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, et al. Differential 
expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-
28, in normal and inflamed intestine and colon cancer. Dig Dis Sci. 
2004;49:653-61. 
258. Heuschkel RB, MacDonald TT, Monteleone G, et al. Imbalance of stromelysin-
1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel 
disease. Gut. 2000;47:57-62. 
259. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression 
of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J 
Pathol. 1996;148:519-26. 
260. Stallmach A, Chan CC, Ecker KW, et al. Comparable expression of matrix 
metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut. 
2000;47:415-22. 
Introduction - 51 
 
261. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct 
expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), 
macrophage metalloelastase (MMP-12), and tissue inhibitor of 
metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 
1998;152:1005-14. 
262. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix 
metalloproteinases and their tissue inhibitors in colon mucosa of patients with 
inflammatory bowel disease. Gut. 2000;47:63-73. 
263. Wheatcroft AC, Hollander AP, Croucher LJ, et al. Evidence of in situ stability 
of the type IV collagen triple helix in human inflammatory bowel disease using 
a denaturation specific epitope antibody. Matrix Biol. 1999;18:361-72. 
264. Corbel M, Caulet-Maugendre S, Germain N, et al. Inhibition of bleomycin-
induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor 
batimastat. J Pathol. 2001;193:538-45. 
265. Tan RJ, Fattman CL, Niehouse LM, et al. Matrix metalloproteinases promote 
inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir 
Cell Mol Biol. 2006;35:289-97. 
266. Warnaar N, Hofker HS, Maathuis MH, et al. Matrix metalloproteinases as 
profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis. 
2006;12:863-69. 
267. McKaig BC, McWilliams D, Watson SA, et al. Expression and regulation of 
tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by 
intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol. 
2003;162:1355-60. 
268. Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic 
fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J. 
2006;20:444-54. 
269. Opdenakker G, Dillen C, Fiten P, et al. Remnant epitopes, autoimmunity and 
glycosylation. Biochim Biophys Acta. 2006;1760:610-615. 
270. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of 
metalloproteinase 9 attenuates experimental colitis in mice: central role of 
epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008. 
52 - Chapter 1 
 
271. Kobayashi K, Arimura Y, Goto A, et al. Therapeutic implications of the specific 
inhibition of causative matrix metalloproteinases in experimental colitis 
induced by dextran sulphate sodium. J Pathol. 2006;209:376-83. 
272. Medina C, Videla S, Radomski A, et al. Therapeutic effect of phenantroline in 
two rat models of inflammatory bowel disease. Scand J Gastroenterol. 
2001;36:1314-19. 
273. Garg P, Rojas M, Ravi A, et al. Selective ablation of matrix metalloproteinase-
2 exacerbates experimental colitis: contrasting role of gelatinases in the 
pathogenesis of colitis. J Immunol. 2006;177:4103-12. 
274. Van den Steen PE, Proost P, Wuyts A, et al. Neutrophil gelatinase B 
potentiates interleukin-8 tenfold by aminoterminal processing, whereas it 
degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 
intact. Blood. 2000;96:2673-81. 
275. Anderson F, Game BA, Atchley D, et al. IFN-gamma pretreatment augments 
immune complex-induced matrix metalloproteinase-1 expression in U937 
histiocytes. Clin Immunol. 2002;102:200-207. 
276. Dumin JA, Dickeson SK, Stricker TP, et al. Pro-collagenase-1 (matrix 
metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from 
keratinocytes migrating on type I collagen. J Biol Chem. 2001;276:29368-74. 
277. Ghaffari A, Li Y, Karami A, et al. Fibroblast extracellular matrix gene 
expression in response to keratinocyte-releasable stratifin. J Cell Biochem. 
2006;98:383-93. 
278. Abe M, Kawamoto K, Okamoto H, et al. Induction of collagenase-2 (matrix 
metalloproteinase-8) gene expression by interleukin-1beta in human gingival 
fibroblasts. J Periodontal Res. 2001;36:153-59. 
279. Devarajan P, Mookhtiar K, Van Wart H, et al. Structure and expression of the 
cDNA encoding human neutrophil collagenase. Blood. 1991;77:2731-38. 
280. Im HJ, Li X, Muddasani P, et al. Basic fibroblast growth factor accelerates 
matrix degradation via a neuro-endocrine pathway in human adult articular 
chondrocytes. J Cell Physiol. 2008;215:452-63. 
Introduction - 53 
 
281. Yang CM, Chien CS, Yao CC, et al. Mechanical strain induces collagenase-3 
(MMP-13) expression in MC3T3-E1 osteoblastic cells. J Biol Chem. 
2004;279:22158-65. 
282. Galboiz Y, Shapiro S, Lahat N, et al. Modulation of monocytes matrix 
metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: 
implications to multiple sclerosis. J Neuroimmunol. 2002;131:191-200. 
283. Haque NS, Fallon JT, Pan JJ, et al. Chemokine receptor-8 (CCR8) mediates 
human vascular smooth muscle cell chemotaxis and metalloproteinase-2 
secretion. Blood. 2004;103:1296-304. 
284. Wisithphrom K, Windsor LJ. The effects of tumor necrosis factor-alpha, 
interleukin-1beta, interleukin-6, and transforming growth factor-beta1 on pulp 
fibroblast mediated collagen degradation. J Endod. 2006;32:853-61. 
285. Yakubenko VP, Lobb RR, Plow EF, et al. Differential induction of gelatinase B 
(MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-
mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell 
Res. 2000;260:73-84. 
286. Brown RD, Jones GM, Laird RE, et al. Cytokines regulate matrix 
metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res 
Commun. 2007;362:200-205. 
287. Ichiyama T, Kajimoto M, Hasegawa M, et al. Cysteinyl leukotrienes enhance 
tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human 
monocytes/macrophages. Clin Exp Allergy. 2007;37:608-14. 
288. Owen CA, Hu Z, Barrick B, et al. Inducible expression of tissue inhibitor of 
metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of 
neutrophils. Am J Respir Cell Mol Biol. 2003;29:283-94. 
289. Blindt R, Vogt F, Lamby D, et al. Characterization of differential gene 
expression in quiescent and invasive human arterial smooth muscle cells. J 
Vasc Res. 2002;39:340-352. 
290. Hanemaaijer R, Koolwijk P, le Clercq L, et al. Regulation of matrix 
metalloproteinase expression in human vein and microvascular endothelial 
cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. 
Biochem J. 1993;296 ( Pt 3):803-9. 
54 - Chapter 1 
 
291. Mix KS, Attur MG, Al Mussawir H, et al. Transcriptional repression of matrix 
metalloproteinase gene expression by the orphan nuclear receptor NURR1 in 
cartilage. J Biol Chem. 2007;282:9492-504. 
292. Tamai K, Ishikawa H, Mauviel A, et al. Interferon-gamma coordinately 
upregulates matrix metalloprotease (MMP)-1 and MMP-3, but not tissue 
inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes. J 
Invest Dermatol. 1995;104:384-90. 
293. Unoki H, Bujo H, Jiang M, et al. Macrophages regulate tumor necrosis factor-
alpha expression in adipocytes through the secretion of matrix 
metalloproteinase-3. Int J Obes (Lond). 2008;32:902-11. 
294. Warstat K, Pap T, Klein G, et al. Co-activation of synovial fibroblasts by 
laminin-111 and transforming growth factor-beta induces expression of matrix 
metalloproteinases 3 and 10 independently of nuclear factor-kappaB. Ann 
Rheum Dis. 2008;67:559-62. 
295. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase 
members in leukocytes emphasize monocytes as major inflammatory 
mediators in multiple sclerosis. Brain. 2003;126:2738-49. 
296. Rechardt O, Elomaa O, Vaalamo M, et al. Stromelysin-2 is upregulated during 
normal wound repair and is induced by cytokines. J Invest Dermatol. 
2000;115:778-87. 
297. Bertram C, Hass R. MMP-7 is involved in the aging of primary human 
mammary epithelial cells (HMEC). Exp Gerontol. 2008;43:209-17. 
298. Graesslin O, Cortez A, Fauvet R, et al. Metalloproteinase-2, -7 and -9 and 
tissue inhibitor of metalloproteinase-1 and -2 expression in normal, 
hyperplastic and neoplastic endometrium: a clinical-pathological correlation 
study. Ann Oncol. 2006;17:637-45. 
299. Pirila E, Korpi JT, Korkiamaki T, et al. Collagenase-2 (MMP-8) and matrilysin-
2 (MMP-26) expression in human wounds of different etiologies. Wound 
Repair Regen. 2007;15:47-57. 
300. Ripley D, Tunuguntla R, Susi L, et al. Expression of matrix metalloproteinase-
26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and 
ovarian carcinoma. Int J Gynecol Cancer. 2006;16:1794-800. 
Introduction - 55 
 
301. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed 
in human tumors and showing the minimal domain organization required for 
secretion, latency, and activity. Cancer Res. 2000;60:4745-51. 
302. Cury PR, Canavez F, de Araujo VC, et al. Substance P regulates the 
expression of matrix metalloproteinases and tissue inhibitors of 
metalloproteinase in cultured human gingival fibroblasts. J Periodontal Res. 
2008;43:255-60. 
303. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver 
fibrosis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G245-G249. 
304. Lambert CA, Colige AC, Munaut C, et al. Distinct pathways in the over-
expression of matrix metalloproteinases in human fibroblasts by relaxation of 
mechanical tension. Matrix Biol. 2001;20:397-408. 
305. Schonherr E, Schaefer L, O'Connell BC, et al. Matrix metalloproteinase 
expression by endothelial cells in collagen lattices changes during co-culture 
with fibroblasts and upon induction of decorin expression. J Cell Physiol. 
2001;187:37-47. 
306. Toft-Hansen H, Nuttall RK, Edwards DR, et al. Key metalloproteinases are 
expressed by specific cell types in experimental autoimmune 
encephalomyelitis. J Immunol. 2004;173:5209-18. 
307. Milner JM, Rowan AD, Cawston TE, et al. Metalloproteinase and inhibitor 
expression profiling of resorbing cartilage reveals pro-collagenase activation 
as a critical step for collagenolysis. Arthritis Res Ther. 2006;8:R142. 
308. Nocito A, Dahm F, Jochum W, et al. Serotonin regulates macrophage-
mediated angiogenesis in a mouse model of colon cancer allografts. Cancer 
Res. 2008;68:5152-58. 
309. Beck IM, Muller M, Mentlein R, et al. Matrix metalloproteinase-19 expression 
in keratinocytes is repressed by transcription factors Tst-1 and Skn-1a: 
implications for keratinocyte differentiation. J Invest Dermatol. 2007;127:1107-
14. 
310. van Horssen J, Vos CM, Admiraal L, et al. Matrix metalloproteinase-19 is 
highly expressed in active multiple sclerosis lesions. Neuropathol Appl 
Neurobiol. 2006;32:585-93. 
56 - Chapter 1 
 
311. Zhang Y, Yan Q, Li W, et al. Fluoride down-regulates the expression of matrix 
metalloproteinase-20 in human fetal tooth ameloblast-lineage cells in vitro. Eur 
J Oral Sci. 2006;114 Suppl 1:105-10. 
312. Skoog T, Elomaa O, Pasonen-Seppanen SM, et al. Matrix Metalloproteinase-
21 Expression Is Associated with Keratinocyte Differentiation and Upregulated 
by Retinoic Acid in HaCaT Cells. J Invest Dermatol. 2008. 
313. Velasco G, Pendas AM, Fueyo A, et al. Cloning and characterization of 
human MMP-23, a new matrix metalloproteinase predominantly expressed in 
reproductive tissues and lacking conserved domains in other family members. 
J Biol Chem. 1999;274:4570-4576. 
314. Saarialho-Kere U, Kerkela E, Jahkola T, et al. Epilysin (MMP-28) expression 







Expression of  
Matrix Metalloproteinases-2 and -9 in 
Intestinal Tissue of Patients with 
Inflammatory Bowel Disease (IBD) 




Martin J.W. Meijer 
Frank J.G.M. Kubben 
Cornelis F.M. Sier 
Laurens Kruidenier 
Wim van Duijn 
Marlies van den Berg 
Ruud A. van Hogezand 
Cornelis B.H.W. Lamers 
Hein W. Verspaget 
 
Department of Gastroenterology and Hepatology 
Leiden University Medical Center 
The Netherlands 
 
This Study was published in Dig Liver Dis 2005;37: 584-592 
58  -  Chapter 2 
Abstract 
Background/aims. Matrix metalloproteinases are major contributors in the 
breakdown and reconstitution of basement membranes and extracellular matrix in 
pathophysiological processes. We assessed the expression of matrix 
metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel 
disease. 
Patients/methods. Resected tissue specimens from patients with Crohn’s 
disease or ulcerative colitis and control tissue from patients  with a colorectal 
carcinoma were used for enzyme-linked immunosorbent assay, zymography, 
activity assay, reverse transcription polymerase chain reaction and 
immunohistochemistry to evaluate the expression of these matrix 
metalloproteinases. 
Results. Matrix metalloproteinase-2 and more strongly matrix metalloproteinase-9 
protein and mRNA were markedly increased in inflammatory bowel disease 
tissues, with the highest levels in severely inflamed tissues. Immunohistochemistry 
showed that matrix metalloproteinase-2 was present in the extracellular matrix of 
the submucosa, with a lower but more generalized expression in the severely 
inflamed regions. Matrix metalloproteinase-9 was most prominent in 
polymorphonuclear leukocytes and was increased, also in activity, in all 
inflammatory bowel disease tissues. An increased matrix metalloproteinase-9 
expression in the extracellular matrix was observed in relation to the severity of 
inflammation.  
Conclusions. Matrix metalloproteinases-2 and -9 are enhanced in the intestinal 
tissue and seem to be actively involved in the inflammatory and remodelling 
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Introduction 
Inflammatory bowel diseases (IBD), i.e., Crohn’s disease (CD) and ulcerative colitis 
(UC), are characterized by inflammation and ulceration of the gastrointestinal tract, 
with numerous gastrointestinal tract and systemic complications, but of unknown 
specific aetiology.
1
 In the pathophysiological process of IBD, a variety of 
inflammatory mediators, such as proteolytic enzymes, cytokines and growth 
factors, and many kinds of cells, leukocytes and stromal cells, are implicated in the 
tissue injury and healing processes.
2
 Matrix metalloproteinases (MMPs) are a 
family of Zn
2+
-containing neutral proteinases and are thought to be major 
contributors to breakdown and reconstitution of extracellular matrix (ECM) in 
physiological processes, like tissue remodelling during development, growth and 
wound repair, and in pathological conditions, including destructive diseases, such 
as arthritis, atherosclerotic plaque rupture and tumour progression.
3-5
 In general, 
MMPs are secreted as inactive proenzymes that require proteolytic cleavage for 
activation. The proteolytic activity of MMPs is precisely regulated by the balance 
between zymogen activation and enzyme inhibition through endogenous inhibitors, 
such as α-macroglobulins and tissue inhibitors of metalloproteinases (TIMPs).
6
 To 
date, over 20 members of the MMPs family have been found in vertebrates. 
Depending on substrate specificity, amino acid similarity and identifiable sequence 
modules, MMPs are divided into four major subgroups: collagenases, stromelysins, 
gelatinases and membrane-type MMPs. Gelatinases are composed of two 
members: MMP-2 (gelatinase A), a 72 kD  proteinase, and MMP-9 (gelatinase B), 
a 92 kDa proteinase, which specifically degrade basement membrane (BM) type IV 
collagen, as well as gelatin, collagen type I, V, VII, X, elastin, laminin and 
fibronectin.
7,8
 MMP-2, a most commonly expressed enzyme in normal adult tissue, 
is primarily produced by stromal cells. MMP-9 is mainly synthesized by 
inflammatory cells, particularly polymorphonuclear leukocytes (PMNL).
3,9-11
 The 
expression of MMP-2 and MMP-9 has been found to change in different situations, 
such as embryonic development, diverse pathophysiological conditions and during 
culture.
6,12
 For example, MMPs are proposed to be major factors for intestinal 
tissue injury mediated by T cells in IBD.
13,14
 Previous studies by other groups and 
us showed an aberrant expression of MMPs in CD or UC, either on the protein or 
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mRNA level, or immunohistochemically.
15-22
 In the present study, we evaluated the 
expression of MMP-2 and MMP-9 protein, both in level and localization, and their 
mRNA gene products in relation to mucosal inflammation in patients with CD or 
UC. 
 
Patients and methods 
Patients and tissue samples 
The samples in this study were obtained from surgical resection specimens and 
include pairs of macroscopically inflamed and normal-appearing (non-inflamed) 
mucosa from patients with CD or UC, both clinically and histologically confirmed, 
with normal tissue from patients with a colorectal carcinoma, at least 10 cm from 
the tumour, as controls. Details on the tissue specimens included and patients 
characteristics are described in a previous study.
23
 For the enzyme-linked 
immunosorbent assay (ELISA) assessments, frozen tissues were used from 16 
patients with CD, 14 patients with UC and 16 controls. The reverse transcription 
polymerase chain reaction (RT-PCR) samples consisted of 5 CD, 5 UC and 10 
controls. A total of 47 surgically resected, formalin-fixed, paraffin-embedded 
intestinal tissue specimens, obtained from the Pathology Department of the Leiden 
University Medical Center, were immunohistochemically stained for MMP-2 (CD: n 
= 15, UC: n = 14 and control: n = 15) and for MMP-9 (CD and UC: n = 12 and 
control: n = 16), respectively. 
 
Determination of MMPs by ELISA, zymography and activity assays 
Frozen intestinal tissue samples were homogenized on ice by adding 1 ml 0.1 M 
Tris–HCl/0.1% Tween-80 buffer per 60 mg sample.
23
 MMP-2 and MMP-9 levels in 
the homogenized tissue samples were measured by our highly specific ELISAs, 
which measured the grand total of pro-enzyme, active- and inhibitor-complexed 
forms of the respective MMP, as previously described.
24,25
 In brief, a polyclonal 
anti-MMP-2 antibody or monoclonal anti-MMP-9 antibody was used as catching 
antibody and appropriately diluted samples were incubated overnight at 4 
0
C. 
Immunodetection of MMP-2 was performed using polyclonal anti-MMP-2 followed 
by biotin-labelled goat anti-rabbit-IgG and of MMP-9 with biotin-labelled polyclonal 
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anti-MMP-9 antibody. After incubation with avidin-peroxidase the chromogenic 
substrate 3,3,5,5 -tetramethyl benzidine in the presence of hydrogen peroxide was 
added and the reaction was stopped with H2SO4 and the absorption was measured 
at 450 nm. The amount of MMP was calculated from the parallel standard curve 
and expressed in ng MMP per mg protein. Gelatin-zymography was performed to 
determine the level of the active and pro-enzyme forms of MMPs, as previously 
described.
26
 In brief, standardized homogenate protein amounts in 2% (w/v) 
sodium dodecyl sulphate were electrophorised on gelatin-polyacrylamide gels, 
through which the MMP isoforms are separated on molecular weight and the pro-
enzymes become activated. The gels were subsequently incubated overnight at  
37 
0
C , stained and analyzed for gelatin digestion by laser densitometry. The levels 
were expressed in arbitrary units (AU) related to a uniform internal standard, 
consisting of a colorectal cancer homogenate, containing MMP-2 and MMP-9, used 
in each gel. Active MMP-2 and MMP-9 were also determined by highly specific 
biochemical immunosorbent activity assays (BIA). In brief, microtitre plates were 
coated with the respective MMP antibodies as for the ELISAs. Samples at various 
appropriate dilutions were added and incubated overnight at 4 
0
C. MMP activity 
was determined by adding modified pro-urokinase and peptide substrate S-2444, 
with subsequent absorption measurement at 405 nm overtime and finally 
expressed in U/mg protein.
25 
 
Reverse transcription polymerase chain reaction 
Oligonucleotide primers (Table 1) for the RT-PCR were derived from the DNA 
sequence database of the NCBI (Bethesda, MD, USA). Primer sets were designed 
using the Primers3 Output computer program (Whitehead Institute for Biomedical 
Research, Cambridge, MA, USA). The MMP-2 and MMP-9 PCR products span 
three introns to prevent interference of contamination by genomic DNA. Specificity 
of the primers was checked with the NCBI BLAST program. β-actin was used as a 
control to normalize PCR signals from the different samples. Total RNA was 
isolated from tissue samples by the method of Chomczynski and Sacchi.
27
 The 
integrity and quality of the purified RNA were analysed by 1.5% agarose 
gel/ethidium-bromide staining and the 260/280 nm absorbance ratio. Moloney 
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Murine Leukemia Virus (M-MLV) reverse transcriptase was used for cDNA 
synthesis from DNAse-treated RNA. The PCR was started at 94 
0
C for 3 min 
followed by 30 cycles for MMP-2 and MMP-9, and 28 cycles for β-actin. Each cycle 
consisted of a denaturation step (at 94 
0
C for 30 s.), an annealing step for 45 s (at 
56 
0
C for MMP-2 and β-actin, 59 
0
C for MMP-9) and extension step (at 72 
0
C for 1 
min), followed by a final elongation step (at 72 
0
C for 7 min). The reaction was 
performed in a Whatman T Gradient cycler (Biometra, Goettingen, Germany) and 
the amplified products were electrophorised on 1.5% agarose gels containing 
ethidium-bromide (0.5 g/ml) and visualized under ultraviolet light. An RT-PCR, 
which contained RNA but not M-MLV reverse transcriptase, was used to check 
contamination with genomic DNA. The Scion imaging program (Frederick, 
Maryland, USA, (www.scioncorp.com) was used to semi-quantify the band density 
in the gels. The MMP/β-actin ratios times 10 for MMP-2 and times 100 for MMP-9 
were expressed as AU.  
 
Table 1. Oligonucleotide primers for RT-PCR 
MRNA   Gene  Sense primer      Antisense primer       Product size 
NM-004530  MMP-2  AGGATCATTGGCTACACACC  AGCTGTCATAGGATGTGCCC  535 
NM-004994  MMP-9  CGCAGACATCGTCATCCAGT  GGATTGGCCTTGGAAGATGA  406 
NM-001101  β-actin  GGGTCAGAAGGATTCCTATG  GGTCTCAAACATGATCTGGG  238 
 
Immunohistochemical staining for MMPs 
To assess the localization of MMP-2 and MMP-9 within the intestinal tissues, 
indirect immunohistochemical staining of the MMPs was performed as described 
previously.
23,25
 In brief, paraffin tissue sections, treated with proteinase K for  
MMP-2 antigen retrieval, were incubated with rabbit polyclonal anti-human MMP 
antibodies, similar to those used in the ELISAs. Subsequently, the sections were 
incubated with biotinylated goat anti-rabbit Ig, peroxidase-labelled streptavidin and 
stained with 3-amino-9-ethylcarbazole and haematoxylin. Control sections 
incubated with pre-immune serum or buffer instead of the primary antibodies 
showed no staining. The immunohistochemical staining was semiquantitatively 
assessed using the following scoring system: 0 = no staining, 1 = a few positive 
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cells/areas of tissue or a low staining intensity in all cells, 2 = a minority of the 
cells/areas of tissue positive or a moderate staining intensity in all cells, 3 = a 
majority of the cells/areas of tissue positive and/or a moderate staining intensity in 
all cells and 4 = all cells or areas of tissue strongly positive. 
 
Statistical analysis 
The ELISA, zymography, BIA and RT-PCR results are given as mean ± S.E.M. and 
those of the immunohistochemical evaluation as median with inter-quartile range. 
Significance of the differences between groups were assessed using the Mann–
Whitney U-test or the Wilcoxon signed-ranks test for paired data. Differences were 




The amount of MMP-2 in the intestinal tissue, as determined by ELISA, showed a 
tendency to increase in relation with severity of inflammation in IBD (Fig. 1).  In 
non-inflamed IBD tissue, the amount of MMP-2 was elevated to a near twofold 
higher level compared to control tissue [11.6 ± 1.1 ng/mg protein versus 6.9 ± 0.8 
ng/mg protein]. In inflamed IBD tissue the MMP-2 level was even higher (16.7 ± 
1.7), though not significantly different from non-inflamed tissue. The MMP-2 levels 
between similar tissues of CD and UC did not show any statistically significant 
difference, in both inflamed and non-inflamed tissues of the diseases, but all were 
significantly higher than in the control tissues (Table 2). The zymographic analyses 
revealed that both the active and the pro-enzyme form of MMP-2 are increased in 
IBD (Fig. 2), without major differences between inflamed and non-inflamed tissues 
(Fig. 3) and between CD and UC (Table 3). Despite the increased protein levels, as 
determined by ELISA and zymography, the biochemical activity of MMP-2 was 
found to be not increased in both non-inflamed and inflamed CD and UC tissue 
(Table 4). With RT-PCR also, a two- to threefold increase in the expression of 
MMP-2 mRNA was found in the IBD tissues, although the increase was less 
impressive compared to the protein levels, in comparison to control tissues (Fig. 4). 
Immunohistochemically MMP-2 was most prominently present in the ECM of the 
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Table 2. ELISA results of MMP-2 and MMP-9 in intestinal tissues 
Control (n = 16)  CD (n = 16)       UC (n = 14) 
          Non-inflamed Inflamed   Non-inflamed Inflamed 
MMP-2    6.9 ± 0.8   9.9 ± 1.3*
 
14.4 ± 2.0*    13.4 ± 1.8* 19.2 ± 2.9* 
MMP-9    6.0 ± 1.0   27.7 ± 6.3* 38.2 ± 8.7*,
†





MMPs presented in ng/mg protein (mean ± S.E.M). 
* 0.0005 < P < 0.04 vs. controls. 
† P = 0.08 vs. non-inflamed. 
†† P = 0.02 vs. non-inflamed. 
 
 
Table 3. Zymography results of MMP-2 and MMP-9 in intestinal tissues 
 Control 
(n=16) 
CD (n = 14)  UC (n = 14)  
  Non-inflamed Inflamed Non-inflamed Inflamed 
MMP-2      
Act 0.29 ± 0.06 0.99 ± 0.30 0.69 ± 0.16 * 0.28 ± 0.06 0.99 ± 0.17 * 
††
 
Pro 0.64 ± 0.10 4.11 ± 0.93 * 2.16 ± 0.42 * 1.96 ± 0.23 * 2.79 ± 0.40 * 
†
 
MMP-9      
Act 0.62 ± 0.13 4.41 ± 1.22 * 2.66 ± 0.54 * 1.78 ± 0.62 3.98 ± 0.61 * 
††
 
Pro 1.18 ± 0.19 6.43 ± 0.94 * 8.32 ± 1.24 * 2.64 ± 0.48 * 9.41 ± 1.00 * 
††
 
MMPs presented in AU (mean ± S.E.M.). 
* 0.0005 < P < 0.05 vs. controls, † P = 0.08 vs. non-inflamed, †† P < 0.004 vs. non-inflamed 
 
 




CD (n = 14)  UC (n = 14) 
 
  
Non-inflamed Inflamed Non-inflamed Inflamed 
MMP-2 8.1 ± 1.8 6.1 ± 2.0 6.3 ± 3.0 1.9 ± 1.0 * 8.0 ± 3.9 
MMP-9 6.2 ± 2.5 11.4 ± 3.3 14.9 ± 4.8 32.2 ± 8.7 * 54.5 ± 14.4 * 
†
 
MMPs presented in U/mg protein (mean ± S.E.M.). 
* 0.0005 < P < 0.05 vs. controls, † P = 0.008 vs. non-inflamed.  











Figure 1. MMP-2 (open bars) and MMP-9 (grey bars) ELISA results in mean ± S.E.M. There 
was a highly significant difference between control and IBD tissues; the MMP levels 
increased with inflammation. 
*
P ≤ 0.005 vs. controls;
(†) 
P = 0.07; 
†
P  = 0.005 vs. non-
inflamed. IBD: inflammatory bowel disease. 
 
 
Figure 2. Example gelatin zymograms of non-inflamed and inflamed IBD tissue 
homogenates compared to control tissue and internal standard, identifying pro- and active 
MMP-2 and MMP-9. St: internal standard, C: control, CD: Crohn’s disease, UC: ulcerative 
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Figure 3. MMP-2 (hatched bars) and MMP-9 (dotted bars) zymography results in mean ± 
S.E.M. Both the active and pro-enzyme forms of MMP-2 and MMP-9 were increased in IBD 
tissues, only pro-MMP-9 increased further with inflammation.
*
P ≤ 0.02 vs. controls; †P = 
0.0005 vs. non-inflamed, AU: arbitrary units, IBD: inflammatory bowel disease, act: active 














Figure 4. MMP-2 (open bars) and MMP-9 (hatched bars) RT-PCR results in mean ± S.E.M. 
Similar to the expression pattern of the proteins there was an increase in mRNA in IBD 
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submucosa in every tissue group (Table 5 and Fig. 5A). This diffuse MMP-2 
staining was patchy and relatively strong in the deeper layer of the submucosa in 
the control tissues and in non-inflamed regions of IBD tissues, but was found to be 
significantly decreased in severely inflamed regions, where it was seen throughout 
the submucosa (Fig. 5B and C). This decreased staining intensity in inflamed 
tissue was observed in CD as well as in UC, although in the latter, the overall 
MMP-2 staining was found to be more prominent [non-inflamed: UC 2.5 (1.3–2.5) 
versus CD 1.3 (0.5–2.0) and inflamed: UC 1.5 (1.0–1.5) versus CD 0.5 (0.5–1.0); 
both P = 0.02]. In addition, a weak diffuse cytoplasmic staining for MMP-2 was  
 
Figure 5. The prominent location of MMP-2 was in the submucosa, especially in controls (A, 
×200); in inflamed tissues of CD and UC (B and C, ×200) MMP-2 was seen as a weak but 
more generalized positive reaction in the ECM. 
68  -  Chapter 2 
present in some epithelial cells of all tissue groups. In some cases, we also found a 
positive staining of the basement membrane (BM) and/or (myo)fibroblasts 
underneath the luminal epithelium, not related to the positive staining in epithelial 
cells (data not shown). 
 
 
Table 5. Predominant immunohistochemical expression of MMP-2 and MMP-9 in intestinal 
tissues 
  
Control (n=16) IBD 
   
   Non-inflamed  Inflamed  
MMP-2       
  submucosa 2.0 (1.5-2.5) 
a
 2.0 (1.0-2.5)  1.0 (0.5-1.5) *
†
 (n = 29) 
MMP-9       
PMNL  0.8 (0.5-1.9) 2.0 (1.0-2.0) *  2.0 (1.5-2.9) * (n = 24) 
Matrix  0.5 (0.5-0.5) 0.5 (0.0-0.5)  1.0 (0.5-1.5) *
†
 (n = 24) 
PMNL: polymorphonuclear leukocytes 
a




MMP-9 in the intestinal mucosa was found to have a similar pattern to that of  
MMP-2. An elevated protein level in non-inflamed IBD tissue increased nearly 
fourfold (25.7 ± 5.4 versus 6.0 ± 1.0), and it further increased in inflamed IBD tissue 
up to sevenfold (44.3 ± 6.7), compared to controls (Fig. 1). Again no significant 
differences in the MMP-9 levels between inflamed tissues of CD and UC, as well 
as between non-inflamed tissues, were found (Table 2), but all were enhanced 
compared to control tissues. With zymography both the active and the pro-enzyme 
form of MMP-9 were found to be significantly increased in IBD (Fig.2), and 
predominantly pro-MMP-9 was found to increase further with inflammation (Fig. 3)  
in both CD and, particularly, UC (Table 3). In addition, the biochemical activity of 
MMP-9 was found to be increased in non-inflamed and inflamed CD and UC tissue, 
although it only reached statistical significance in UC (Table 4). Similar to the 
protein level, the expression of MMP-9 mRNA was also increased in the IBD 
tissues, twofold in non-inflamed and about fourfold in inflamed tissue, although no 
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statistical significance was reached (Fig. 4). Immunohistochemically, a pronounced 
positive staining for MMP-9 in PMNL was found throughout the intestinal walls. An 
increased immunoreactivity of granular MMP-9 positive PMNL was observed in all 
IBD tissues, both non-inflamed and inflamed, compared to controls (Fig. 6A-C and 
Table 5). In addition, a weak positive reaction of MMP-9 was found in the ECM, 
which was found to be increased with severity of the inflammation in IBD tissues 
(Table 5). Occasionally macrophages positive for MMP-9 were found, 
predominantly in inflamed areas (Fig. 6D and E). In normal tissues and non-
inflamed IBD tissues, no other major cell types showed MMP-9 staining. Overall, 




IBD is characterised by a high intestinal tissue turnover during the sequence of 
inflammation, tissue destruction and healing. During inflammatory processes there 
are different phases, which include the acute reaction, breakdown and proliferation 
of cells, and remodelling of tissue, with overlap between these phases, indicating 
that destruction and healing of tissue form a continuum. In the present study, we 
found the expression of MMP-2 at both the protein and mRNA level to be increased 
in intestinal IBD tissues, with the highest levels in inflamed areas, as analyzed on 
full thickness mucosal tissues. Immunohistochemical evaluations showed that in 
the severely inflamed regions the MMP-2 staining was distributed throughout the 
ECM within the mucosa and submucosa, although the intensity was less than in 
controls and non-inflamed IBD tissues, where it was found only in the submucosa. 
Apparently, there is a generalized demand of MMP-2 from inflammatory tissues in 
IBD, indicative of MMP-2 involvement in the enhanced intestinal tissue turnover. 
Yet, this was not reflected by an enhanced activity of MMP-2 as assessed by the 
BIA assay of the homogenates. Thus, the increased MMP-2 protein level does not 
seem to be under-balanced by endogenous inhibitors with respect to its activity. 
MMP-2 is most commonly expressed and can be isolated in large quantities from 
normal quiescent tissues and is believed to participate in the maintenance of  
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Figure 6. A pronounced positive staining for MMP-9 in leukocytes in inflamed areas of CD 
was found (A, ×200); neutrophils in inflamed tissue of CD were strongly positive for MMP-9 
(B, ×1000); few leukocytes in control tissue were MMP-9 positive (C, ×400); MMP-9 in cells 
and ECM in UC inflamed area surrounding a necrotic region (D, ×200); and MMP-9 positive 
macrophages in inflamed tissue of UC (E, ×1000). 
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 postulated that the 
activation of MMP-2 contributed to the degradation of the basal membrane type IV 
collagen and loss of epithelial organization in active IBD. In addition, Pender et al.
31
 
showed that membrane type-1 MMP, an important activator of MMP-2, is 
upregulated in IBD tissue. More recent studies also showed the enhanced 
expression of MMP-2 in IBD intestine, particularly in the stromal compartment, e.g. 
(myo)fibroblasts, which participates in the ECM remodelling, collagen and 
basement membrane turnover leading to intestinal ulceration, epithelial damage 
and/or fistula formation.
19-21,32
 From these studies and our observations we 
conclude that MMP-2 mainly participates in the intestinal tissue remodelling, in 
addition to its role in acute inflammation in IBD. MMP-2 is known to be able to 
cleave/activate cytokines, growth factors and MMPs themselves.
33-35
 The 
resultants, processed by MMP-2, are important modulators in the inflammatory 
reactions and healing process in IBD, such as interleukin (IL)-1, an important 
proinflammatory cytokine, fibroblast growth factor (FGF) receptor-1 ectodomain, 
which modulates the angiogenic activity of FGF, inactivated monocyte 
chemoattractant protein (MCP)-3, all affecting the inflammatory response.
36,37
 
There seems to be consensus about the increased protein level of MMP-2 in 
intestinal IBD tissues, either determined by ELISA, zymography or western 
blotting.
18,20,22 
Yet, about the localization and mRNA expression of MMP-2 in IBD 
there remains some controversy. The predominant cell type identified to contain 
MMP-2 mRNA were the myofibroblasts underneath the epithelium and fibroblasts 
within the submucosa.
19,22,32
 Immunohistochemically, however, either no,
16
 diffuse 
(present study) or diverse positive cells
22
 were seen. One of the main reasons of 
this inconsistency is probably the sequestration of MMP-2 to the matrix 
components, which prohibits an exact localization.
38
 Similar to the study by von 
Lampe et al.
19
, we found a (marginally) elevated MMP-2 mRNA level in inflamed 
intestinal IBD tissue. Although the post-transcriptional regulation of MMP-2 is 
probably more important than the transcriptional regulation in the expression of 
MMP-2, the enhanced MMP-2 mRNA expression in IBD might also be the result of 
a higher demand due to tissue remodelling rather than the effect of inflammatory 
mediators on the transcription of the MMP-2 gene. The regulation of the MMP-2 
72  -  Chapter 2 
gene transcription, for example, is not induced by proinflammatory cytokines, like 
IL-1 or tumour necrosis factor (TNF)-α, because the promoter region of MMP-2 
lacks an AP-1 binding site, as present in other MMP genes, which binds the 
transcriptional factor AP-1 induced by proinflammatory agents.
10 
Yet, transforming 
growth factor (TGF)-β, which is a potential modulator and inhibitor of the 
inflammatory reaction in IBD, induces the transcription and prolongs the half-life 
time of MMP-2 mRNA.
10,39
 Thus, the production of MMP-2 seems to be delicately 
regulated during inflammatory and healing processes in IBD. 
In general, the constitutive expression of MMPs is rather low, with the exception of 
the neutrophil MMPs MMP-8 and MMP-9.
4,5
 It is believed that MMP-9 is stored in 
the secondary and tertiary granules of neutrophils for rapid release into 
inflammatory sites.
5
 We found the amount of MMP-9 protein to be increased in 
relation to inflammation in full thickness IBD mucosal tissue, in both CD and UC. 
This increased expression of MMP-9 was previously reported by several other 
groups, either by zymographic analysis or immunohistochemically, confirmed by in 
situ hybridisation for mRNA.
15,18,22
 Uniformly, the PMNL were identified as the main 
source of MMP-9 within intestinal tissues, with occasionally positive macrophages, 
whereas myofibroblasts were found to be MMP-9 negative, the latter also 
confirmed  by in vitro studies.
32
 A diffuse matrix/ECM positivity for MMP-9 was also 
occasionally noticed, probably caused by sequestration of the excreted MMP-9 to 
the stroma, as mentioned previously for MMP-2. Interestingly, all studies reported 
an enhanced level of MMP-9 in the non-involved/non-inflamed IBD tissue, 
sometimes without a clear difference from the inflamed tissue.
18
 This phenomenon 
seems to be due to the fact that macroscopically non-involved IBD tissue does 
have an increased amount of inflammatory cells, particularly PMNL containing 
MMP-9,
18
 as exemplified by increased myeloperoxidase levels.
40
 In general, the 
studies demonstrate that MMP-9 participates actively in the inflammatory process 
of IBD, especially in the acute phase. Our BIA analysis also revealed an enhanced 
MMP-9 activity in association with severity of inflammation of the tissue in CD as 
well as, and most prominently, in UC. Apparently, this enhanced MMP-9 activity in 
severely inflamed IBD tissue is not counteracted by the simultaneously twofold 
increased level of TIMP-1 (unpublished observation). An improper activity of  
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MMP-9 is thought to cause the destruction of tissue via the degradation of 
components of the ECM and, in addition, to influence the generation or activation 
of neutrophilic chemokines, promoting neutrophil migration across the basement 
membrane of capillaries.
3,5,8,41 
The ECM fragments produced by the activation of 
MMP-9 are also known to be chemotactic for inflammatory cells.
7
 In a previous 
study, we also showed that TNF-α is an important regulator of the transcription of 
MMP-9 mRNA in blood leukocytes in patients with CD.
42
 Furthermore, Sanceau et 
al.
43
 reported that TNF-α can activate the MMP-9 gene transcription through 
regulation of the nuclear factor (NF)-κB activation. Recently, Kirkegaard et al.
22
 
reported that MMP-9 contributes to fistula formation in CD through degradation of 
the ECM, whereas, it has been reported that MMP-9 has a function in tissue repair 
by facilitating re-epithelialisation and degradation of denatured collagen.
30
 Thus, 
similar to MMP-2, MMP-9 also seems to contribute to the different phases of the 
intestinal inflammatory process, from damage to repair, which is not specific for 
IBD and has also been observed in other inflammatory processes and even in 
malignant diseases.
3-8 
In the context of the involvement of TNF-α in the regulation 
of MMP-9 synthesis, it would be interesting to assess the effects of the very 
effective treatment of patients with CD with the (chimeric monoclonal) antibodies 
against TNF-α on the expression of this MMP. Taken together, MMP-2 and MMP-9 
in the intestinal tissue seem to be actively involved in the inflammatory and 
remodelling processes in IBD. Further evaluation of these factors in relation to 
treatment response and clinical course of the diseases is warranted. 
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Abstract 
Background/aims. Previous studies have shown an upregulation of matrix 
metalloproteinases (MMPs) in intestinal tissue of patients with inflammatory bowel 
disease (IBD) and significant clinical improvement after administration of the anti-
TNF-α antibody infliximab. The aims of our study were to determine expression 
and secretion of MMP-1, -2, -3, -9, and their inhibitors TIMP-1, -2 by IBD versus 
control intestinal mucosa ex vivo and to assess the regulatory capacity by 
infliximab of the proteolytic phenotype. 
Methods. Intestinal mucosal explants from 20 IBD and 15 control patients were 
cultured with or without infliximab and/or the T-cell activator pokeweed mitogen 
(PWM). Explants and culture supernatants were analyzed for MMPs, TIMPs, and 
TNF-α protein, activity and/or mRNA levels. All patients were genotyped for 
functional TNF-α, MMP, and TIMP single nucleotide polymorphism (SNP) loci. 
Results. Expression of MMP and TIMP protein/activity in basal medium was higher 
in IBD versus control explants. Dependent on genotype at SNP loci, infliximab 
downregulated MMP-1, -3, and -9 relative to TIMP-1 and -2 and also decreased 
MMP-1 and -3 activities, while PWM enhanced these levels, partly counteracted 
again by infliximab. The expression of MMP-2 relative to TIMP did not change by 
treatment with infliximab and/or PWM. 
Conclusions. The high expression of MMPs in patients with IBD suggests a role 
for these proteinases in the pathogenesis of this disease. Infliximab seems to 
induce a genotype-associated matrix protective phenotype, which may contribute 
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Introduction 
Patients with Crohn’s disease (CD) suffer from multifocal transmural inflammation 
potentially affecting the whole gastrointestinal lining, but most often localized in the 
ileocecal region, while patients with ulcerative colitis (UC) have a more superficial 
continuous mucosal inflammation, affecting the colon only. In both forms of 
inflammatory bowel disease (IBD), the sustained inflammation may cause severe 
tissue damage, translating into clinical complaints such as diarrhea, cramps, weight 
loss, blood iron deficiency, etc. When refractory to medical treatment or due to 
complications this may result in surgical resection of the affected bowel. Early 
studies have shown an upregulation of several cytokines in IBD and TNF-α seems 







 and cultured intestinal 
biopsies.
5
 Considering its pleiotropic proinflammatory nature, a chimeric 
monoclonal antihuman TNF-α antibody was engineered6 and found to be 
beneficial to a large proportion of CD and UC patients refractory to standard 
treatment with steroids.
7-9
 Matrix metalloproteinases (MMPs) constitute a family of 
diverse matrix degrading zinc- and calcium-activated neutral endoproteinases, 
some of which are under cytokine control and are implicated in a wide range of 
biological processes including angiogenesis, implantation, and cancer 
metastasis.
10
 A marked upregulation of MMP-1, -2, -3, -7, -9,-10, -12, -13, and -14 
mRNA and/or (active) protein levels has been demonstrated in the intestinal 
mucosa of IBD patients, shifting the balance between these proteinases and their 
natural inhibitors, i.e., tissue inhibitors of metalloproteinases (TIMPs),
11
 toward a 
net proteolytic activity.
12-17 
The enhanced expression of MMPs near ulcera in 
inflamed IBD intestinal tissue reinforces the potential pathogenic role of these 
proteinases. Also, in the rat trinitrobenzenesulfonic acid and human pokeweed 
mitogen (PWM)-activated fetal intestinal models of IBD the application of MMP 
inhibitors was associated with a decrease in inflammation score and/or tissue 
damage,
18-20 
while in the murine dextran sodium sulfate model of UC inhibition of 
macrophage migration inhibitory factor was associated with reduction of 
inflammation, tissue damage, and diminished MMP-13 expression.
21 
 Based on 
these data, we speculated that infliximab might be of clinical benefit through an 
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inhibition of TNF-α-mediated increase in net MMP activity. We experimentally 
manipulated the concentration of bioavailable TNF-α in IBD mucosa ex vivo and 
studied the effects on the expression and/or activities of MMP-1, -2, -3, -9, and 
TIMP-1, -2. Recently, a number of single nucleotide polymorphisms (SNPs) in the 
genes coding for TNF-α, MMPs, and TIMPs have been described and several of 
these SNPs were shown to be functional and/or related to the pathogenesis of 
various diseases.
22-27
 We therefore also examined the effects of these SNPs on 
TNF-α-regulated MMP and TIMP expression. 
 
Patients and methods 
Patients and tissue samples 
Demographic and clinical data of the patients are depicted in Table 1. Diagnosis of 
CD or UC was based on standard clinical, endoscopic, radiologic, and 
histopathologic findings. Judged by the presence of ulcera, erythematous 
appearance, marked bowel wall thickening, and/or loss of circular folding, surgically 
resected IBD tissue was considered macroscopically normal or affected. The 
control group consisted of three patients with diverticular disease and 12 patients 
with neoplasia; normal tissue was collected at least 10 cm away from affected 
tissue. Most IBD but none of the control patients received immunosuppressive 
therapy prior to surgery. 
 
Tissue culture 
Resection specimens were obtained at the Pathology Department of the Leiden 
University Medical Center within 1 hour after surgical removal and transported in  
L-15 medium supplemented with penicillin and streptomycin to the laboratory of the 
Gastroenterology Department. After thorough washing in L-15, mucosa and 
submucosa were carefully separated from muscularis externa and serosa. Mucosal 
layers were cut in ≈ 3x3 mm preweighted explants and cultured per 10 parts in  
6-well culture plates containing 3.5 mL CMRL-1066 basic medium, modified 
according to Autrup et al,
28
 with the omission of cortisone. Culture plates were  
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Table 1. Demographic and clinical data of the IBD and control patients included in the 
explant cultures 
             CD     UC     Control 
No. of patients          11     9     15 
Median age in years (range)      34 (16–54)    42 (24–75)   66 (41–83) 
Male/female          4/7     4/5     8/7   
Ileum/colon           5/16    1/10    1/15 
Normal/affected tissue        6/15    1/10    16/0 
No. of patients with 
medication 
— Mesalazine          8     4    -  
— Steroids           9     7    - 
— Azathioprine, 
cyclosporine          6     6    - 
— Infliximab          1     0    -  
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis. 
 
positioned in a sealed box (Billups-Rothenberg, Del Mar, CA), which was 
subsequently filled with 95% O2/ 5% CO2 according to the manufacturer’s 
instructions and placed on a rocking platform. Explants were cultured for 72 hours 
at 37 
0
C with replenishment of medium at 24 and 48 hours, and supernatants and 
explants were stored at -70 
0
C until subsequent analysis. Infliximab (Centocor, The 
Netherlands, final concentration 0.14 mg/mL corresponding to physiological plasma 
concentration in CD patients and completely neutralizing TNF-α biological 
activity
29
) and T/B cell activator pokeweed mitogen (PWM, Sigma, The 
Netherlands, final dilution 1:100 according to manufacturer’s protocol) were added 
to parallel incubations. 
 
Immunohistochemistry 
Frozen explants were cut into 7-µm sections and fixed in formaldehyde and 
Carnoy’s modified medium. After blocking of endogenous peroxidase and 
nonspecific binding by 0.3% hydrogen peroxide in methanol and normal goat 
serum, respectively, sections were incubated overnight with mouse antihuman 
cytokeratin 18 antibody (Santa Cruz Bio-technology, Santa Cruz, CA). 
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Subsequently, biotinylated goat antimouse antibody and streptavidin-HRP 
conjugate (DAKO, Glostrup, Denmark) were added. Conversion of amino-9-
ethylcarbazole in the presence of hydrogen peroxide resulted in a clear red 




Tissue homogenates (25 mg/mL) were prepared in 0.1 M Tris-HCl, 0.1% Tween 
80, pH 7.5, using a Potter device (B. Braun, Germany).
30 
The TNF-α (Biosource, 
Camarillo, CA), MMP-2, -9 (in-house), TIMP-1,-2 (R&D Systems, Minneapolis, MN) 
protein levels in tissue homogenates and/or culture supernatants were measured in 
parallel with appropriate standards by highly specific enzyme-linked 
immunosorbent assays (ELISA) according to the manufacturer’s instructions or as 
described previously.
31,32
 Values of TNF-α obtained from infliximab containing 
samples were multiplied 5-fold to correct for 80% inhibition of measurement of 
TNF-α by this antibody.
33 
The MMP ELISAs recognize latent, active, and TIMP-
complexed forms with comparable high efficiencies. Levels of MMP-1 and -3 were 
measured by specific immunocapture bioactivity assays from Amersham 
Biosciences (Arlington Heights, IL).
34 
Briefly, MMP was captured from samples by 
immobilized MMP-specific antibodies and incubated in buffer with/without  
p-aminophenyl mercuric acetate (APMA) to measure the total of APMA activatable 
and endogenously active MMP (MMPt) or active MMP only (MMPa), respectively. 
Subsequently, pro-urokinase modified to contain an MMP recognition cleavage site 
was added and the color of chromogenic substrate converted by MMP-activated 
urokinase was measured at 405 nm. Values are expressed in arbitrary units and 
show good linear correlation with sample MMP protein. 
 
Semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) 
Intestinal mucosa in 4 mL guanidinium thiocyanate solution was homogenized 
using a Turrax device (IKA-Werke, Germany) and RNA was isolated as described 
previously.
35
 Four micrograms of DNAse (Sigma)-treated RNA were reverse  
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transcribed with MMLV reverse transcriptase (Invitrogen, The Netherlands) in a 
final volume of 40 µL according to the manufacturer’s protocol with only small 
modifications. Subsequently, cDNA was diluted 20–40,000-fold in a final volume of 
25 µL and amplified with Red Taq DNA polymerase (Sigma) and target-specific 
primers using a thermal cycler from Biometra (Germany). The PCR protocol 
consisted of a 3’ DNA denaturation step at 94 °C, 28–33 amplification cycles (30 
sec at 94 °C, 45 sec at 56–60 °C and 1 min at 72 °C each) and a final extension 
step of 7 minutes at 72 °C. Oligonucleotide primers were published elsewhere
36
 or 
designed using the Primer3 software (Whitehead Institute for Biomedical Research, 
Cambridge, MA) and are as follows (sense, antisense, 5’ to 3’): 
GGGTCAGAAGGATTCCTATG and GGTCTCAAACATGATCTGGG (β-actin); 
GATATCGGGGCTTTGATGTA and TCCTTGGGGTATCCGTGTAG (MMP-1); 
AGGATCATTGGCTACACACC and AGCTGTCATAGGATGTGCCC (MMP-2); 
CGATGCAGCCATTTCTGATA and TGTGACAAGGTGCAAGCTAAG  
(MMP-3); CGCAGACATCGTCATCCAGT and GGATTGGCCTTGGAAGATGA 
(MMP-9); CCCCAGGGACCTCTCTCTAA and GGAAGACCCCTCCCAGATAG 
(TNF-α) resulting in 238, 398, 535, 486, 406, and 413 bp products. The amplified 
DNA was visualized on agarose gel by UV transillumination, scanned using SCION 
software (www.scioncorp.com), and quantified essentially as described by Murphy 
et al,
37 
with β-actin normalized values representing expression in arbitrary units 
relative to a positive standard run in parallel. Appropriate RNA-MMLV and cDNA 
controls were run along and always found to be negative. 
 
Single nucleotide polymorphism analysis 
Genomic DNA reconstituted in Tris-EDTA buffer was routinely obtained using an 
adapted blood leukocyte DNA isolation protocol.
38 
The genotype at (SNP) loci 
MMP-1 -1607 1G/2G, MMP-3 -1613 5T/6T, MMP-9 -1562 C/T, TIMP-1 +372 T/C, 
TIMP-2 +303 G/A, and TNF-α -308 G/A were determined by restriction fragment 
length polymorphism (RFLP) analysis. Primers, restriction enzymes, and gel 
restriction fragment pattern corresponding to genotype are specified in Table 2. 
The SNP at MMP-2 -1306 C/T was analyzed by tetra primer amplification refractory 
mutational system (ARMS) PCR, the principles of which are described elsewhere.
39 
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Table 2. Specification of primers and restriction enzymes used for analysis of SNPs in MMP, 
TIMP, and TNF-α genes with size of PCR products on agarose gel and inferred genotype. 
 
Gene/SNP  Forward and reverse primers     Restriction  Products  
                  Enzyme  (bp)/genotype 
 
MMP-1         GAAATTGTAGTTAAATCCTTAGAAAG    EcoN I  120;120+99+21;99+21 
–1607 1G/2G        TATGGATTCCTGTTTTCTTTCTGC       1G1G;1G2G;2G2G 
 
 
MMP-2    ACCAGACAAGCCTGAACTTGTCTGA               542+379;542+379+211; 




MMP-3    CTTCCTGGAATTCACATCACTGCCACCACT  Tth111 I       130;130+97+32; 
–1613 5T/6T   GGTTCTCCATTCCTTTGATGGGGGGAAAGA        97+32  6T6T;6T5T;5T5T 
 
MMP-9    ATGGCTCATGCCCGTAATC      SpH I   352;352+208+144; 
–1562 C/T    TCACCTTCTTCAAAGCCCTATT            208+144  CC;CT;TT 
 
TIMP-1    GCACATCACTACCTGCAGTC      BssS I           175;175+155+20; 
+372 T/C   GAAACAAGCCCACGATTTAG       155+20 TT or T;CT;CC or C 
 
TIMP-2    CCTCCTCGGCAGTGTGTG      TspR I   12+16;112+97+24+16; 
+303 G/A   TAGGAACAGCCCCACTTCTG          97+24+16 GG;GA;AA 
 
TNF-α    GAGGCAATAGGTTTTGAGGGCCAT    Nco I    126+21;147+126+21; 
–308 G/A    GGGACACACAAGCATCAAG                   147  GG;GA;AA 
 
SNP, single nucleotide polymorphism; PCR, polymerase chain reaction. Analysis of SNP 
MMP-2 –1306 was performed by tetra primer ARMS PCR which involves four 
oligonucleotide primers but no restriction enzyme. Primers and restriction enzymes for the 
analysis of SNPs at MMP-1, MMP-3, TIMP-1 and TNF-α loci are from references 55, 56, 57, 
and 58, respectively. 
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Analysis of SNP MMP-2 -1306 was performed by tetra primer ARMS PCR, which 
involves four oligonucleotide primers but no restriction enzyme. Primers and 
restriction enzymes for the analysis of SNPs at MMP-1, MMP-3, TIMP-1, and  
TNF-α loci are from previous publications,55-58 respectively. 
 
Statistical analysis 
At the protein level, data are presented as means ± SEM and statistical 
significance of differences between groups was assessed by (paired) Student’s t-
test. At the mRNA level, data are presented as median (range) and statistical 
analysis was performed by Mann–Whitney U- and Wilcoxon signed ranks test. 
Correlations were calculated by Spearman’s ranks test; all P-values are two-tailed 




Validation of culture 
After 72 hours of culture in basal medium, lamina propria, muscularis mucosae, 
and submucosa were still clearly identifiable. Mucosa contained considerable 
numbers of crypts and lamina propria was covered by large stretches of   
cytokeratin-18-expressing columnar epithelial cells, with interindividual variation 
depending on starting tissue. Occasional mucosal edema was noted (Fig. 1). 
Addition of PWM caused significant time-dependent deterioration of tissue and 
after 72 hours crypts and epithelial coverage were no more present. In the lamina 
propria, condensed nuclei heavily stained with eosin were frequently observed at 
72 hours, most likely representing activated lymphocytes. Addition of infliximab to 
basal medium or next to PWM did not alter explant morphological appearance. 
Replenishment of medium at 24 and 48 hours more closely maintained 
physiological pH as judged by medium color but did not improve explant 
morphology. 
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Figure 1. Immunohistochemical staining of cultured intestinal explants. Preculture tissue of 
a control patient (A) and after 24, 48, and 72 hours in basal medium (B–D, respectively). 
Note the good preservation of morphology and presence of red-colored cytokeratin-18-
expressing epithelial cells. After incubation with PWM for 24 hours, tissue was still well 
preserved (E). However, prolonged incubation resulted in a gradual deterioration at 48 and 
72 hours (F versus G). Fibrotic (H,I) and normal-appearing tissue (J–N) from a CD patient. 
After 72 hours culture in basal medium, morphology is well preserved (I, K) compared with 
preculture tissue (H, J). Incubation with PWM resulted in severe tissue destruction at 72 
hours (M) and infliximab did not improve morphology, either next to PWM treatment (N) or 
added to basal medium (L). Similar results were obtained for (affected) CD, UC, and 
controls.




Figure 2. A–E: Basal protein expression/secretion by control intestinal explants. Preculture 
tissue homogenates (0) and supernatants at indicated times were measured. A: MMP 
protein in ng MMP/mg preincubation explant weight (mean ± SEM), n = 10 –15. **P <  0.01, 
*P  < 0.05 versus level 24 hours earlier. B: MMP-1 activity in U MMP/mg preincubation 
explant weight (mean ± SEM) n =  9 –10. ***P < 0.001, **P < 0.01, *P < 0.05 versus level 24 

























































































































Figure 2 continued. C: MMP-3 activity in U MMP/mg preincubation explant weight 
(mean ± SEM) n = 6. **P < 0.01, *P < 0.05 versus level 24 hours earlier. D: TIMP protein 
in ng or pg TIMP/mg preincubation explant weight (mean ± SEM), n = 6. ***P < 0.001, 
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Figure 2 continued. E: TNF-α 
protein in pg  TNF-α/mg pre-
incubation explant weight 
(mean ± SEM), n = 9 –15. **P 
< 0.01, *P < 0.05 versus level 







Production of MMPs 
During culture significant amounts of MMPs were continuously secreted into the 
medium (Fig. 2A,B), with a substantial fraction of MMP-1, -3 (30–50%) and the 
gelatinases (MMP-2: 15–55%, MMP-9: > 75%, data not shown) in the active form, 
as determined by BIA and gelatin zymography, respectively. Before culture, IBD 
explants already contained more MMP-2 (2-fold, P = 0.005), MMP-3t (3-fold, NS), 
and MMP-9 (10-fold, P = 0.002) compared to control tissue, while preculture  
MMP-1 and MMP-3a levels were below the detection limit of our BIA assay. After 
72 hours MMP secretion in culture medium with/without infliximab and/or PWM by 
IBD explants was also significantly higher (Figs. 3, 4). Within the IBD group, UC 
compared to CD explants expressed higher MMP levels, i.e., basal MMP-1t:  
44.6 ± 15.1 versus 27.6 ± 7.4 (10
3
) U/mg, MMP-2: 27.3 ± 3.1 versus 24.4 ± 2.4 
ng/mg, MMP-3t: 7.2 ± 2.4 versus 4.3 ± 1.0 (10
2
) U/mg, and MMP-9: 3.1± 0.7 
versus 2.2 ± 0.5 ng/mg at 72 hours, although not statistically significant. Addition of 
PWM resulted in opposite MMP-responses: MMP-2 level was downregulated about 
50% compared to basal supernatants, whereas MMP-1, -3, and -9 levels were 
upregulated up to 40%. Incubation with infliximab also revealed divergent 
regulation pathways: basal and PWM immunostimulated MMP-2 secretion were not 
affected, but secretion of MMP-1, -3, and -9 was significantly downregulated by up 
to 40%, irrespective of tissue group. Remarkably, macroscopic disease had no 
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Figure 3. Cumulative MMP protein secretion by cultured intestinal explants at 72 hours (in 
ng MMP/mg preincubation explant weight, mean ± SEM). Explants from 15-20 IBD and 7-15 
control patients were cultured w/wo infliximab and/or PWM. ***P < 0.001, **P<0.01, *P<0.05 
versus corresponding explants from controls. $$$P < 0.001, $$P < 0.01, $ P < 0.05 versus 
basal incubation within same tissue group;  ###P  < 0.001, ##P < 0.01 versus PWM 
incubation within same tissue group. 
 
IBD tissue was 1.9 ± 0.7 compared to 1.6 ± 0.5 ng/mg for normal IBD tissue, n = 5, 
paired t-test, P = 0.4; in case of MMP-1 and -3 only inflamed tissue was analyzed). 
Also, tissue location, i.e., ileum versus colon, had no effect (data not shown). 
Subsets of inflamed IBD and control tissues were also analyzed for mRNA 
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Figure 4-A. Cumulative MMP-t activity secretion (in U MMP/mg preincubation explant 
weight, mean ± SEM) by cultured inflamed IBD and control explants (MMP-1: n = 14–16 and 
6–9; MMP-3: n = 13 versus 6, respectively) after 72 hours. **P < 0.01, *P <0.05 compared to 
corresponding control incubation, $$P < 0.01, $P < 0.05 versus basal incubation within 
same group, ##P <0.01, #P < 0.05 versus PWM incubation within same group. MMP activity 
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Figure 4-B. Cumulative MMP-a activity secretion (in U MMP/mg preincubation explant 
weight, mean ± SEM) by cultured inflamed IBD and control explants (MMP-1: n = 14–16 and 
6–9; MMP-3: n = 13 versus 6, respectively) after 72 hours. **P < 0.01, *P <0.05 compared to 
corresponding control incubation, $$P < 0.01, $P < 0.05 versus basal incubation within 
same group, ##P <0.01, #P < 0.05 versus PWM incubation within same group. MMP activity 
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compared to controls, and significant induction was observed during culture  
(MMP-2, -9: 4–16-fold and MMP-1, -3: 100–500-fold, see also Table X online 
supplementary material). Opposite to the protein, CD, UC, and control MMP mRNA 
levels at 72 hours appeared similar in corresponding incubations, although some 
differences were observed. Infliximab downregulated basal MMP mRNA 
expression, particularly MMP-1 and -3 in CD and controls but not UC, and when 
the results from CD and control tissue were combined, this was highly statistically 
significant (median percent change (range): - 40.9 ( - 74.1 to 89.9, P < 0.05) and  
- 51.0 ( - 78.8 to 37.4, P < 0.01), MMP-1 and -3, respectively). Incubation with 
PWM upregulated MMP mRNA expression 1.5–12-fold but concurrent incubation 
with infliximab could not prevent this increase. 
 
Expression of TIMP-1 and TIMP-2 
Affected IBD and normal control tissues were also analyzed for TIMP secretion. 
Both TIMPs were continuously produced and secreted throughout culture (Fig. 2C), 
with part of the TIMP-2 secretion reflecting release from the large protein pool 
already present in starting tissue. Before culture, IBD and control explants (n = 13 
versus 6) contained similar amounts of TIMP (60 ± 50 versus 0 ± 0 pg/mg TIMP-1 
and 267.2 ± 20.4 versus 217.5 ± 17.5 pg/mg TIMP-2, both NS) but 72 hours basal 
secretion was higher by IBD explants, especially in the case of TIMP-2 (Fig. 5). 
Within IBD, UC compared to CD explants expressed somewhat more TIMP, i.e., 
basal TIMP-1, -2 at 72 hours 48.0 ± 9.2 versus 28.9 ± 5.6 ng/mg and 7.5 ± 0.7 
versus 6.2 ± 0.3 (10
2
) pg/mg, P = NS, respectively. Addition of infliximab and/or 
PWM decreased TIMP protein secretion in all groups, but did not affect relative 
protein levels between corresponding incubations of IBD versus control tissue. 
 
Production of MMP relative to TIMP 
The effect of treatment on the weight ratio between MMP and TIMP is shown in 
Table 3. The MMP-2/TIMP ratios remained relatively stable. However, addition of 
infliximab to basal medium decreased the weight ratio between MMP-1t, MMP-3t, 
and MMP-9 versus TIMP-1 and/or TIMP-2 in CD, UC, and controls and when all 
groups were combined this effect was highly statistically significant. Apparently,  





























Figure 5. Cumulative TIMP protein secretion (in ng or pg TIMP/mg preincubation explant 
weight, mean ± SEM) by cultured intestinal inflamed IBD and control explants (n = 13 and 6, 
respectively) after 72 hours. ***P < 0.001, *P < 0.05 compared to corresponding control 
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Table 3. Effect of incubation with infliximab and PWM on secretion of MMP relative to TIMP 
protein (mean ± SEM) by combined cultured inflamed CD, UC, and control intestinal 
explants (n = 13 and 6, respectively) 
Ratio Basal Infliximab PWM PWM + infliximab 
MMP-2/TIMP-1 0.8 ± 0.1 1.0 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 
MMP-2/TIMP-2 37.1 ± 1.9 38.6 ± 2.7 36.5 ± 3.1 36.2 ± 2.7 
MMP-9/TIMP-1 (x10
3
) 55.5 ± 8.9 42.0 ± 8.0** 121.9 ± 15.0** 80.2 ±  11.2*
##
 
MMP-9/TIMP-2 3.4 ± 0.7 2.4 ± 0.6** 7.7 ± 1.0*** 4.6 ± 0.7*
### 
MMP-1t/TIMP-1 93.2 ± 15.3 87.8 ± 14.0 127.8 ± 22.1** 110.0 ± 18.4* 
MMP-1t/TIMP-2 4.9 ± 0.9 4.1± 0.8** 7.5 ± 1.6** 5.8 ± 1.1*
#
 
MMP-3t/TIMP-1 12.4 ± 1.4 11.2 ± 1.3 19.7 ± 2.1** 17.7 ± 2.1** 
MMP-3t/TIMP-2 0.7 ± 0.1 0.5 ± 0.1* 1.2 ± 0.2*** 1.0 ± 0.2
#
 
CD, Crohn’s disease; UC, ulcerative colitis; PWM, pokeweed mitogen. MMP-2 and MMP-9 
versus TIMP reflect actual weight ratios, MMP-1 and MMP-3 versus TIMP values are in 
arbitrary units. ***P <0.001, **P < 0.01, *P < 0.05 versus basal incubation, 
###
P < 0.001, 
##
P < 0.01, 
#
P < 0.05 versus PWM. 
 
levels of these MMPs are more dramatically reduced than either TIMP-1 or TIMP-2 
when infliximab is added. Conversely, incubation with PWM increased these 
MMP/TIMP ratios toward a more proteolytic phenotype, and infliximab was able to 
partially inhibit these increases, although not fully back to control levels. The 
MMP/TIMP ratios in corresponding incubations from CD and UC compared to 
controls were higher, but statistical significance was not reached. 
 
Production of TNF-α and relation to MMP/TIMP Expression 
Explants also continuously secreted TNF-α into the medium, although peak 
production was observed during the first 24 hours (Fig. 2D). Secretion was 
paralleled by a concurrent increase of TNF-α in tissue homogenates (data not 
shown). Before culture, CD and UC explants contained similar high TNF-α levels 
compared to controls (0.80 ± 0.18 versus 0.25 ± 0.11 pg/mg, P < 0.05, n = 17 IBD 
versus 15 controls), and they had secreted more TNF-α , although not statistically 
significant, after PWM stimulation at 72 hours (Fig. 6). Incubation with infliximab 
only marginally affected basal TNF-α secretion. PWM, however, increased TNF-α 
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Figure 6. TNF-α protein secretion by intestinal inflamed IBD (n = 12–13) and control (n =  
6–9) explants at 72 hours, cultured w/wo infliximab and/or PWM. Mean ± SEM in pg  
TNF-α /mg preincubation weights are shown. The TNF-α levels determined in medium 
supplemented with infliximab were multiplied 5-fold to correct for 80% inhibition of the TNF-α 
ELISA results by infliximab. *P < 0.05 versus control, $$$P < 0.001, $$P < 0.01, $P < 0.05 
versus basal incubation within same group. 
 
levels 8–12-fold and infliximab was able to partially prevent this increase, although 
again not statistically significant. These results were essentially the same at the  
mRNA level (data not shown). There was a strong positive correlation of 72 hours 
basal TNF-α levels with MMP-3 total activity, MMP-9 and TIMP-1 protein secretion 
(0.58 < r <  0.74, P <  0.05, all groups combined, n = 18 –22). Importantly, basal 
TNF-α was also positively correlated with MMP-9/TIMP-1, MMP-9/TIMP-2, and 
MMP-3t/TIMP-2 (0.67 < r < 0.85, P < 0.01, n = 18), whereas a strong negative 
correlation was observed versus MMP-2/TIMP-1 (r = - 0.71, P < 0.01). All 
correlations were lost when explants were treated with PWM. Finally, MMP-3 is 
known to be a physiological activator of MMP-1. In our experiments, active MMP-3 
and active MMP-1 were highly correlated independent of incubation with PWM 
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Genotype at SNP loci and effect on protein and mRNA expression 
Using RFLP or tetra primer ARMS PCR, relevant SNP loci in the DNA of IBD 
patients and controls were genotyped. Explants with at least one 2G, 5T, or A allele 
at MMP-1 -1607, MMP-3 -1613, or TNF-α -308, respectively, were shown to 
express more corresponding protein in medium with/without PWM and/or infliximab 
compared to explants with alternative allelic composition (Table 4), although not 
statistically significant. Allelic composition often did not affect the response of 
explants to infliximab or PWM; for instance, PWM significantly decreased MMP-2 
protein expression in explants with the CC as well as in explants with the CT or TT 
genotype (CC basal compared to PWM: 20.1 ± 2.3 versus 12.4 ± 1.5 and CT + TT: 
22.4 ± 2.2 versus 13.5 ± 2.0 ng/mg, both P < 0.001). However, in explants with the 
CC but not CT or TT genotype at MMP-9 -1562 infliximab significantly 
downregulated MMP-9 protein levels, while PWM caused an upregulation. Also, 
only in explants with at least one 2G or 5T allele at the MMP-1 -1607 versus  
MMP-3 -1613 locus, infliximab decreased total MMP-1 and MMP-3 secretion, 
respectively. At the mRNA level, explants with the CC genotype at MMP-2 -1306 
expressed more MMP-2 than explants with the CT or TT genotype, although not 
statistically significant, and only explants with the 6T6T genotype at MMP-3 -1613 
responded to incubation with infliximab by decreasing MMP-3 production (P < 0.05, 
see also Table XX online supplementary material). 
 
Discussion 
We have shown a generalized increased ex vivo expression of MMP-1, -2, -3, -9, 
and TIMP-1, -2 protein by explants from CD and UC versus control patients. The 
enhanced production of MMPs and TIMPs by IBD tissue corresponds to results 
from previous studies concerning expression levels of these markers in vivo
12-17 
and could contribute to the tissue damage seen in IBD. In our experiments we 
observed that UC compared to CD explants expressed more MMP and TIMP, 
perhaps reflecting the more severe inflammation of the starting tissue of the former 
as measured by myeloperoxidase content (16.4 ± 1.4 versus 11.4 ± 1.1 U/g,  
P < 0.05). The protein level of MMP-2 dropped nearly 2-fold when the explants 
were activated by PWM, an inducer of the in vitro inflammatory process, while 
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Table 4. Genotype at selected SNP loci and effect on MMP, TIMP and TNF-α protein 




Start Basal Infliximab PWM 
PWM + 
Infliximab 
CC 14-21 0.7 ± 0.1
† 20.1 ± 
2.3 






CT or TT 9-12 1.1 ± 0.2 
22.4 ± 
2.2 





CC 18-25 0.3 ± 0.1 2.0 ± 0.3 
1.5 ± 
0.3*** 






CT or TT 5-8 0.5 ± 0.3 2.0 ± 0.8 1.9 ± 1.4 2.6 ± 0.7 2.6 ± 0.9
# 




 U/mg 1G2G or 
2G2G 
12-15 ND 3.4 ± 0.9 2.9 ± 0.9* 3.8 ± 1.1 3.5 ± 1.0* 
5T5T or 
5T6T 











20.8 ± 4.0 22.8 ± 4.3 23.2 ± 3.6 
TIMP-1 



















GA 7 2.3 ± 0.3 5.2 ± 0.5 5.5 ± 0.7 4.3 ± 0.6 4.5 ± 0.5 














SNP, single nucleotide polymorphism; IBD, inflammatory bowel disease; ND, not 
determined, below threshold of assays. Distribution of IBD and control tissue over genotypes 
is similar (Fisher’s Exact test, not shown). IBD values in case of MMP-2 and MMP-9 are 
taken from inflamed and noninflamed tissue, otherwise only inflamed tissue was measured. 
MMP-9 expression by explants with CT or TT genotype is significantly lower when infliximab 
is added next to PWM, but is not reflected in depicted figures because PWM value is based 
on n = 8, PWM + infliximab on n = 5 and test is based on paired n = 5.***P < 0.001, **P < 




P < 0.05 versus PWM incubation,  
†
 P 
< 0.05 versus corresponding incubation of explants with alternative genotype. Statistical 
significance was not assessed between starting material and medium. 
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MMP-1, -3, and -9 production was enhanced or remained stable. However, mRNA 
levels of all four MMPs were similar or increased compared to basal incubation 
when PWM was added. Apparently, PWM activation may affect MMP 
posttranscriptional processes, particularly of MMP-2, resulting in the observed 
divergence of regulation of MMP protein production and secretion. When infliximab 
was added to basal medium, MMP-2 protein and mRNA levels remained similar, 
while MMP-1, -3, and -9 protein and/or mRNA were decreased. Clearly, the 
expression of MMP-2 in this explant culture system is not affected by TNF-α, 
whereas the basal expression of MMP-1, -3, and –9 protein appears to be 
substantially dependent on TNF-α, confirming previous observations on the 
regulation of these MMPs by this cytokine.
40
 The downregulation of MMP-1, -3 
protein by infliximab was paralleled by a decrease in corresponding mRNA in CD 
and control but not UC explants. This might point to aberrant regulation pathways 
of MMP-1 and -3 in UC compared to CD and controls, possibly related to specific 
pathogenic mechanisms. It can be argued that both absolute and relative levels of 
MMPs and TIMPs are physiologically relevant. Infliximab added to basal medium 
resulted in downregulation of the MMP-9 versus TIMP ratio, while MMP-2 versus 
TIMP remained constant. Importantly, addition of this drug also decreased the level 
of total MMP-1 and MMP-3 over TIMP, particularly TIMP-2, together with a 
downregulation of active MMP-1 and -3. These observations point to an 
antiproteolytic and matrix protective phenotype induced by infliximab. Conversely, 
addition of PWM increased the ratio of MMP-1, MMP-3, and MMP-9 to TIMP and 
also increased net MMP-1 and -3 activity, shifting the balance to a more proteolytic 
phenotype, possibly resulting in the observed significant epithelial cell targeted 
tissue degradation. Treatment with infliximab was able to partially prevent this 
PWM-induced increase, although not fully back to control levels. Therefore, our 
results indicate a clear relationship between expression of TNF-α and MMP-1, -3, 
and -9 net activity in CD, UC, and normal control tissue. This is corroborated by the 
finding of a positive correlation between TNF-α versus MMP-9/TIMP,  
MMP-3/TIMP-2, and TNF-α versus MMP-3 total activity in basal medium and of 
similar TNF-α and MMP/TIMP levels in corresponding incubations of IBD 
compared to control explants. However, despite less impressive differences in 
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TNF-α secretion, MMP activity levels were much higher in IBD compared to 
controls, stressing the importance of other proinflammatory pathways in 
upregulating MMPs. Our results on TNF-α reveal less enhancement compared to 
previous publications concerning TNF-α production by IBD mucosal biopsies.5,41 
Obviously, from surgical resection until culture our tissues had been exposed to 
more severe physical stress, perhaps upregulating TNF-α production processes. 
The duration of disease in our IBD study population was often several years, and 
as shown by Dionne et al,
42 
this may downregulate TNF-α production. Alternatively, 
from many of our patients the removed bowel was affected by stricturing 
processes, perhaps paralleled by decreased capacity for production of TNF-α 
compared to solely inflamed tissue. Also, a large proportion of our patients were 
treated with corticosteroids and/or disease-modifying drugs like azathioprine or 
cyclosporine prior to surgical resection, possibly affecting TNF-α secretion during 
culture. Several studies have reported on functional SNP loci in the genes coding 
for MMP, TIMP, and TNF-α. We found increased production of corresponding 
protein or mRNA by explants with two C or at least one 2G, 5T or A allele at the 
MMP-2 -1306, MMP-1 -1607, MMP-3 -1613, and TNF-α –308 loci, respectively, 
confirming results in previous publications.
24,43-45 
We also found an inhibitory effect 
of infliximab on MMP protein or mRNA production especially in explants with the 
CC and 1G2G or 2G2G genotype at SNP loci MMP-9 -1562 and MMP-1 -1607, 
respectively. These results may be relevant for future selection of infliximab 
responsive patients, but first have to be confirmed in larger studies. Experimental 
manipulation of cultured (human) intestinal IBD mucosa, as described here, may 
provide a new valuable tool in this respect. Despite the physical stress exerted on 
the tissue, the presence of bacteria, and the absence of fetal calf serum, we were 
able to preserve gross morphology up to 72 hours, with maintenance of crypts and 
cytokeratin-18-expressing epithelial cells, even when medium was not replenished. 
Possibly the presence of retinoic acid may play a central role, due to its anabolic 
effects on epithelial cells
46
 and its attenuation of extracellular matrix degradation by 
stromal cells.
47
 Given the large availability of surgical resection specimens, culture 
of IBD intestinal mucosa may offer an inexpensive way of monitoring drug efficacy, 
cytokine and proteinase expression, etc. In the past there have been several 
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reports describing potential mechanisms of infliximab action, i.e., downregulation of 
adhesion molecules on endothelial cells and production of IL-6 by fibroblasts,
48 
antibody and/or complement-dependent (cellular) cytotoxicity,
49 
induction of 
apoptosis in T lymphocytes,
50 
and restoration of gut barrier function.
51
  Our results 
demonstrate another potential mechanism of action, i.e., downregulation of excess 
MMP-1, -3, and -9 activity and parallel the observed downregulation of serum 
levels of various MMP members in rheumatoid arthritis
52
 and CD patients
53
 treated 
with infliximab. Our results reinforce the potential destructive capacities of MMPs in 
IBD pathogenesis, the pivotal role of TNF-α in regulating MMP-1, -3, and -9 
activity, and the rationale for developing therapeutic intervention strategies utilizing 
specific MMP inhibitors for treating patients with CD or UC, as also previously 
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Abstract 
Background/aims. Matrix metalloproteinases (MMPs) are actively involved in the 
pathogenesis of Crohn’s disease (CD). We assessed the effect of the anti-tumor 
necrosis factor- α (TNF-α) monoclonal antibody infliximab on the in vitro and in vivo 
expression of MMP-2 and MMP-9 in CD. 
Methods. Infliximab-treated fistulizing (n =10) or active disease (n = 7) CD 
patients, from an in-house study, and fistulizing CD patients (n = 42) and active CD 
patients (n = 24) from 2 placebo controlled studies were evaluated for serum MMP 
levels and clinical response. Biopsies were evaluated immunohistochemically for 
the MMPs. Whole blood cultures stimulated with lipopolysaccharide 
(LPS)/infliximab were evaluated for MMP mRNA and protein levels. 
Results. Serum MMP-2 levels in CD patients increased during follow-up, similarly 
in responders and nonresponders, by infliximab. Immunohistochemistry showed no 
clear MMP-2 change in biopsies. Serum MMP-9 levels, however, showed a 
consistent pattern of decrease in most CD patients, particularly in those 
responding, and MMP-9-positive polymorphonuclear leukocytes in biopsies also 
decreased by infliximab. LPS stimulation of whole blood increased the MMP-9 
levels in plasma significantly in CD patients and controls, but infliximab had no 
effect on the secretion. Long-term LPS stimulation raised leukocyte MMP-9 mRNA 
levels 16-fold and infliximab inhibited this induction by 80%. 
Conclusions. Infliximab treatment increases MMP-2 and decreases MMP-9 in 
serum of patients with CD, the latter also in the intestine, which extends and 
confirms our previous ex vivo explants observations. However, these changes 
were not strictly associated with the response to treatment. The enhanced 
leukocyte MMP-9 expression in CD seems to be regulated by TNF-α. 
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Introduction 
Infliximab, a chimeric IgG1 anti-tumor necrosis factor (TNF)-α monoclonal 
antibody, is a successful immunotherapeutic agent for Crohn’s disease (CD). The 
treatment with infliximab results in a high clinical efficacy, rapid onset of action, and 
prolonged effect in patients with moderate to severe active CD, which have not 
responded to conventional therapy, and in fistulizing CD patients. Simultaneously, 
the quality of life of these patients is essentially improved.
1-3
 The proposed 
immunological mechanisms of infliximab include the suppression of TNF-α 
bioactivity and the lysis of TNF-α-producing cells, such as monocytes and 
lymphocytes, via complement fixation, antibody-dependent cellular cytotoxicity 
(ADCC), and Fc portion binding of the IgG1 antibody. Furthermore, infliximab 
downregulates mucosal Th1 cytokines, reduces the expression of IFN-γ and other 
inflammatory molecules, such as intercellular adhesion molecule (ICAM)-1 and 
vascular adhesion molecule (VCAM)-1.
4-6
  





 Usually, MMPs are synthesized as 
preproenzymes and are secreted in a proenzyme form that requires proteolytic 
cleavage for activation in most cases.
8,9
 The activity of MMPs is precisely regulated 
within tissues by the balance between zymogen activation and enzyme inhibition. 
Factors that regulate activity of the MMPs include endogenous inhibitors,               
α-macroglobulins, and tissue inhibitors of metalloproteinases (TIMPs) and the 
MMPs themselves.
10,11
 MMPs are implicated in the inflammatory response, wound 
healing, tissue remodeling, cell growth, migration, apoptosis, cell-cell 
communication, tumor invasion, and metastasis.
8,12-15
 MMPs exert their activity by 
the degradation of a class of biological molecules that include not only the 
components of extracellular matrix (ECM) but also an increasing family of bioactive 
modulators, such as cytokines, growth factor receptors, other proteinases, 
coagulation factors, chemotactic molecules, and adhesion molecules.
14
 In the 
pathogenesis of CD, MMPs are believed to be associated with the injury of gut 
tissue mediated by TNF-α and Th1 cytokines. One of the mechanisms by which 
TNF-α causes intestinal tissue injury is believed to be the enhancement of the 
MMP production at local sites.
16-18 
MMP-2 (72 kDa, gelatinase A) and MMP-9 (92 
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kDa, gelatinase B) are the two members of the gelatinase subgroup of MMPs. The 
substrates of MMP-2 and MMP-9 specifically include not only basement membrane 
(BM) type IV collagen and other components like gelatin, collagen type I, V, VII, X, 
elastin, laminin, and fibronectin, but also numerous bioactive molecules, such as 
fibroblast growth factor receptor (FGFR)-1, prointerleukin (IL)-1, and ICAM-1.
19-22
 
Previous studies showed that MMP-2 and -9 are actively involved in the 
pathophysiological processes, including fistula formation, in the intestine of 
inflammatory bowel disease (IBD) patients.
23-30
 After treatment with infliximab the 
elevated levels of MMP-1 and -3 in serum of patients with rheumatoid arthritis were 
reported to be reduced.
31
 The role of MMPs in the treatment of CD patients with 
infliximab, however, is still poorly understood. Recently, we showed that infliximab 
induces a matrix protective MMP-phenotype in ex vivo cultures of mucosa from 
patients with inflammatory bowel disease.
32
 In the present study we explored 
further this relationship between the clinical efficacy of infliximab and the 
expression levels of MMP-2 and -9 in patients with CD and describe the in vivo and 
in vitro regulation of the expression of these 2 gelatinases by infliximab. 
 
Patients and methods 
Clinical studies 
In the present study we included patients that participated in an expanded access 
program for infliximab treatment of CD in our institute, i.e., in-house study,
3
 and a 
subgroup of patients that participated in an international multicenter, placebo-
controlled trial of infliximab either for the treatment of fistulas in patients with CD or 
for the treatment of active CD.
1,2
 The in-house study was approved by the medical 
ethics committee and patients were only included after informed consent. The 
eligibility of patients in these studies was described previously.
3,33
 Briefly, the age 
of confirmed patients with CD had to be between 18 and 65 years. For inclusion in 
the fistula treatment groups, patients had to have single or multiple draining 
abdominal or perianal fistulas of at least 3 months’ duration. Patients who had had 
CD for at least 6 months, with CD Activity Index (CDAI) scores equal or above 220, 
were eligible for the treatment with infliximab for active CD. Analyses of efficacy 
evaluated the number of patients with a reduction of half or more in the number of 
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draining fistulas from baseline as responders or those with complete healing 
(defined as the absence of any draining fistulas) as healers at 2 consecutive visits. 
Changes in scores of the CDAI and the open fistulas scores were also evaluated. 
Failure of treatment was defined as changes in medication that were not permitted 
in the protocol, surgery related to CD, or no return for follow-up visit. 
 
Protocol 1. Fistulas 
Within 2 weeks of screening, eligible patients (n = 10, one patient also with active 
disease) for the in-house study received infliximab 5 mg/kg (body weight) and 
patients from the international trial were randomly assigned to receive 1 of 3 
treatments at weeks 0, 2, and 6: placebo (n = 14) or 5 or 10 mg/kg of infliximab 
(total n = 28). Study drug was administered intravenously over a 2-hour period. 
After the first infusion of study medication, patients returned for clinical and 
laboratory assessments at weeks 2, 6, 10, 14, and/or 18. Serum samples were 
collected, if possible, at each study visit through week 18. 
 
Protocol 2. Active disease 
Patients in the in-house study received a single dose of 5 mg of infliximab per 
kilogram of body weight (total n = 7) in an intravenous infusion, administered over a 
2-hour period. Disease activity according to the CDAI and/or blood serum samples 
were assessed at days 0, 3, weeks 2, 4, 8, and 12. In the international study 
patients were randomly assigned to receive a single dose of either placebo (n = 7) 
or 5, 10, or 20 mg/kg of infliximab (total n = 17). Disease activity was assessed and 
serum samples were collected at weeks 0 and 4. 
 
In vitro study 
Patients, volunteers, and blood samples 
Patients with CD (n = 7) were treated with infliximab for fistulizing and/or active 
disease in the in-house study. Blood from healthy volunteers (n = 5) was obtained, 
with their permission, from the central blood transfusion laboratory. Heparinized 
blood samples were obtained from patients before and 2 hours after a single 
infusion of infliximab of 5 mg/kg over a 2-hour period. For the blood samples from 
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the healthy volunteers a concentration of 75 µg infliximab per mL blood was added. 
At 37 °C and 5% CO2, whole blood samples with/without infliximab were stimulated 
with/without lipopolysaccharide (LPS) (Sigma, St. Louis, MO) at 0.1 µg/ml blood for 
1.5–24 hours for MMPs and TNF-α mRNA and protein determinations.
34
 The 
plasma was subsequently separated from the blood sample by centrifugation at  
4 °C, and stored at -70 °C until further analysis. Leukocytes isolation was 
performed by adding lysis buffer containing 0.16 M NH4Cl, 10 mM KHCO3, and 
0.01 mM K2-EDTA (pH 7.4 at 0°C) to the samples. After erythrocytes were 
degraded the sample was centrifuged at 4 °C and lysis was repeated to obtain 
pure leukocytes. The leukocytes were immediately used to isolate RNA. 
 
Determination of MMPs by ELISA 
MMP-2 and MMP-9 levels in the samples were measured by our highly specific 
enzyme-linked immunosorbent assays (ELISA), which measure the total of 
proenzyme, active-, and inhibitor-complexed forms of the respective MMP, as 
described previously.
30,32,35
 In brief, a polyclonal anti-MMP-2 antibody or 
monoclonal anti-MMP-9 antibody was used as catching antibody and appropriately 
diluted samples were incubated overnight at 4 °C. Immunodetection of MMP-2 was 
performed using polyclonal anti-MMP-2 followed by biotin-labeled goat antirabbit-
IgG and of MMP-9 with biotin-labeled polyclonal anti-MMP-9 antibody. After 
incubation with avidin-peroxidase the chromogenic substrate 3,3,5,5-tetramethyl 
benzidine in the presence of hydrogenperoxide was added and the reaction was 
stopped with H2SO4 and the absorption was measured at 450 nm. The amount of 
MMP was calculated from the parallel standard curve and expressed in ng MMP 
per mL serum or plasma. 
 
Immunohistochemical staining for MMPs 
Standardized colonic biopsies of 6 patients from the in-house study (4 with 
fistulizing and 2 with active disease) were obtained at the start of the study, as well 
as at day 3 and week 2 of follow-up. To assess the localization of MMP-2 and 
MMP-9 within the intestinal tissues, indirect immunohistochemical staining of the 
MMPs was performed as described previously.
30
 In brief, paraffin tissue sections, 
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treated with proteinase K for MMP-2 antigen retrieval, were incubated with rabbit 
polyclonal antihuman MMP antibodies, similar to those used in the ELISAs. 
Subsequently, the sections were incubated with biotinylated goat antirabbit Ig, 
peroxidase-labeled streptavidin, and stained with 3-amino-9-ethylcarbazole and 
hematoxylin. Control sections incubated with preimmune serum or buffer instead of 
the primary antibodies showed no staining. The immunohistochemical staining was 
semiquantitatively assessed using the following scoring system: 0 = no staining,  
1 = a few positive cells/areas of tissue or a low staining intensity in all cells, 2 = a 
minority of the cells/areas of tissue positive or a moderate staining intensity in all 
cells, 3 = a majority of the cells/areas of tissue positive and/or a moderate staining 
intensity in all cells, 4 = all cells or areas of tissue strongly positive. 
 
Reverse transcription–polymerase chain reaction (RT-PCR) 
Oligonucleotide primers (Table 1) for RT-PCR were derived from the DNA 
sequence database of the NCBI (Bethesda, MD). Primer sets were designed using 
the Primers3 Output computer program (Whitehead Institute for Biomedical 
Research, Cambridge, MA). The MMP-2 and MMP-9 PCR products span 3 introns 
to prevent interference of contamination by genomic DNA. Specificity of the primers 
was checked with the NCBI BLAST program. β2-microglobulin (β2-M) was used as 
a control to normalize PCR signals from the different samples. Total RNA was 
isolated from blood samples by the method of Chomczynski and Sacchi.
36
 The 
integrity and quality of the purified RNA were analyzed by 1.5% agarose 
gel/ethidium-bromide staining and the 260/280 nm absorbance ratio. Moloney 
Murine Leukemia Virus (M-MLV) reverse transcriptase was used for cDNA 
synthesis from DNAse-treated RNA. The PCR was started at 94 °C for 3 minutes, 
followed by 30 cycles for MMP-2 and MMP-9, and 28 cycles for β2-M. Each cycle 
consisted of a denaturation step (at 94 °C for 30 sec), an annealing step for 45 sec 
(at 56 °C for MMP-2 and β2-M, 59 °C for MMP-9), and extension step (at 72 °C for 
1 min), followed by a final elongation step (at 72 °C for 7 min), as described 
previously.
32
 The reaction was performed in a Whatman T Gradient cycler 
(Biometra, Goettingen, Germany) and the amplified products were electrophorized 
on 1.5% agarose gels containing ethidium-bromide (0.5 g/mL) and visualized under 
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Table 1. Oligonucleotide primers for RT-PCR. 


















RT-PCR, reverse transcription–polymerase chain reaction; MMP, matrix metalloproteinase. 
 
ultraviolet light. RT-PCR, which contained RNA but not M-MLV reverse 
transcriptase, was used to check contamination with genomic DNA. The Scion 
imaging program (Frederick, MD, www.scioncorp.com) was used to semiquantify 
the band density in the gels, expressed in arbitrary units (AU). 
 
Statistical analysis 
The results of the MMP ELISAs are given as mean ± SEM, the clinical, 
immunohistochemical, and mRNA data are presented as median with interquartile 
range. The Wilcoxon signed-rank test or the paired Student t-test was used to 
evaluate difference between paired data and the Mann–Whitney U-test or the 
Student t-test for unpaired data, where applicable. Differences were considered 





The serum MMP-2 level in patients with fistulas from the in-house study (n = 6) 
responding to treatment with infliximab showed a steady increase from 605 ± 78 
(ng/mL) at day 0 up to 834 ± 46 at week 14 (P = 0.08). Correspondingly, the 
open/draining fistulas score in these patients was decreased at the end of follow-
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up from 3 (2–6) to 1 (0–1) (P = 0.03); most of these responders already had signs 
of improvement at week 2. Except for the first 3 days, where the level of MMP-2 in 
the nonresponders of the patients with fistulas (n = 4) decreased due to 1 outlier, 
also the nonresponding patients showed a gradual increase up to 649 ± 107 at the 
end of follow-up. The open fistulas scores in this group remained at 1, and all these 
nonresponding patients had genitourinary fistulas. Similarly, from day 0 to week 10 
in the international study the serum MMP-2 level in fistulizing CD patients 
increased in both placebo (n.s.) and infliximab (P = 0.003) treated patients, and in 
both responders/healers and nonresponders/nonhealers (0.02 < P < 0.08), with a 
general decrease after week 10. Baseline MMP-2 levels at inclusion were 
comparable between all subgroups (Fig. 1). Also in CD patients with active disease 
(n = 7) from the in-house study who responded to the treatment with infliximab, the 
improvement of disease activity was accompanied by a significant increase of the 
serum MMP-2 level from 364 ± 54 (ng/mL) at day 0 to 656 ± 53 at week 8 (P = 
0.03). The CDAI decreased significantly from 365 (264–461) down to 50 (10 –189) 
 
 
Figure 1. Serum MMP-2 levels in all subgroups of patients with fistulas from the 
international study showed a similar pattern, i.e., slightly increasing during the follow-up, with 
a slight decrease at the end. MMP: matrix metalloproteinase. Placebo: n = 14; all infliximab: 
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at the corresponding timepoints (P = 0.04). At the end of follow-up, i.e., week 12, 
the MMP-2 level started to decrease and the CDAI started to increase again. One  
patient showed no improvement with the infliximab treatment and the serum  
MMP-2 level in this patient remained stable over time. The serum MMP-2 level in 
patients with active disease from the international study did not show consistent 
and significant changes at the end of 4 weeks follow-up compared with day 0 in 
both placebo and infliximab-treated groups (Table 2), although at higher dosages a 
tendency to increase was clearly discernable. 
 










n = 6 
Infliximab 
20 mg/kg 
n = 7 
MMP-2 Day 0 780 ± 170 935 ± 411 658 ± 126 780 ± 80 
 Week 4 715 ± 225 879 ± 160 998 ± 118 898 ± 172 
MMP-9 Day 0 344 ± 79 180 ± 62 286 ± 111 255 ± 48 




MMP, matrix metalloproteinase. MMPs presented in ng/mL (mean ± SEM). 
 
MMP-9 
The MMP-9 serum level of the in-house patients with fistulizing disease in both 
responders and nonresponders was hardly affected by the infliximab therapy, 
although at the end of follow-up a decrease was noticed from 297 ± 41 to 267 ±  76 
and from 441 ± 48 to 240 ± 61 ng/mL, respectively. In the international study there 
seemed to be a general trend to a decreased MMP-9 level where the infliximab-
treated patients and responders/healers seemed to have a slightly lower level at 
week 6 to 18 than the placebo treated and nonresponding/nonhealing patients, 
although no statistical significance was reached (Fig. 2). Active disease patients 
from the in-house study who responded to infliximab had a decreased MMP-9 
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serum level from day 3 after treatment onwards. The MMP-9 serum level fell from 
419 ± 88 at the beginning of the study down to 236 ± 26 at week 4 (P = 0.05), and 
remained at this lower level to the end of the follow-up, 230 ± 52 (P = 0.05), 
accompanying the decrease in CDAI. The MMP-9 level in the 1 patient who did not 
respond to the treatment also showed a reduction of MMP-9 serum levels during 
the follow-up. In the international study the levels of MMP-9 in the active CD 
patients were also decreased in both the placebo and infliximab-treated groups at 
the end of the follow-up, except for the 5 mg/kg infliximab group, but no statistical 
significance was reached (Table 2). 
 
Immunohistochemical results  
A patchy and relatively strong positive immunoreaction to MMP-2 was present in 
the ECM of submucosa in noninflamed tissues (Fig. 3B). In inflamed tissues a 
positive staining of MMP-2 was observed in endothelial cells and the ECM of the 
lamina propria (Fig. 3B,C). There were no major differences between patients with 
fistulas or with active disease. Overall, the immunohistochemical expression 
pattern of MMP-2 did not seem to change by the treatment with infliximab therapy 
(data not shown). The immunoreactivity for MMP-9 was predominantly present in 
the polymorphonuclear leukocytes (PMNL). A relatively high PMNL positive 
staining for MMP-9 was observed in the tissues before treatment [median score 2 
(IQR 1–2.5)]. Follow-up biopsies after treatment with infliximab revealed a 
decreased intensity of MMP-9 staining already at day 3 [1 (1–1.8), n.s.], which was 
even lower at week 2 [0.5 (0–1.3), P < 0.05] in 5 out of 6 patients, 4 of them with a 
good clinical response (Fig. 4B,C). Interestingly, in most of the tissue sections we 
found enteroendocrine cells to be positive for MMP-9, independent of treatment 
with infliximab (Fig. 4D). 
 
In vitro study 
Whole blood cultures revealed that the levels of MMP-2 in plasma of both CD 
patients and controls were not affected by stimulation with LPS or with LPS in the 
presence of infliximab for 1.5 or 24 hours. However, the levels of MMP-2 in the 
plasma of CD patients were in general lower than that in healthy controls (Table 3).  











Figure 2. In contrast to the serum levels of MMP-2, MMP-9 levels in patients with fistulas 
from the international study showed a trend to decrease in all groups during the follow-up, 
with a slight increase at the end. MMP: matrix metalloproteinase. Placebo: n = 14; all 
infliximab: n = 28; responders: n = 22; nonresponders: n = 19; healers: n = 18; nonhealers:  
n = 23. 
 
 
Figure 3. In patients with fistulas a patchy 
MMP-2 expression was immunohisto-
chemically observed in the submucosa (A, 
negative control, and B, MMP-2 staining, 
both x200). After infliximab therapy for 2 
weeks (C, x200) the immunoreaction to 
MMP-2 in endothelial cells (arrow) and 
lamina propria of inflamed tissue was 






































    ↓         ↓        ↓ 
    ↓   Treatment       
C 
B A 
Infliximab and gelatinases in CD - 123 
 
Figure 4. MMP-9 immunostaining was predominantly present in polymorphonuclear 
leukocytes within the lamina propria (A, negative control, and B, MMP-9 staining, both 
x200). After treatment of this patient with infliximab for 2 weeks MMP-9 staining was found 
to be decreased (C, x200). The positive immunoreaction of MMP-9 in enteroendocrine cells 
(arrow) was frequently observed (D, x1000). MMP: matrix metalloproteinase  
 
With RT-PCR no detectable MMP-2 mRNA level was found in leukocytes of both 
CD patients and healthy volunteers. In contrast to the levels of MMP-2, MMP-9 
levels in patients’ plasma were higher, compared with those in healthy volunteers. 
After a 1.5-hour LPS stimulation the levels of MMP-9 were significantly increased in 
CD patients and in controls, both more than 2-fold higher than the unstimulated 
cultures, with the increase in the CD patients significantly higher than that in the 
healthy volunteers (P = 0.05). Infliximab was found not to affect MMP-9 protein 
levels of this short-term LPS stimulation (Table 3). After 24 hours, LPS stimulation 
A B 
C D 
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Table 3. Plasma MMP levels from the in vitro whole blood cultures of CD patients and 
healthy volunteers 
 Patients (n = 7) Volunteers (n = 5) 
MMP-2 1.5h 24h 1.5h 24h 
Blank 380 ± 108 477 ± 148 936 ±200 771 ± 117 
LPS 397 ± 140 639 ± 144 887 ± 120 833 ± 203 
Infliximab+LPS 462 ± 52 421 ± 98 913 ± 346 718 ± 119
 
MMP-9 1.5h 24h 1.5h 24h 
Blank 541 ± 209 315 ± 55 126 ± 18 194 ± 31 
LPS 1132 ± 242** 848 ± 204* 364 ± 75* 679 ± 106*
/
*** 
Infliximab+LPS 1296 ± 412* 878 ± 327 268 ± 46* 550 ± 63*
/
*** 
MMP, Matrix Metalloproteinase; CD, Crohn’s disease; LPS, lipopolysaccharide. *P <0.05, 
**P < 0.01 versus blank; ***P < 0.05 versus 1.5h- incubation. MMPs presented in ng/mL 
(mean ± SEM). 
 
did not further promote leukocytes to synthesize/secrete MMP-9 in CD patients, but 
in the healthy volunteers LPS stimulated the MMP-9 protein synthesis/secretion 
about 2-fold, which was significantly higher in comparison with the level after 1.5 
hours (P < 0.05). Infliximab did not affect the MMP-9 protein secretion after 24 
hours in either patients or healthy volunteers. Interestingly, the 1.5-hour LPS 
stimulation hardly changed the respective MMP-9 mRNA level compared to that of 
the blank samples, whereas TNF-α mRNA was increased 13-fold (Table 4). More 
MMP-9 mRNA was transcribed in leukocytes after 24 hours stimulation with LPS, 
raising up to 16-fold. This transcription of MMP-9 mRNA was mediated by TNF-α 
 
Table 4. MMP-9 and TNF-α mRNA levels in cultured leucocytes from healthy volunteers  
mRNA 1.5h LPS 24h LPS 24h LPS + Infliximab 
MMP-9 0.5 (0.1–1.4) 16 (2–47) 3 (3–7) 
TNF-α 13 (10–121) 4 (3–9) 2 (0.5–4) 
MMP, matrix metalloproteinase; LPS, lipopolysaccharide. The results represent 4 
experiments, with mRNA levels expressed in median relative densitometry units (inter 
quartile range) in comparison with blank samples. 
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as infliximab downregulated the mRNA level by almost 80%. At the same time, the 
TNF-α mRNA level in the 24-hour samples was enhanced by only 4-fold and even 
lower, i.e., 2-fold, in the presence of infliximab. 
 
Discussion 
Treatment with infliximab is very effective in patients with active or fistulizing CD, 
although the mechanism(s) of action have not yet been fully elucidated.
1,2,6
 MMPs 
have been implicated in both disease phenotypes and infliximab was recently 
found to be inducing a mucosa protective MMP-phenotype in ex vivo mucosal IBD 
explants.
23-30,32
 In the present study, we found that these infliximab-induced 
alterations in MMPs are to a large extent also reflected in the serum and in 
intestinal biopsies. We found an increase of serum MMP-2 in both fistulizing and 
active CD patients by the treatment with infliximab, in comparison to baseline, with 
a decline at the end of follow-up after cessation of treatment. The cause of the 
increase in MMP-2 might be related to the turnover of the intestinal tissue in CD, 
especially the remodeling of the ECM components. CD is a chronic and recurrent 
inflammation of the alimentary tract, where remission and relapse of the disease 
alternate and almost inevitably occur. In the inflammatory process the destruction 
and healing of tissue seems to occur simultaneously. This could partially explain 
why the increase of serum MMP-2 is not strictly related to the criteria of clinical 
improvement. During these processes there is formation of granulation tissue, 
especially at ulcerative and fistulizing sites, where the remodeling of tissue actively 
takes place. This granulation tissue differs from the normal tissue in composition of 
cells and matrix components, containing many fibroblasts and endothelial cells. In 
addition, we previously showed that in the inflamed area MMP-2 is significantly 
increased.
30
 The proliferation, differentiation, and (neo)angiogenesis are highly 
promoted by stimulation through induced growth factors, such as transforming 
growth factor (TGF)-β, basic fibroblast growth factor (bFGF), and vascular 
endothelial growth factor (VEGF). The increase of MMP-2 at local sites is probably 
to meet the demand of active ECM turnover. Ågren
37
 also believed that MMP-2 is 
important during the prolonged remodeling phase in wound healing. Apparently, at 
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moments of high tissue demand for MMP-2 the serum levels are low and at 
inclusion of controlled treatment protocols these serum levels start to increase, not 
strictly related to response. The sequestration of MMP-2 to ECM of intestinal IBD 
tissue may also partially contribute to the paradoxical phenomenon, i.e., the 
elevated expression of MMP-2 in inflamed tissue and low level in the circulation.
18 
MMP-2 is constitutively expressed by many cells, especially mesenchymal cells, 
such as fibroblasts and endothelial cells, and has a ubiquitous tissue distribution.
20
 
TNF-α and other proinflammatory cytokines seem not to be major promoting 
factors for the expression of MMP-2 because the gene promoter lacks TPA-
responsive element (TRE). TGF-β, however, is regarded as a stimulator for the 
expression of MMP-2, which might be relevant to the remodeling processes.
20
 Our 
in vitro results do confirm this since the levels of MMP-2 in plasma were not 
affected by the incubation of leukocytes with immunomodulators like LPS and/or 
infliximab. Serum MMP-9 levels, in contrast to MMP-2, in the CD patients were 
found to be reduced by the treatment, with an increase again at the end of the 
follow-up. Similar to the duration of the increase of the MMP-2 level, the decrease 
of MMP-9 also lasted for a time period that coincides with the duration that 
infliximab is maintained at a detectable level in the circulation.
6
 MMP-9 is thought 
to be an active participator in the process of inflammation in CD, especially in the 
acute phase. Unlike other MMPs, MMP-9 is normally stored in secondary and 
tertiary granules of neutrophils poised for rapid release to participate in the reaction 
of the host to exogenous and endogenous stimulation. MMP-9 not only lyses 
components of the ECM, but also influences the generation or activation of c-x-c 
and other chemokines, which attract neutrophils to migrate across the BM of 
capillaries to inflammatory sites.
38
 Kirkegaard et al
29
 recently found MMP-9 to be 
markedly upregulated in and contribute to intestinal fistula formation in CD. During 
the evolvement of tissue repair, overexpression of MMP-9 has been speculated to 
prevent the healing process.
8
 In contrast, Salo et al
39 
concluded that MMP-9 plays 
a prominent role because it participated in every step of the healing process, 
including detachment of epithelial cells from the basal membrane, rolling of cells to 
the wound matrix, and remodeling of the granulation tissue. The neutrophil is the 
most important source of MMP-9 in the acute phase of inflammation.
40
 In the 
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present study, immunohistochemical evaluation showed that MMP-9 predominately 
existed in the neutrophils and to a lesser extent in the ECM of severely 
inflammatory regions. The reduction of the MMP-9 expression in intestinal tissue 
from the infliximab-treated CD patients is probably related to the decrease in the 
number of the inflammatory cells, especially neutrophils and monocytes/ 
macrophages.
41,42
 In addition, our previous ex vivo mucosal IBD explants study 
revealed that within 72 hours infliximab is able to markedly reduce the MMP-9 
synthesis/secretion also.
32
 MMP-9 was also found to be present in enteroendocrine 
cells. The significance of this observation needs to be elucidated further. Perhaps 
there is a similarity with the presence of MMP-7 in intestinal Paneth cells, which is 
believed to be related to the activation of α-defensin.
43,44
 Proinflammatory 
cytokines, such as TNF-α, IL-1β, are able to activate the MMP-9 gene through 
nuclear factor(NF)-κβ to enhance MMP-9 production.
39,45
 LPS stimulates 
monocytes to express MMP-9, which is partly dependent on TNF-α because 
neutralization of TNF-α significantly downregulated the production of MMP-9.
46
 Our 
in vitro study also showed that MMP-9 is released from leukocytes of both CD 
patients and healthy volunteers after short-term 1.5 hours LPS incubation. The 
release of MMP-9 from leukocytes of the CD patients was significantly higher than 
from healthy volunteers. Most likely, the abundance of MMP-9 in the CD 
neutrophils occurred during the process of their maturation activation in response 
to different stimulators, such as TNF-α and bacterial products.
47,48
 TNF-α seemed 
not to be involved in the process of MMP-9 secretion by neutrophils in vitro, as 
infliximab did not affect the level of MMP-9 in plasma. The transcription of MMP-9 
mRNA was found to be hardly affected by short-term LPS stimulation, probably 
because of the increased production of other immediate response mRNAs like that 
of TNF-α. Further incubation with LPS for 24 hours increased the level of MMP-9 
significantly in healthy volunteers rather than in CD patients. The MMP-9 mRNA 
was also strongly upregulated. Infliximab did suppress this increase of MMP-9 
mRNA, therefore we conclude that TNF-α is involved in the promotion of the 
transcription of MMP-9 mRNA. In the CD patients the MMP-9-producing blood cells 
probably lost their potential ability to further induce MMP-9 synthesis. We speculate 
that monocytes are the main MMP-9-producing blood cell type responding to the 
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long-term LPS incubation in this study. Pugin et al
46
 previously reported that the 
maximal level of monocytic MMP-9 synthesis was between 24-48 hours after LPS 
stimulation. Other studies also showed that LPS could activate monocytes to 
express the MMP-9 gene and protein, although they did not implicate TNF-α in 
their studies.
49,50
 The MMP-9 changes we observed in the serological follow-up of 
our patients are, however, most likely a reflection of what is happening at the 
mucosal level, also based on our explant studies, and less so an immediate effect 
of infliximab on circulating blood cell MMP-9 production and secretion. 
In conclusion, the serum MMP-2 and MMP-9 level in CD patients display an 
inverse changing pattern, i.e., an increase of MMP-2 and a decrease of MMP-9 
during the treatment with infliximab, although not strictly related to the clinical effect 
of infliximab. The enhanced leukocyte MMP-9 expression in CD seems to be 
regulated by and responsive to TNF-α mediation. These clinical findings reinforce 
previous observations in experimental models showing MMP-2 to be protective and 
MMP-9 to be enhancing dextran sodium sulfate-induced colitis, rendering the latter 
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Abstract 
Background/aims. Matrix metalloproteinases are associated with matrix turnover 
in both physiological and pathological conditions. We postulate an association 
between aberrant matrix metalloproteinases proteolytic activity and the intestinal 
tissue destruction, seen in patients with Crohn’s disease and/or ulcerative colitis. 
Methods. Surgically resected inflamed and non-inflamed ileum and colon 
with/without extensive fibrosis from 122 Crohn’s disease, 20 ulcerative colitis and 
62 control patients were homogenized. Protein levels of matrix metalloproteinases 
and tissue inhibitor of metalloproteinases were measured by enzyme-linked 
immunosorbent assays (ELISA), while matrix metalloproteinases and 
myeloperoxidase activity were measured by specific activity assays. 
Results. Expression of total levels of matrix metalloproteinases-1, -2, -3 and -9 
relative to tissue inhibitor of metalloproteinases-1 and -2 was increased in inflamed 
inflammatory bowel disease compared to non-inflamed inflammatory bowel disease 
and control intestinal mucosa. Also, net matrix metalloproteinases-1, -2, -3 and -9 
activity in inflamed inflammatory bowel disease was increased, with similar 
expression profiles in Crohn’s disease and ulcerative colitis. Within inflamed 
inflammatory bowel disease, a close correlation of matrix metalloproteinases with 
myeloperoxidase was observed. The expression of matrix metalloproteinases and 
tissue inhibitor of metalloproteinases was similar in inflamed Crohn’s disease tissue 
with or without extensive fibrosis and not related to fistulizing disease. 
Conclusions. We have shown increased net matrix metalloproteinases activity in 
intestinal inflammatory bowel disease tissue, likely to contribute to the tissue 
damage and remodelling seen in inflammatory bowel disease. 
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Introduction 
Crohn’s disease (CD) and ulcerative colitis (UC) are the major forms of chronic 
idiopathic inflammatory bowel disease (IBD). CD is characterized by periodic, 
segmental and often transmural infiltration of potentially the whole gastrointestinal 
tract, especially the ileocaecal area, by a variety of immune cells like T and B 
lymphocytes, histiocytes (developing into granulomas/giant cells) and 
granulocytes.
1
 The inflammatory infiltrate and resident cells secrete pro-
inflammatory chemokines and cytokines, proteinases, reactive oxygen radicals, 
etc., which cause extensive morphological damage manifested by ulcera, 
abcesses, fissures and fistulae. In a subset of patients the sustained intestinal 
inflammation activates (myo)fibroblasts and smooth muscle cells to deposit 
massive amounts of collagen III and V, resulting in fibrotic strictures, halting food 
passage and necessitating surgical removal of the affected bowel.
2,3
 Idiopathic UC 
affects the superficial mucosal layers of the colon, often starting from the rectum 
and extending proximally over the years.
4
 Although stenotic development is not as 
common as with CD, in UC the inflammatory infiltrate may also result in extensive 
mucosal damage, with surgical removal of part or the whole colon as the final 
clinical outcome. 
The matrix metalloproteinases (MMP) are a family of calcium and zinc containing 
neutral endoproteinases implicated in matrix tissue turnover during normal growth, 
development and reproduction but are also involved in several pathological 
conditions, i.e. cancer metastasis, rheumatoid arthritis, atherosclerosis, psoriasis, 
etc.
5
 They have been shown to degrade a considerable number of important 
structural matrix molecules (Table 1), and an altered production of MMPs might 
contribute to the tissue morphological changes seen in IBD patients. Actually, 
reports have demonstrated an increased level of several MMPs in inflamed 
intestine of IBD patients, which was accompanied by an insufficient upregulation of 
the endogenous MMP inhibitors, i.e., tissue inhibitor of metalloproteinases 
(TIMP).
6-14
 These studies do not report, however, about the actual activity of these 
MMPs in the IBD tissues. Also, in several models of IBD, e.g., DSS- and TNBS-
induced colitis in rats and mice, immune infiltration was clearly associated with an 
upregulation of MMPs and the mucosal damage could be reversed by application 
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of specific MMP inhibitors.
15-17
 However, in fibrotic and stenotic areas, the 
increased synthesis of collagens by mesenchymal cells may actually lead to a 
thickening of the bowel wall probably because of dysregulated MMP matrix 
degradative capacity. For example, in fistulae with chronic inflammation and 
fibrosis only a moderate upregulation of MMP-3 and -9 versus TIMP was observed 
opposite to the massive upregulation of these MMP members in areas with acute 
inflammation without fibrosis.
18
 Given the potential relevance in IBD pathogenesis, 
their interactions and substrate diversity (Table 1), we not only measured MMP-1,  
-2, -3, -9 and TIMP-1, -2 protein levels by ELISA but also their activity by specific 
immunocapture bioactivity assays. We show an upregulation of these MMPs 
relative to TIMP, associated with higher (patho)physiological MMP activity in 
inflamed IBD intestinal mucosa compared with non-inflamed tissue from both IBD 
and control patients. In CD patients, MMP levels were independent of the 
macroscopical/histological co-presence of fibrosis and were not related to the 
incidence of fistulae during follow-up. 
 
Table 1. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) analyzed in this 
study, with their characteristics.
5,38 






MMP-1 Interstitial collagenase 
Collagenase-1 
Fibrillar collagens, pro-MMP-2 and -9 52 and 41 
MMP-2 Gelatinase A Collagens, gelatins, elastins, laminin 72 and 66 
MMP-3 Stromelysin-1 Extracellular glycoproteins, non-fibrillar 
collagens, pro-MMPs 
57, 45 and 
28 
MMP-9 Gelatinase B Collagens, gelatins, elastins, laminin 92 and 85 
 
TIMP-1 Fibroblast collagenase 
inhibitor 
Collagenase inhibitor 
(pro-) MMP-9 28 
TIMP-2 CSC-21K (pro-) MMP-2 21 
a
kDa = kilo Dalton 
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Materials and methods 
Tissue samples 
Over the period 1983–2002 macroscopically inflamed/affected as well as non-
inflamed/unaffected intestinal mucosa was prospectively collected immediately 
after surgical resection from 122 (49 male (M)/73 female (F)) CD and 20 (6 M/14 F) 
UC patients at the departments of Surgery, Pathology and Gastroenterology-
Hepatology of our hospital and stored at −70 
0
C (Table 2). The IBD patients under-
went operation because of stricturing processes, fistulae and/or luminal disease 
activity refractory to medical therapy (aminosalicylates, corticosteroids, 
azathioprine, methotrexate and/or anti-TNF-α antibody infliximab). Severe  fibrosis 
in inflamed CD mucosa, often manifested by a thickened wall and narrowed lumen, 
was documented in the histopathology reports from the Pathology department. 
Incidence of peri-anal, entero–entero, entero–viscero and/or enterocutaneous 
fistulae in CD patients in their clinical history and during follow-up (evaluation 
period median 24.7, range 3.3–58.5 years) was recorded in patient files from the 
Gastroenterology department. Also, from 62 (26 M/36 F) colorectal carcinoma or 
adenoma patients, macroscopically normal control mucosa at least 10 cm away 
from the surgically resected neoplasia was collected. Reflecting the early onset, 
CD and UC compared to control patients were younger at time of surgery (Table 
2). Intestinal mucosa was homogenized in 1 ml 0.1 M Tris–HCl, 0.1% Tween 80, 
pH 7.5 per 60 mg tissue using a Potter device (B Braun, Germany) as described 
previously.
19
 Protein concentration was determined by the method of Lowry et al.
20
 
and myeloperoxidase (MPO) activity was measured as described elsewhere, 
based on the conversion of the ortho-dianisidine dihydrochloride MPO substrate in 




Determination of MMP and TIMP by ELISA and BIA 
Levels of MMP-2 and -9 protein were measured in appropriately diluted 
homogenates by our in-house ELISAs, as described previously.
8
 TIMP-1 and -2 
proteins were measured by commercially available ELISAs from R&D systems, 
according to the manufacturer’s instructions.
22
 MMP-1, -2, -3, and -9 activities were 
determined by highly specific immunosorbent activity assays (BIAs) from  
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Table 2. Patient and tissue specifications 
 CD UC IBD Controls P-value
a
 



















































47, 66, 12 NA 47, 66, 27 NA NA 










NA = not applicable.  
a P-value IBD vs. controls, note the relative abundance of ileum relative to colon tissue and 
young age at surgery in IBD. 
b In addition, 15 inflamed and 9 non-inflamed CD tissues with unspecified intestinal origin 
were collected. 
c Mild treatment: patients received no medication or were treated with mesalazine; Strong 
treatment: corticosteroids, azathioprine, infliximab, etc. 
d Protein measurements on multiple tissue resection specimens with similar inflammation 
status and collected at the same surgery were averaged. 
 
Amersham Biosciences, essentially as described elsewhere.
8,23,24
 In brief, sample 
MMPs were captured by immobilized MMP mono-specific antibodies in microtitre 
plates. After incubation in buffer with (for total MMP activity) or without (for 
endogenously active MMP) latent MMP activating p-aminophenyl mercuric acetate 
(APMA), pro-urokinase modified to contain a MMP recognition cleavage site was 
added. The MMP-activated pro-urokinase subsequently converted peptide 
substrate S-2444 and absorption was measured at 405 nm. Results are expressed 
as arbitrary units/mg protein. 
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Statistical analysis 
Kolmogorov–Smirnov analysis of data sets revealed statistically significant 
deviation from normal distribution, thus unpaired and paired differences were 
assessed by non-parametric Mann–Whitney U-tests and Wilcoxon signed-ranks 
tests, respectively. Correlation between two variables was performed by Spearman 
ranks correlation test or Pearson Chi-square test. Differences and correlations 
were deemed statistically significant when two-tailed P-value ≤0.05. All tests were 
performed using SPSS statistical software, version 11.0. 
 
Results 
A consistent upregulation of MMP protein, along with MPO activity, was observed 
in inflamed IBD intestinal mucosa (Fig. 1). Total levels of MMP-1 activity (BIA with 
APMA) and MMP-2 and -9 protein were upregulated 2.5-, 1.8- and 6.8-fold 
compared to controls, respectively, while the overexpression of total MMP-3 activity 
was even more impressive (18.6 versus 0.0 U/mg). The increase in total MMP 
protein/activity was only partially compensated by TIMPs: TIMP-1 was upregulated 
1.7-fold, while TIMP-2 levels were similar between IBD and control tissue. When 
compared to (paired) non-inflamed IBD tissue, MMPs and TIMP-1 were 1.8–7.8 
versus 1.9-fold upregulated, respectively, while non-inflamed IBD compared to 
control mucosa expressed higher levels of MMP-3 and -9 (2.4 versus 0.0 U/mg and 
9.7 versus 5.5 ng/mg) along with a small increase in MPO activity. The magnitude 
of the overexpression of MMP relative to TIMP in inflamed IBD is shown in Table 3. 
The increase in absolute and relative MMP and TIMP levels was paralleled by an 
increase in net (BIA without APMA) MMP activity in inflamed IBD versus control 
tissue (Fig 2: MMP-1, -2, -3 and -9: 5.6 versus 2.7, 1.2 versus 0, 5.7 versus 0,  
181 versus 65 U/mg, respectively) and in net MMP-3 activity compared to non-
inflamed IBD tissue. In non-inflamed IBD versus control tissue, the relative 
expression of MMP-3 and MMP-9 to TIMP was increased as well (Table 3), but this 
was not sufficient to significantly increase their net MMP activity (Fig. 2). 
Expression of MMP, TIMP and MPO appeared very similar in CD compared to UC 
with corresponding inflammation status; only in inflamed CD tissue total MMP-1  
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Figure 1. Total MMP, TIMP and MPO protein/activity expression (median + 75th percentile) 
by inflamed and non-inflamed IBD vs. normal control intestinal mucosa. n = 28, 25, 16 
(MMP-1t); 70, 50, 22 (MMP-3t); 178–179, 140, 62 (MPO, MMP-2, -9 and TIMP-1, -2) for 
inflamed IBD, non-inflamed IBD and controls, respectively. ***P < 0.001, **P < 0.01, *P < 
0.05 vs. control; 
$$$
P < 0.001, 
$$
P < 0.01, 
$
P < 0.05 vs. paired non-inflamed IBD (n = 25, 47 
and 127–128 for MMP-1, -3t and MMP-2, -9, TIMP-1, -2, MPO, respectively). MMP-1 and -3 
activities (U/mg protein) were measured by BIA (+APMA) and MMP-2, -9 and TIMP-1,-2 
(ng/mg) by ELISA, respectively. Note the logarithmic scale on the y-axis. 
 
activity was found to be lower [respectively, 5.9 (0.0–120.7) versus 23.0 (0.0–
187.4) U/mg, P < 0.05] whereas TIMP-2 was found to be higher [respectively, 6.7 
(2.1–16.2) versus 5.5 (3.2–10.20) ng/mg, P < 0.01]. In inflamed CD, most of these 
protein markers were slightly downregulated when patients were treated with 
strong medication compared with mild medication prior to surgery, while these 
findings were essentially reproduced in non-inflamed CD (data not shown). The 
distribution of ileal and colonic tissues is different between the IBD and control 
groups and therefore the altered expression of MMPs in IBD might thus be 
attributed to a higher proportion of ileum tissue in this group (Table 2). However, 
when the above analyses were repeated stratified according to tissue origin, i.e., 
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Figure 2. Net MMP activity (median + 75th percentile) in inflamed and non-inflamed IBD 
vs. macroscopically normal control intestinal mucosa. n = 28, 25, 16 (MMP-1a); 70, 52, 22 
(MMP-2, -3, -9a) for inflamed IBD, non-inflamed IBD and controls, respectively. ***P < 0.001, 
*P < 0.05 vs. controls; 
$$$
P < 0.001 vs. paired non-inflamed IBD (n = 25 for MMP-1 and  
n = 49 for MMP-2, -3 and -9a). MMP activities (U/mg protein) were measured by BIA with 
omission of APMA. For graphical purposes, actual MMP-9 values are 100-fold larger than 
depicted. 
 
Within the inflamed IBD tissues, expression of MMPs and TIMPs was often 
correlated to MPO activity. Notably, the net MMP-3 activity was strongly correlated 
with MPO, as were the total MMP-3/TIMP ratios (0.41 ≤ ρ ≤ 0.47, P < 0.001). Also, 
net MMP-1 activity was associated with MPO (ρ = 0.38, P < 0.05), but the levels of 
total MMP-1/TIMP were not. Remarkably, net gelatinase activities were not 
correlated with MPO, while the MMP-9, but not the MMP-2, and the MMP-9/TIMP 
ratios were (0.42 ≤ ρ ≤ 0.47, P < 0.001). Finally, no difference in expression of any 
of the MMP, TIMP or MPO parameters was observed in inflamed CD tissue in 
relation to the co-presence of fibrosis and none of these markers were related to 
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Figure 3. MMP, TIMP and MPO protein/activity expression (median + 75th percentile) by 
inflamed CD intestinal mucosa with or without extensive fibrosis (a) and with or without 
fistulizing disease during follow-up (b) (unpaired data). n = 7–10 (MMP-1t, MMP-1a); 16–31 
(MMP-2a, MMP-3t, MMP-3a, MMP-9a); 40–103 (MPO, MMP-2, -9 and TIMP-1, -2). Note the 









































MMP-1t   MMP-3t  TIMP-1   MMP-1a  MMP-3a          MPO 
     MMP-2   MMP-9     TIMP-2  MMP-2a   MMP-9a 
MMP-1t   MMP-3t  TIMP-1   MMP-1a  MMP-3a          MPO 
     MMP-2   MMP-9     TIMP-2  MMP-2a   MMP-9a 
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Table 3. Median (range) MMP over TIMP ratios in inflamed and non-inflamed IBD vs. control 
intestinal mucosa. 
Ratio Inflamed IBD Non-inflamed IBD Controls 
MMP-1/TIMP-1 1.1 (0.0–14.3) 0.7 (0.0–23.4) 0.6 (0.0–21.0) 
MMP-1/TIMP-2 1.5 (0.0–38.2)** 0.7 (0.0–35.9) 0.4 (0.0–10.7) 
MMP-2/TIMP-1 12.0 (0.8–87.8) 12.2 (2.3–1787.6) 11.8 (2.0–85.5) 
MMP-2/TIMP-2 14.4 (0.8–90.7)***
,†






 0.5 (0.0–6.8)*  0.0 (0.0–0.9) 
MMP-3/TIMP-2 2.8 (0.0–66.3)***
,†
 0.3 (0.0–23.5)* 0.0 (0.0–0.6) 
MMP-9/TIMP-1 4.3 (0.2–33.0)***
,†
 2.5 (0.1–259.0)*** 1.3 (0.1–7.5) 
MMP-9/TIMP-2 5.1 (0.2–67.2)***
,†
  1.5 (0.1–100.9)*** 0.9 (0.1–5.1) 
n = 28, 25, 16 (MMP-1); 70, 50, 22 (MMP-3) and 179, 139-140, 62 (MMP-2, -9), 
respectively. MMP-1 and -3 were measured in BIA with APMA and ratios to TIMP are in 
U/ng, MMP-2 and -9 were measured in ELISA and ratios have no unit.* P < 0.05 vs. 
controls.** P  < 0.01 vs. controls.*** P < 0.001 vs. controls.
†
 P < 0.001 vs. paired non-
inflamed IBD (n = 25 (MMP-1), 47 (MMP-3), 127-128 (MMP-2, -9)). 
 
Discussion 
We have shown an upregulation of MMP-1, -2, -3 and -9 protein relative to  
TIMP-1, -2 in inflamed CD and UC versus non-inflamed IBD and normal intestinal 
mucosa, while non-inflamed IBD already contained more MMP-3 and -9 relative to 
TIMP compared to control tissue. More importantly, however, also the net activity 
of MMP-1, -2, -3 and -9 was increased in inflamed IBD and within this group,  
MMP-1 and -3 activities were correlated with MPO level. There are several 
mechanisms by which the inflammatory infiltrate might induce net MMP activity. 
The cytokines secreted by lymphocytes, monocytes and neutrophils, i.e., TNF-α, 
IL-1β, IFN-γ, etc., have been shown to induce synthesis of MMPs relative to TIMP 
not only in the inflammatory cells themselves, but also in the resident cells.
25-27
 The 
induced MMPs might be activated by the MPO generated chlorinated oxidants,
28
 
while these radicals were also shown to degrade TIMP.
29
 In addition, MMP-14, the 
natural activator of MMP-2, seems to be upregulated in IBD,
14
 leading to increased 
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active MMP-2 and the latter can proteolytically activate MMP-9.
30
 Also, the 
increased MPO activity likely reflects an inflammatory infiltrate at least partly 
consisting of neutrophils, and neutrophil-derived elastase was shown to degrade 
TIMP and activate MMP.
31
 As mentioned before, MMP-1, -2, -3 and -9 collectively 
are capable of cleaving various structural matrix molecules. Also, they have been 
shown to cleave several non-structural proteins as well, for instance, MMP-9 
potentiates pro-inflammatory interleukin-8 by removing the first six aminoterminal 
aminoacids
32
 and processes IL-1β into an active form,33 while MMP-2 and MMP-9 
both degrade substance P, an important neurokine.
34,35
 Furthermore, MMP-1 
degrades IGFBP thus releasing IGF mitogenic activity,
36 
while MMP-3 inactivates 
α(2)-antiplasmin, thus favouring local plasmin mediated proteolysis.37 In 
combination, the increased levels of these MMPs probably mediate not only the 
structural damage to the tissue but may also propagate the excessive immune 
response seen in intestinal tissue from IBD patients. Importantly, the medication 
our patients received, whether mesalazine, corticosteroids, azathioprine, etc., could 
not prevent the increase in MMP over TIMP. This is in support of our hypothesis of 
MMP-mediated tissue damage necessitating surgery. However, some of the high 
MMP protein/activity levels we observed in inflamed IBD tissue may also 
counteract tissue damage. For instance, MMP-2 was demonstrated to protect 
against colitis probably by increasing intestinal barrier function.
38
 In inflamed CD 
tissue with versus without extensive fibrosis, MMP and TIMP protein/activity levels 
were found to be similar, corroborating the results obtained by Warnaar et al.
39 
These authors also demonstrated increased MMP expression in the healthy 
proximal margin of resected ileal CD tissue by immunohistochemistry and on the 
mRNA level, suggesting an active role for MMPs in fibrosis, perhaps in facilitating 
(myo)fibroblast migration.
40
 This hypothesis is confirmed by the inhibition of 
bleomycin-induced pulmonary fibrosis in mice and of TNBS-induced colonic 





Alternatively, the MMPs might intentionally counteract the process 
of fibrosis but may simply not be sufficiently upregulated to degrade the excessive 
collagen deposition.
18,42,43 
In our study, the MMP levels in resected inflamed (and 
non-inflamed, not shown) CD tissue were not related to the incidence of fistulae 
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during follow-up. In a previous report, Kirkegaard et al.
18 
demonstrated increased 
MMP levels within fistulae of CD patients. These observations indicate that the 
inflammatory process is accompanied by increased MMP proteolytic activity but 
that is not indicative as such for the fistulizing phenotype of CD. In that respect we 
recently also noticed that infliximab treatment of ex vivo explants of inflamed 
intestinal tissue from IBD patients decreased MMP-1, -3 and -9 protein and activity 
relative to the TIMPs, but not that of MMP-2, which in patients with CD was also 
reflected in the serum during treatment follow-up.
44,45 
In summary, our study 
extends previous reports by showing an association between upregulated levels of 
MMP-1, -2,-3, -9 and morphological damage, i.e., ulcers and also stenotic strictures 
in intestinal tissue from IBD patients, not only at the MMP protein but particularly at 
the activity level. Future studies should focus on proof of in vivo activity, for 
instance by detection of proteolytic fragments likely to originate from cleavage by 
MMP, which could be followed by trials involving administration of specific MMP  
(-1, -3, -9) inhibitors to IBD patients suffering from relapse. 
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Abstract 
Background/aims. To study the (functional) relevance of single nucleotide 
polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2,  
-3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor 
(TNF)-α in the etiopathogenesis of inflammatory bowel diseases (IBD), that may 
enhance susceptibility and/or disease severity. 
Methods. Genomic DNA from 134 Crohn’s disease (CD), 111 ulcerative colitis 
(UC) patients and 248 control subjects was isolated from resected intestinal tissue 
or blood. Allelic composition at SNP loci was determined by PCR-RFLP or tetra 
primer ARMS PCR. 
Results. The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was 
found to increase CD susceptibility (39% vs  23.8%, P  = 0.018 and 67.9% vs 
51.6%, P  = 0.055, respectively), while women with this genotype were less prone 
to development of fistulae during follow-up (41.4% vs  68.3%, P = 0.025). Male IBD 
or CD patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 
in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01). The 
5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic 
complications in CD during follow-up (91.2% vs  71.8%, P = 0.022) but seemed to 
protect against colonic involvement of this disease at first endoscopic/radiologic 
examination (35.3% vs  59.5%, P = 0.017). 
Conclusions. Allelic composition at the examined SNPs in genes coding for  
TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing 
disease, stricture pathogenesis and first disease localization. These findings 
reinforce the important role of these proteins in IBD. 
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Introduction 
Crohn’s disease (CD) is characterized by chronic, patchy, transmural inflammation 
of the gastrointestinal tract, predominantly in the ileocecal area, while ulcerative 
colitis (UC) is manifested by chronic, continuous, rather superficial inflammation of 
the mucosal layers of the colon.
1,2
 The incidence and prevalence of  both CD and 
UC have increased in the Western population since the second World War,
3,4
 and 
lately also increased in developing industrializing countries. Although there has 
been much controversy regarding etiology and pathogenesis of both forms of 
inflammatory bowel disease (IBD), recent evidence points to an exaggerated 
immune response to enteric bacterial flora in genetically susceptible individuals. 
Based on a higher disease concordance in monozygotic vs dizygotic twins,
5
 a 
higher frequency of IBD in certain families and ethnic groups,
6,7
 the association of 
IBD with genetic disorders like Turner’s and Hermansky-Pudlak syndrome,
8,9
 the 
presence of  a genetic component in IBD is evident. Indeed, large-scale genome-
wide linkage studies have mapped several regions of  the human genome to IBD, 
i.e., 16q12 (IBD1),12q13 (IBD2), 6p21 (IBD3), 14q11 (IBD4), 19p13 (IBD5), 
5q31-q33 (IBD6) and Xq21.3
10-15
 and subsequent research has identified several 
CD predisposing mutations in the IBD1 gene encoding NOD2.
16
 However, the 
different chromosomal locations found to be associated with IBD in these studies 
suggest disease heterogeneity: different sets of  disease predisposing mutations 
may lead to a similar clinical outcome. This is corroborated by evidence obtained 
from animal models, where distinct genetic manipulations, for instance deletion of  
the DNA encoding TCR-α, IL-10 or TNF-α 3’UTR AU repeat motifs, all lead to ileitis 
and/or colitis.
17-19
 Therefore, genes on other loci, not identified in the studies 
mentioned above, may also contribute to IBD susceptibility and worthy considering 
in this respect are the matrix metalloproteinases (MMPs) and their natural 
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). The MMPs constitute 
a group of  neutral, Ca- and Zn-activated endoproteinases and are involved in 
physiological matrix turnover during embryogenesis, angiogenesis, etc.
20
 
Production is tightly regulated at the transcriptional and post-transcriptional levels, 
and excessive MMP-mediated tissue destruction is prevented by strictly regulated 
activation mechanisms of  the latent pro-enzyme and inhibition of  the active 
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enzyme in a 1:1 stoichiometry by TIMPs. Recently, several functional single 
nucleotide polymorphisms (SNPs) in the genes encoding MMPs and TIMPs have 
been described. The insertion of  an additional guanosine residue at -1607 in the 
promoter of  MMP-1 creates a PEA3 consensus sequence next to an AP-1 binding 
site upregulating promoter activity, while the insertion of  an additional thymidine at 
-1613 of  the MMP-3 promoter results in decreased mRNA transcription.
21,22
 The    
-1306 C/T transition in the promoter of MMP-2 results in decreased binding affinity 
for stimulating protein Sp1, leading to decreased mRNA transcription.
23
 In contrast, 
the -1562 C/T transition in the promoter of MMP-9 results in the removal of a 
binding site for an unknown repressor protein, thus elevating transcription.
24
 In 
TIMP-1 and -2 SNPs have been found in the exon part of the genes (+372 T/C and 
+303G/A, respectively). Although no effect on transcriptional activity/mRNA stability 
was observed, these SNPs might serve as markers in association studies.
25
 Both 
MMP and TIMP expression are affected by TNF-α and this proinflammatory 
cytokine is known to play a pivotal role in IBD, particularly CD but also UC, as 
demonstrated by impressive clinical improvement following anti-TNF-α antibody  
infliximab administration.
26,27
 The G/A transition at -308 in the TNF-α promoter 
might result in increased levels of  circulating TNF-α protein,28 thus inducing extra 
MMPs and/or TIMPs. Of note, the gene encoding TNF-α is mapped to the 6p21 
IBD3 region, while the MMP and TIMP genes have not been mapped to any known 
IBD region (MMP-1, -3: 11q22-q23; MMP-2: 16q13; MMP-9: 20q11.2-q13.1;  
TIMP-1: Xp11.3-p11.23 and TIMP-2: 17q25). Conceivably, direct and indirect SNP-
linked overproduction of  MMPs and/or downregulation of  TIMPs, would result in 
net destruction of tissue, impairment of  intestinal barrier function, influx of bacteria 
and consequently excessive immune response, thus predisposing to or worsening 
IBD. Therefore, we analyzed the genotype distributions at these SNP loci of the 
genes encoding MMP-1, -2, -3, -9, TIMP-1, -2 and TNF-α in CD, UC and controls. 
Recently, we measured MMP and TIMP protein/activity levels in a large group of  
resected intestinal IBD tissues (Meijer et al, submitted) and here the expression 
data in a subgroup of which we also had DNA, are correlated to MMP, TIMP and 
TNF genotypes. 
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Materials and methods 
Surgically resected intestinal mucosa from predominantly Dutch Caucasian 
patients with CD (n = 134, 40% male, median age at surgery 36.3 years, range 
11.6-78.7 years) or UC [n = 111, 42% male, 37.8 (15.9-81.9) years], was collected 
in the period 1983-2002 at the department of Pathology, LUMC and stored at  
–70 
0
C. The control group consisted of 79 patients with colorectal carcinoma [CRC, 
macroscopically normal tissue obtained at least 10 cm away from evident 
neoplasia, 43% male, median age at surgery 56.4 (19.0-85.0) years] and 169 
healthy volunteers [37% male, age at blood collection date 33.3 (18.2-72.9) years], 
recruited among spouses of  patients from the outpatient clinic and through 
advertisement. Informed consent from participants and approval of the LUMC 
ethics committee for the study protocol was obtained.
29 
In both the IBD and control 
groups, more than 95% of the participants were of Caucasian origin. Resected 
tissue was homogenized with a Turrax device, blood was centrifuged and genomic 
DNA was isolated using the salting out method
30
 and reconstituted to 10 ng/µL in 
0.01 mol/L Tris/0.1 mmol/L EDTA, pH = 7.5. Differential diagnosis of CD or UC was 
established by routine clinical, radiological and histological findings. Age at onset, 
localization at first endoscopy/radiology and development of fistulae and stenotic 
processes in a subset of CD patients (n =123) were recorded in medical files. The 
measurement of myeloperoxidase was according to the procedure described by 
Kruidenier et al,
31
 while the MMP and TIMP protein/activity levels in IBD and CRC 
control tissue were measured previously by our group (Meijer et al.
32
 and 
submitted). In brief, homogenates obtained from surgically resected tissue were 
appropriately diluted. The MMPs and TIMPs antigen levels were measured by 
ELISAs (MMP-2, -9, TIMP-1, -2) or by highly sensitive bio-immuno activity assays 
(BIA) involving the conversion of chromogenic peptide S-2444 by MMP-activated 
pro-urokinase (MMP-1,-3), with all BIAs performed in the presence of APMA to 
account for total MMP antigen levels. Allelic composition at the SNPs of interest 
was determined by PCR-RFLP (MMP-1, -3, -9, TIMP-1, -2) or tetra primer ARMS 
PCR (MMP-2), as described previously.
32,33
 Differences between groups were 
assessed by Chi-square, Kruskal-Wallis or Mann-Whitney U tests, as indicated. 
Statistical significance was reached if  two-tailed P value ≤ 0.05 
158 - Chapter 6 
Results 
Allelic composition at SNP loci of MMP, TIMP and TNF genes  
Between IBD and controls, no significant differences in genotype distribution were 
found at -1607 1G/2G and -1306 C/T of MMP-1 and -2 promoters, respectively 
(Table 1). Also, 1G MMP-1 (55.4 vs 51.4%) and C wild-type (75.5 vs 76.8%)  
MMP-2 allelic frequencies were similar in both groups. The MMP-3 and MMP-9 
genotype distribution at -1613 5T/6T and -1562 C/T, respectively, were also similar. 
The TIMP-1 gene is located on the X-chromosome, thus the results are presented 
according to gender. In both men and women the T (T) genotype seems relatively 
abundant in IBD (men T 61.6 vs 51.6%; women TT 31.2 vs 23.8%) and especially 
in CD (men T 67.9 vs 51.6%, P = 0.055; women TT 39.0 vs 23.8%, P = 0.018, 
Table 2). No differences in genotype distribution were observed for TIMP-2 and 
TNF-α at +303 G/A and -308 G/A, respectively (Table 1). For all SNPs, genotype 
frequencies in the control group are similar to what was expected from the Hardy-
Weinberg equilibrium, except for MMP-2 (CC, CT, TT: 61.9, 29.9, 8.2 observed vs 
59.0, 35.7, 5.3% expected, χ
2
 = 6.36, P < 0.05). Genotype and allelic frequencies 
for all SNPs examined were similar in CD versus UC and also in the healthy 
volunteers vs the carcinoma controls. As MMPs and TIMPs are involved in cancer 
and metastasis, all analyses were repeated with a control group consisting only of 
the healthy volunteers (n = 169), yielding similar results as mentioned above. 
 
Effect of MMP and TNF-α SNPs on CD phenotype 
The median age at onset of disease in 123 CD patients with a full medical record 
was 21.5 (range 0.3-61.5) years. Patients stratified according to genotype at the 
SNPs examined had similar ages at onset (Table 3). At first endoscopic/radiologic 
examination, in 53.3% of the patients colonic w/wo ileal involvement was evident. 
The MMP-3 genotype was associated with disease localization (P = 0.04 for all 
three groups) and further analysis revealed a lower chance of colonic involvement 
at first endoscopy/radiology in patients with the 5T5T MMP-3 genotype (P = 0.017, 
5T5T vs 5T6T and 6T6T combined). However, this genotype also conferred a 
major risk to development of stenotic complications: 91.2% of patients carrying the 
5T5T genotype suffered from stenotic complications compared to 71.8% for the 
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Table 1. Genotype distributions at SNP loci in IBD patients compared to controls 














MMP-1 -1607 1G/2G 1G1G 31 26.6 1G 55.4 51.4 
 11q22-q23 1G2G 49 49.6 2G 44.6 48.6 
  2G2G 20.1 23.8    
MMP-2 -1306 C/T CC 57.7 61.9 C 75.5 76.8 
 16q13 CT 35.6 29.9 T 24.5 23.2 
  TT 6.7 8.2    
MMP-3 -1613 5T/6T 5T5T 29.2 27.9 5T 52.3 52
 
 11q23 5T6T 46.3 48.4 6T 47.7 48
 
  6T6T 24.6 23.8   
 




CT + TT 27.6 30.3 T 14.4 16 




C 38.4 48.4 C 38.4 48.4 
♀, TIMP-1
1




TC 43.3 53.6 C 47.2 49.3 
  CC 25.5 22.5    
TIMP-2 +303 G/A GG 77.5 78.7 G 88.3 89.1 
 17q25 GA + AA 22.5 21.3 A 11.7 10.9 
TNF-α -308 G/A GG 68.8 69.7 G 82.0 83.0 
 6p21 GA + AA 31.4 30.3 A 18.0 17.0 
n = 239-240/245 IBD patients vs n = 244/248 controls with successful genotype 
determinations. 
1
For TIMP-1, ♂ these numbers are 99/101 vs 93/96 and for TIMP-1, ♀ 
141/144 vs 151/152. Note: for MMP-9, TNF-α and TIMP-2 frequency of the homozygote 
mutant genotype (TT, AA and AA, respectively), was below 5% and these groups were 
combined with the corresponding heterozygote group, solely for the purpose of accurate 
statistical analysis. No statistically significant differences (Chi-Square testing) in genotype 
distributions or allele frequencies were found between IBD and controls. 
 
160 - Chapter 6 























♂ T 67.9 51.6 0.055 T 67.9 51.6 0.055 
 C 32.1 48.4  C 32.1 48.4  
TIMP-1, 
♀ TT 39 23.8 0.018 T 56.5 50.7 0.238 
 TC 35.1 53.6  C 43.5 49.3  
 CC 26 22.5      
♂: n = 53/54 vs 93/96; ♀: n = 77/80 vs 151/152 successful genotype determinations, 
respectively. 
1
P-value, Chi-Square test. 
 
other genotypes (P = 0.022). The allelic polymorphisms at other SNP loci were not 
associated with disease localization or stricture involvement. Of all CD patients, 
80/123 or 65.0% developed peri-anal, entero-entero or entero-cutaneous fistulae 
during follow-up. Female patients with the TT genotype at +372 SNP of TIMP-1 
appeared less prone to develop fistulae (P = 0.08), and when the TT group was 
compared with the combined TC and CC group, this result was statistically 
significant (P = 0.025). 
 
Effect of SNPs on protein expression 
Male IBD patients carrying the T allele at SNP +372 expressed lower levels of  
TIMP-1 in inflamed tissue compared to those carrying the C allele, P = 0.009  
(Fig. 1), with similar MPO levels in both groups [median 24.2 (range 9.1-80.4) vs 
28.6 (2.5-75.9) U/g, P = 0.194]. In male CD patients a similar pattern in TIMP-1 
expression was observed [6.8 (1.7-18.6) vs 9.2 (1.8-19.9) ng/mg TIMP-1, n = 46 vs 
19, T vs C allele, respectively], although not longer statistically significant (P = 
0.065). However, female IBD or CD patients carrying the TT, TC or CC genotype 
expressed similar levels of TIMP-1 in inflamed tissue. The respective protein 
expression was not affected by genotype at other MMP and TIMP SNPs in 
inflamed intestinal tissue. In non-inflamed IBD and control CRC tissue, no 
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Table 3. Effect of MMP, TIMP and TNF-α allelic SNP composition on age at onset of 
disease, colon involvement at first endoscopic/radiologic examination and development of 
fistulae or stenotic strictures during follow-up [median 24.7 (range 3.3-58.5) yr] in CD   






























1G1G 38 20.7 (0.3-45.6) 52.6 71.1 84.2 
  1G2G 54 22.4 (7.0-61.5) 50 63 75.9 
  2G2G 26-27 21.0 (3.4-40.2) 57.7 63 70.4 
MMP-2 -1306 C/T CC 66-67 20.1 (5.8-61.5) 57.6 64.2 74.6 
  CT+TT 52 
2




5T5T 34 22.4 (0.3-53.6) 35.3 
a
 70.6 91.2 
a
 
  5T6T 54 19.3 (3.4-61.5) 63 66.7 74.1 
  6T6T 30-31 23.5 (7.2-49.1) 53.3 58.1 67.7 
MMP-9 -1562 C/T CC 88-89 21.0 (0.3-61.5) 53.4 68.5 75.3 
  CT + TT 30 
2
 22.7 (7.2-45.5) 50 56.7 83.3 
♂, TIMP-1 +372 T/C T 32 18.9 (0.3-48.3) 53.1 78.1 87.5 
  C 17 18.5 (5.9-61.5) 52.9 76.5 94.1 
♀, TIMP-1 +372 T/C TT 29 24.3 (7.0-56.8) 55.2 41.4 c 69.0 
  TC 22-23 23.5 (3.4-39.6) 45.5 69.6 78.3 
  CC 18 22.2 (10.4-49.1) 55.6 66.7 55.6 
TIMP-2 +303 G/A GG 91-92 21.5 (0.3-61.5) 56.0 68.5 77.2 
  GA + AA 27 
2
 22.4 (3.4-56.8) 40.7 55.6 77.8 
TNF-α -308 G/A GG 79-80 22.6 (0.3-61.5) 50.6 68.8 78.8 
  GA + AA 39 
2
 18.9 (3.4-45.5) 56.4 59.0 74.4 
1
 Expressed as (% of patients); 
2
 Only 7, 1, 2 and 4 patients were carrying the MMP-2, -9, 
TIMP-2 or TNF-α mutant genotype, respectively, and were combined with the heterozygote 
group for statistical purposes. Differences in phenotype between genotypes were tested for 
statistical significance by Kruskal-Wallis/Mann-Whitney U (onset) or Chi-Square test (colon 
involvement/fistulae and stricture development); 
a
P ≤ 0.03 vs 5T6T and 6T6T combined; 
c
P 
= 0.025 vs TC and CC combined. 
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differences in protein levels were observed between patients stratified to genotype. 
Finally, allelic composition at TNF-α-308 G/A was not associated with higher or 
lower levels of MMPs or TIMPs in inflamed and non-inflamed IBD or control tissue. 
 
Figure 1. Protein expression in inflamed IBD tissue stratified to genotype. Values represent 
the median + 75
th
 percentile and are in ng/mg (MMP-2, -9, TIMP-1, -2) or in arbitrary 
units/mg (MMP-1, -3). From left to right; MMP-1: 1G1G, 1G2G, 2G2G (n = 6, 17, 5); MMP-2: 
CC, CT + TT (n = 99, 77); MMP-3: 5T5T, 5T6T, 6T6T (n = 21, 33, 16); MMP-9: CC, CT + TT 
(n = 129, 46); TIMP-1 male: T, C (n = 47, 24); TIMP-1 female: TT, TC, CC (n = 42, 37, 26); 
TIMP-2: GG, GA + AA (n = 135, 41). 
b
 P < 0.01, Mann-Whitney U test. 
 
Discussion 
In this study we found increased susceptibility to CD in men and women carrying 
the T and TT genotype, respectively, at TIMP-1 SNP +372. The X chromosome 
region p11.3-p11.23 might thus represent a novel linkage marker in IBD, extending 
the results obtained in previous genome-wide linkage studies.
14,34
 Women with this 
genotype also appear less prone to the development of  fistulae. The direct or 
indirect involvement of the X-chromosome in CD etiopathogenesis is further 
corroborated by a higher incidence of CD in women compared to men,
35
 the 
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association of CD with X-linked Turner’s syndrome
8
 and the higher incidence of  
extra-intestinal complications and surgery recurrence rates in female compared to 
male CD patients.
36
 Importantly, in men the T allele at SNP +372 was 
accompanied with a lower TIMP-1 protein expression in inflamed tissue. The lower 
TIMP-1 protein levels relative to MMP in susceptible individuals might shift the 
balance to a more proteolytic mucosal Crohn’s disease phenotype. The TIMP-1 
SNP might also be linked to other markers on the X-chromosome increasing CD 
susceptibility and conferring protection against fistulae pathogenesis thus 
explaining the observed results in women. We observed no association between 
allelic composition at MMP-3 SNP-1613 and susceptibility to IBD. Our findings in 
UC confirm previous publications on primary sclerosing cholangitis and UC,
22,37
 but 
those on CD are different from the results obtained by the group of  Pender et al,
38
 
who noted increased susceptibility to sporadic, but not familial CD in individuals 
carrying the 5T allele. These contrasting results might arise from a different 
proportion of sporadic versus familial cases in our study. We also found a 
decreased chance of colonic involvement at first endoscopic/radiologic examination 
and a higher incidence of stenotic complications in patients carrying the 5T5T 
MMP-3 genotype at SNP -1613. Previously, over transmission of  the 5T allele was 
associated with ileal localisation and stenosis in CD CARD15 mutation carriers
38
 
and the group of  Warnaar et al.
39
 reported increased levels of  MMP-3 in stenotic 
and pre-stenotic resected CD ileum, pointing to an MMP-3 mediated altered clinical 
course of  CD patients by an, as yet, unidentified mechanism. The 5T5T genotype 




 MMP-3 protein expression, but in 
our study patients stratified according to MMP-3 genotype expressed similar  
MMP-3 total activity. Previously, the A allele at TNF-α SNP -308 was reported to 




 and the incidence of  fistulae in CD,
45
 possibly 
mediated by an increased promoter activity.
46,47
 In contrast, we found no effect of  
allelic composition at this SNP on disease risk and phenotype, in line with other 
reports,
48,49
 adding further complexity to this matter. As mentioned before, the 
patient populations might differ dependent on the genetic (ethnic) background, thus 
explaining the contrasting results. We could not demonstrate an association of  
MMP-1, -2, -9 and TIMP-2 SNPs with disease susceptibility or clinical course of  
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disease, in line with previous (genome-wide) linkage reports.
11-13,37,50
 As other 
studies have clearly shown the involvement of  these proteins in IBD pathology,
51,52
 
it seems that they primarily function as mediators/effectors instead of  initiators 
during IBD etiopathogenesis. However, the regulation of these proteins by 
immunosuppressive medication, such as infliximab, might be dependent on the 
allelic composition at the SNPs examined, as previously shown by ex vivo explant 
studies from our group.
32
 In principle, enhanced MMP expression might also be 
associated with SNPs in other genes, for instance with those encoding cytokines 
regulating MMP expression, e.g., IL-1β44 and TNF-α. Dependent on the presence 
of relevant cis-acting elements in the promoter sequence, especially MMP-1 and 
MMP-9 would be affected,
53,54
 but we found no effect. In summary, several studies 
reported associations between SNPs in diverse genes and IBD.
16,48, 55-59
 We have 
focused on the SNPs in genes coding for matrix remodeling proteins, i.e., MMPs 
and TIMPs, and believe the T allele at SNP +372 T/C in TIMP-1 might be involved 
in CD susceptibility in both sexes and in men by down-regulating TIMP-1 
expression, while the 5T5T genotype at MMP-3 -1613 might protect for colonic 
disease localization but also confers a major risk to stenotic complications. These 
findings reinforce the potential role of MMP and TIMPs in IBD and should be 
confirmed in larger prospective follow-up studies. 
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Abstract 
Background/aims. Recurrence of disease after surgically induced remission 
constitutes a major and largely unpredictable problem in Crohn’s disease (CD). 
Matrix metalloproteinases (MMP) and the tissue inhibitors of metalloproteinases 
(TIMP) are involved in the (etio)pathogenesis of CD and may thereby also affect 
postsurgical outcome. We studied the predictive value of 1) allelic composition at 
MMP, TIMP, and TNF-α single nucleotide polymorphism loci, and 2) MMP and 
TIMP intestinal protein levels relative to important clinical variables for recurrence 
of CD after resection of diseased bowel. 
Methods. From 87 CD patients with a full medical record, surgically resected 
tissue was homogenized and analyzed for single nucleotide polymorphism (SNP) 
genotype and MMP-TIMP protein levels. The prognostic value of these parameters 
was determined using the uni- and multivariate Cox proportional hazards analyses. 
Results. The T-allele at TIMP-1 SNP +372 T/C was found to be associated with an 
increased risk for surgical recurrence. Higher levels of TIMP-1, TIMP-2, and  
MMP-9 in noninflamed CD tissue, but not in inflamed tissue, and negative smoking 
status independently protected against diagnostic and/or surgical recurrence. 
Conclusions.  The TIMP-1 SNP +372 T allele with an increased risk of recurrence 
is in line with our previous results demonstrating increased CD susceptibility and 
low TIMP-1 protein expression associated with this allele. High TIMP and MMP-9 
levels in non-inflamed tissue are predictive of a favorable disease recurrence in 
CD. The contribution of MMP-9 and TIMPs to disease recurrence appears not to be 




 Recurrence  in CD - 175 
Introduction 
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal 
tract. Although the etiology is largely unknown, current understanding suggests 
that the sustained immune infiltration manifests as an aberrant reaction to luminal 
bacteria in genetically susceptible individuals.
1
 It is characterized by chronic, 
segmental, and transmural inflammation of the bowel wall, particularly ileocolonic, 
treated with immunomodulating drugs to induce clinical remission. Despite 
advances in medical therapy, still a large proportion of CD patients will eventually 
require resection of diseased bowel, with an estimated cumulative probability 
during the first decade after diagnosis ranging between 30% and 60%.
2,3
 One year 
after resection, endoscopic and clinical recurrence occurs in 70% and 20% of 
patients, respectively.
4
 The cumulative second surgical recurrence rate amounts to 
35.9% 10 years after first bowel resection, with a small but substantial group at 
hazard for even more subsequent resections (third surgical recurrence rate 39.8% 
5 years after the second bowel resection).
5
 Several studies focused on identifying 
predictive variables for postsurgical recurrence, including age at onset of disease, 
age at time of surgery, duration of disease before initial operation, type of surgery 
(i.e., laparoscopic versus open conventional), disease localization, gender, 
histology, etc., with sometimes inconclusive or even contrasting results.
6-14
 
Smoking behavior, however, was consistently found to adversely affect disease 
prognosis, both in medical and surgically induced remission.
15
 Identification and 
selection of patients prone to recurrence would enhance the effectiveness of 
adjuvant medical therapy with azathioprine, ornidazole, or infliximab,
16-18
 thus 
limiting costs and drug-related side effects.  
Matrix metalloproteinases (MMP) constitute a group of neutral endoproteinases, 
collectively capable of cleaving various intestinal matrix proteins, with proteolytic 
activity tightly regulated by their natural inhibitors, the tissue inhibitors of 
metalloproteinases (TIMPs).
19
 In inflamed CD and ulcerative colitis tissue, several 
MMPs, including MMP-1, -3, -9, and -12 relative to TIMP-1 and -2 are 
overexpressed
20-27
 leading to an increase in net MMP proteolytic activity.
28,29
 Even 
in the macroscopically normal proximal resection margin, an upregulation of  
MMP-3 has been observed.
30
 Part of this proteolytic phenotype seen in 
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inflammatory bowel diseases (IBDs) may be attributed to increased TNF-α 
signaling.
31,32
 In the genes coding for MMPs, TIMPs, and TNF-α, single nucleotide 
polymorphisms (SNPs) have been described, and allelic composition at these 
SNPs may determine protein expression. For instance, MMP-1 protein expression 
is upregulated in cells carrying 2 copies of the 2G allele at MMP-1 promoter  
–1607.
33
 In previous reports, the 5T and T allele at SNP MMP-3 –1613 5T/6T and 
TIMP-1 +372 T/C, respectively, were found to be associated with CD,
34,35
 while 
contradictory results were obtained for the –308 G/A SNP at the TNF-α gene.
36,37
 
Therefore, CD patients with different genetic MMP, TIMP, or TNF-α constitution 
may express different levels of corresponding proteins and follow a different clinical 
course after surgically induced remission. Previously, we determined allelic 
composition at MMP-1, -2, -3, -9, TIMP-1, -2, and TNF-α  SNP loci in CD patients 
and also measured MMP and TIMP protein levels in surgically resected inflamed 
and macroscopically normal tissue.
29,34
 Here we relate the CD SNP allelic 
distribution and tissue protein expression to postsurgical recurrence data in a 
multivariate model including major clinical variables. 
 
Materials and methods 
Patient population 
For this retrospective study, 87 predominantly Dutch Caucasian CD patients with a 
full medical record and prospectively collected resection specimens were included. 
Diagnosis of CD was established by routine endoscopical, radiological, and 
histological examination. Surgical intestinal resections with anastomosis of 
macroscopically normal bowel were performed in the period 1984–2000, median 
follow-up after resection was 8.4 (0.9–19.1) years. Location of disease was often 
ileocecal (n = 66), with 8 and 13 patients undergoing small bowel resection or 
(sub)total colectomy, respectively. Indication for surgery was stenotic narrowed 
tissue, medical refractory disease, or perforation (n = 36, 50, and 1, respectively). 
Diagnostic recurrence was defined as a rise in clinical symptoms with endoscopy 
and/or radiology-confirmed inflammation of previously unaffected bowel. Surgical 
recurrence was defined as resection of diseased tissue macroscopically normal at 
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previous surgery. 
 
Genotype and protein determination 
Resected tissue was collected at the Department of Pathology, LUMC, and stored 
at -70°C until analysis. Mucosa was homogenized with a Turrax device, genomic 
DNA was isolated according to the salting out method
38
 and reconstituted to 10 
ng/µL in 0.01 M Tris / 0.1 mM EDTA, pH 7.5. Allelic composition at the SNP loci 
studied was determined by polymerase chain reaction restriction fragment length 
polymorphism (PCR-RFLP) (MMP-1, -3, -9, TIMP-1, -2, TNF-α) or tetra primer 
ARMS PCR (MMP-2), as described previously.
39,40
 In 1 patient DNA isolation failed 
and the genotype could not be determined. From 85 and 76 patients, respectively, 
inflamed and noninflamed mucosa was obtained and homogenized in 1 mL 0.1 M 
Tris-HCl, 0.1% Tween 80, pH 7.5 per 60 mg tissue using a Potter device (B Braun, 
Germany). Antigen protein levels of MMP-2 and MMP-9 were measured in 
appropriately diluted homogenates by our in-house enzyme-linked immunosorbent 
assays (ELISAs), as described before,
41
 while TIMP-1 and -2 protein were 
measured by commercially available ELISAs from R&D Systems (Minneapolis, 
MN), according to the manufacturer’s instructions. All antigen levels were corrected 
for total protein amount, as determined by the method of Lowry et al.
42
 The protein 
levels of MMP-1, MMP-3, and TNF-α were either not assessed or at a too low 
number for adequate analyses. 
 
Statistical analysis 
Differences between subgroups were calculated using the Mann–Whitney U-test or 
Pearson Chi Square test as indicated. For disease follow-up analyses the clinical 
parameters were dichotomized as follows: smoking habit after surgical resection 
(yes versus no), gender (male versus female), medication before surgical resection 
(mild: nothing or mesalazine versus strong: corticosteroids and/or 
immunomodulatory drugs w/wo mesalazine), age at surgery (≤ 27.6 versus >27.6 
years), age at onset of disease (≤ 16.65 years versus >16.65 years), number of 
former resections (0 versus >0), and time lag between onset of disease and 
surgical resection (≤ 11.89 versus >11.89 years). Cutoff values for continuous 
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clinical variables, MMP, and TIMP levels were optimized using receiver operator 
characteristic (ROC) analyses. Multivariate analyses were performed with the Cox 
proportional hazards method by separately adding variables to the dichotomized 
clinical parameters. Survival curves were constructed using the method of Kaplan 
and Meier including log-rank tests. Differences were considered significant when P 
< 0.05. Analyses were performed using the SPSS statistical package (Release 
11.0, Chicago, IL). 
 
Results 
Clinical parameters and recurrence 
In the univariate Cox analyses the 49 patients with a positive smoking status were 
at increased risk for developing diagnostic recurrence compared to the 38 non-
smokers (hazard ratio [HR] 1.846, P < 0.05; Table 1). Median time of reaching the 
diagnostic recurrence endpoint dropped from 8.2 to 2.8 years (P = 0.02; Fig. 1A). 
Young age at surgery and at onset of disease ( 27.6 and 16.65 years, respectively) 
also exposed patients to earlier diagnostic recurrence. Gender, medication 1 month 
prior to surgery, number of previous resections, and time lag between onset of 
disease and surgery had no effect. In multivariate analyses including all clinical 
variables, only smoking maintained its prognostic value (HR 2.002, P < 0.02). 
Smoking, but not the other clinical parameters, also significantly increased the risk 
for surgical recurrence (HR 4.033, P = 0.001), with the median time lag for re-
resection dropping from 17.2 to 9.3 years (P = 0.0005; Fig. 1B) and proved an 
independent prognostic indicator with a similar hazard ratio in the multivariate 
analyses. However, smoking was not associated with MMP-TIMP genotype or 
tissue protein levels (Suppl. Table X), providing a rationale for further hazard 
analyses including these parameters. 
 
Genotype and tissue MMP-TIMP protein levels versus recurrence 
The allelic distribution at MMP, TIMP, and TNF-α SNP loci was not associated with 
diagnostic recurrence (Table 2). In univariate analyses, only the C allele at SNP 
TIMP-1 +372 T/C was found to be protective against surgical recurrence. Patients 
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Table 1. Cox regression analyses of selected clinical variables in relation to diagnostic (A) 
and surgical (B) recurrence after resection of diseased bowel in 87 CD Patients.  
 
A) Diagnostic recurrence 
  Univariate Multivariate 
Parameter N HR 95% CI P HR 95% CI P 
Smoking 
Negative vs positive 38/49 1.846 
1.091-
3.124 0.022 2.002 1.144-3.504 0.015 
Gender 
Male vs female 35/52 1.445 
0.857-
2.436 NS 1.302 0.721-2.351 NS 
Medication* 
Mild vs strong 38/49 1.441 
0.858-
2.419 NS 1.146 0.626-2.100 NS 
Age at surgery 
≤ 27.6 vs > 27.6 yrs 25/62 0.534 
0.315-
0.904 0.020 0.648 0.298-1.409 NS 
Age at onset of disease 
≤ 16.65 vs > 16.65 yrs 22/65 0.537 
0.313-
0.923 0.024 0.587 0.300-1.150 NS 
Nr of previous resections 
0 vs >0 52/35 0.975 
0.583-
1.630 NS 1.443 0.774-2.689 NS 
Time lag onset of 
disease-resection 
≤ vs > median (11.89 yrs) 44/43 0.847 
0.510-
1.409 NS 0.874 0.459-1.664 NS 
 
B) Surgical recurrence 
  Univariate Multivariate 
Parameter N HR 95% CI P HR 95% CI P 
Smoking 
Negative vs positive 38/49 4.033 
1.733-




Male vs female 35/52 1.906 
0.894-
4.063 NS 1.664 0.730-3.792 NS 
Medication* 
Mild vs strong 38/49 1.202 
0.592-
2.438 NS 0.896 0.380-2.115 NS 
Age at surgery 
≤ 27.6 vs > 27.6 yrs 25/62 0.938 
0.442-
1.989 NS 1.056 0.353-3.156 NS 
Age at onset of disease   
≤ 16.65 vs > 16.65 yrs 22/65 1.532 
0.630-
3.727 NS 1.256 0.451-3.503 NS 
Nr of previous resections 
0 vs >0 52/35 0.932 
0.459-
1.894 NS 1.457 0.605-3.512 NS 
Time lag onset of 
disease-resection  
≤ vs > median (11.89 yrs) 44/43 0.926 
0.462-
1.855 NS 0.719 0.267-1.935 NS 
* Medication: mild = nothing or mesalazine, strong = corticosteroids, immunomodulatory 
drugs w/wo mesalazine one month prior to surgical resection. N, number of patients; HR, 
hazard ratio; CI, confidence interval; P, statistical significance. 
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Table 2. Cox proportional hazard analysis for 86 CD Patients testing allelic distribution at 
MMP, TIMP and TNF-α SNP loci versus clinical parameters in relation to diagnostic (A) and 
surgical (B) recurrence after resection of diseased bowel.  
 
A) Diagnostic recurrence 
  Univariate Multivariate 
Parameter N HR 95% CI P HR 95% CI P 
MMP-1 SNP –1607 1G/2G 








MMP-2 SNP –1306 C/T  








MMP-3 SNP –1613 5T/6T 








MMP-9 SNP –1562 C/T  








TNF-α SNP –308 G/A     








TIMP-1 SNP +372 T/C 








TIMP-2 SNP +303 G/A   









B) Surgical recurrence 
  Univariate Multivariate 
Parameter N HR 95% CI P HR 95% I P 
MMP-1 SNP –1607 1G/2G 








MMP-2 SNP –1306 C/T  








MMP-3 SNP –1613 5T/6T 








MMP-9 SNP –1562 C/T  








TNF-α SNP –308 G/A     








TIMP-1 SNP +372 T/C 







NS (P  
= 0.059) 
TIMP-2 SNP +303 G/A   








N, number of patients; HR, hazard ratio; CI, confidence interval; P, statistical significance. 
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N, 38/7 Log rank=12.18
P=0.0005
 
Figure 1. Kaplan–Meier recurrence-free incidence analysis for smoking status. Positive 
smoking status increased the risk for diagnostic (A) and surgical (B) recurrence, dropping 
median duration between surgery and diagnostic recurrence from 8.2 to 2.8 years and 
between surgery and re-resection from 17.2 to 9.3 years, P < 0.05. N, P = negative or 
positive smoking status after surgery, respectively. X/Y = number of patients / number of 
patients with recurrence. 
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carrying the T(T) or CT compared to C(C) genotype underwent re-resection 10.7 
versus 19.1 years after initial surgery (P < 0.05; Fig. 2A). In the univariate analysis 
we found HR 0.391 (P < 0.04) and this association was borderline non-significant 
in the multivariate analysis (P = 0.059). The TIMP-1 gene is X-linked, a survival 
analysis stratified to gender yielded a similar trend for women (data not shown). 
High levels of TIMP-1, TIMP-2, and remarkably MMP-9 (2.94, 4.66 and 5.11 
ng/mg, respectively) in noninflamed tissue decreased the risk for diagnostic 
recurrence (Table 3). Of these only MMP-9 was found to be an independent 
prognostic variable (HR = 0.498, P < 0.05). High levels of TIMP-1, TIMP-2, and 
MMP-9 ( 2.88, 4.66, and 5.11 ng/mg, respectively) in noninflamed tissue were also 
found to be protective against surgical recurrence. For instance, the median time 
lag between surgery and re-resection was 10.7 years in 17 patients with less than 
or equal to 2.88 ng/mg TIMP-1 in noninflamed tissue while in 59 patients with 
TIMP-1 levels above this threshold it was 17.2 years (P = 0.03; Fig. 2B). A similar 
pattern was observed for MMP-9 (Fig. 2C). These parameters were also 
statistically significant in the multivariate analysis. However, levels of MMP-2 in 
noninflamed tissue and of MMP-2, MMP-9, TIMP-1, and TIMP-2 in inflamed tissue 
were not relevant to the risk for diagnostic or surgical recurrence (Table 3) and 
neither were the MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios (data not shown). 
 
Discussion 
In our relatively small cohort of 87 Dutch CD patients the T allele at SNP TIMP-1 
372 T/C was found to increase the risk for surgical recurrence, although this effect 
just missed statistical significance in multivariate analysis. Patients carrying the 
T(T) or CT compared to C(C) genotype underwent re-resection much earlier (10.7 
versus 19.1 years) after initial surgery. The TIMP-1 genotype had no effect on 
diagnostic recurrence, indicating a late onset or relatively mild influence of this 
polymorphism on CD progression. We also observed an increased risk on surgical 
(and diagnostic) recurrence in patients with a low TIMP-1 protein level in 
noninflamed intestinal tissue. Patients with TIMP-1 ≤ 2.88 ng/mg underwent re- 
resection after 10.7 years, almost 7 years earlier compared to patients with TIMP-1 
levels above this value. We previously reported increased CD susceptibility and 
low TIMP-1 levels associated with the TIMP-1 T allele.
34
 Combined with our current 
data, we postulate that this allele downregulates TIMP-1 expression by an as yet 
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Table 3. Cox proportional hazard analysis for testing MMP and TIMP protein levels in 
noninflamed and inflamed CD Tissue (n = 76 and 85, respectively) versus clinical 
parameters in relation to diagnostic (A) and surgical (B) recurrence after resection of 
diseased bowel. 
 
A) Diagnostic Recurrence 
  Univariate Multivariate 
Parameter N HR 95% CI P HR 95% CI P 
MMP-2 non-inflamed 




1.436 NS 1.024 0.529-1.982 NS 
MMP-9 non-inflamed ≤ 5.11 




0.748 0.004 0.498 0.252-0.984 0.045 
TIMP-1 non-inflamed ≤ 2.94 




0.902 0.021 0.658 0.350-1.237 NS 
TIMP-2 non-inflamed ≤ 4.66 




1.003 0.051 0.661 0.313-1.396 NS 





1.313 NS 0.701 0.387-1.269 NS 





1.720 NS 1.134 0.664-1.938 NS 





1.548 NS 0.941 0.541-1.636 NS 





1.697 NS 1.385 0.789-2.432 NS 
 
B) Surgical Recurrence 
  Univariate Multivariate 
Parameter N HR 95% CI P HR 95% CI P 
MMP-2 non-inflamed 




2.378 NS 1.226 0.483-3.116 NS 
MMP-9 non-inflamed ≤ 5.11 




0.601 0.001 0.279 0.114-0.686 0.005 
TIMP-1 non-inflamed ≤ 2.88 




0.942 0.035 0.403 0.174-0.932 0.034 
TIMP-2 non-inflamed ≤ 4.66 




0.751 0.008 0.328 0.126-0.856 0.022 





2.247 NS 0.979 0.450-2.130 NS 





3.059 NS 1.772 0.845-3.716 NS 





2.198 NS 0.926 0.437-1.960 NS 





1.784 NS 0.998 0.471-2.114 NS 
N, number of patients; HR, hazard ratio; CI, confidence interval; P, statistical significance 
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Figure 2. Kaplan–Meier analysis illustrating surgical recurrence-free incidence curves 
stratified by TIMP-1 SNP + 372 T/C (A), TIMP-1 level (B), and MMP-9 level (C, next page) in 
non-inflamed CD tissue 
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Figure 2, continued. Kaplan–Meier analysis illustrating surgical recurrence-free incidence 
curves stratified by TIMP-1 SNP + 372 T/C (A), TIMP-1 level (B), and MMP-9 level (C) in 
noninflamed CD tissue. Patients carrying the T(T) or CT compared to C(C) genotype 
underwent re-resection 10.7 versus 19.1 years after initial surgery (P < 0.05). High levels of 
both proteins were protective against surgical recurrence and increased median duration to 
re-resection from 10.7 (TIMP-1) or 4.7 (MMP-9) to 17.2 years in both, P  < 0.03. H, L = high 
and low levels in noninflamed tissue (> and ≤ 2.88 [TIMP-1] versus > and  ≤ 5.11 [MMP-9] 
ng/mg). X/Y =  number of patients / number of patients with recurrence. 
 
undefined mechanism, shifting the MMP/TIMP balance to a more proteolytic 
phenotype, enhancing CD susceptibility and worsening CD (postsurgical) 
prognosis. Alternatively, the TIMP-1 SNP is in linkage disequilibrium with another 
predisposing locus. The 372 SNP has been studied in other diseases with possible 
involvement of TIMP-1 in the pathogenesis, i.e., systemic sclerosis, intracranial and 
abdominal aneurysms, with inconclusive results.
43-45
 CD patients with TIMP-2 
levels >4.66 ng/mg in noninflamed tissue were also protected from developing 
surgical recurrence, presumably acting via a similar mechanism as described for 
TIMP-1. As TIMP-1/MMP-9 and TIMP-2/MMP-2 ratios were not associated with 
recurrence-free intervals, it appears that both TIMPs might exert their protective 
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effect through inhibition of other metalloproteinases, for instance MMP-3, -7, -12, or 
-13.
46-48
 Remarkably, MMP-9 levels >5.11 ng/mg in non-inflamed tissue decreased 
the risk for diagnostic and surgical recurrence. In several models, targeting of 
MMP-9 attenuated chronic colitis, underlining the potential pathogenic role of this 
metalloproteinase in CD.
49,50
 However, in CD several disease stages may be 
discerned and possibly, in the early acute phase, a small upregulation of MMP-9 in 
the macroscopically still normal tissue might be beneficial, whereas a large 
overexpression in the chronic active phase may lead to tissue ulceration and/or 
fibrosis. That would concur with our observation that the MMP and TIMP levels in 
the inflamed tissue are not prognostic to the diagnostic and surgical recurrence of 
CD. Recently, a protective role for MMP-2 (but not MMP-9) was demonstrated in 
experimental colitis, adding some credit to our hypothesis.
51
 However, the exact 
mechanisms, proteolytic and nonproteolytic, by which the MMPs and TIMPs might 
be involved in the disease progression and recurrence is not completely clear. 
These factors are not only involved in tissue damage but also in intestinal wound 
healing, re-epitheliazation, myofibroblast and immune cell migration, scar 
formation, fibrogenesis, and neovascularization in the intestine, also after partial 
resection.
52-54
 With regard to the clinical variables, we confirmed the effect of 
smoking also observed in previous publications.
15
 Recently, cigarette smoke was 
shown to upregulate MMPs and induce a proinflammatory response.
55,56
 We found, 
however, no relation between MMP and TIMP levels with smoking and the 
observed association of these proteins with recurrence was also independently 
significant in a multivariate model including smoking status. In summary, we have 
shown an association of the allele distribution at the TIMP-1 +372 T/C locus, the 
levels of TIMP-1, -2, and MMP-9 in non-inflamed tissue, and smoking habit with 
diagnostic and/or surgical recurrence of CD. Our results shed new light on the 
potential role of MMPs and TIMPs in the pathogenesis of recurrence/relapse in CD 
and may help in the identification of patients at risk, improving the effectiveness of 
current postoperative prophylactic treatment and disease management.
57,58
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Introduction 
The studies presented and discussed in this thesis focus on the clinical impact of 
Matrix Metalloproteinases (MMPs)-1, -2, -3, -9 and Tissue Inhibitor of 
Metalloproteinases (TIMP) in chronic inflammatory bowel disease (IBD) and 
evaluate the effect of increased TNF-α signaling on MMP and TIMP expression in 
IBD. First, expression and activity status of gelatinases MMP-2 and MMP-9 was 
determined in IBD compared to control intestinal mucosa. Second, the contribution 
of TNF-α in regulation of MMP-1, -2, -3, -9 and TIMP-1, -2 expression was 
assessed ex vivo and/or in vitro, and in vivo by administration of the chimeric  
TNF-α antibody infliximab®. Subsequently, we correlated the MMP and TIMP 
levels versus allelic composition at MMP, TIMP and TNF-α single nucleotide 
polymorphism (SNP) loci to determine the genetic influence on the respective 
proteins and indirectly on IBD susceptibility and CD phenotype. Finally, these 
SNPs and corresponding proteins in CD tissue were evaluated in a multivariate 
model, including selected clinical variables, for association with diagnostic and 
surgical recurrence. The results are summarized and discussed with reference to 
current literature. 
 
Matrix metalloproteinases in Inflammatory Bowel Disease 
A brief review concerning IBD and MMPs is provided in chapter 1. Two major 
forms of IBD are discerned, i.e., Crohn’s disease (CD) and ulcerative colitis (UC). 
In CD inflammation is segmental and transmural and may involve any part of the 
gastro-intestinal tract with often the ileocecal area involved. In UC, the 
inflammation is continuous and confined to the mucosa. In most patients, disease 
is located in the left part of the colon, but pancolitis also frequently occurs. Annual 
incidence figures have risen since the second World War reaching the current 
plateau of 4-9 (CD) and 9-14 (UC) per 100,000, with concordant prevalence rates 
of 130-175 and 240-275 per 100,000 for CD and UC, respectively. Despite low 
prevalence, IBD is a debilitating disease with 10 years cumulative surgical 
resection rate between 25-60% and represents a high socio-economic burden. 
Therefore, much research is conducted aimed at identifying the etiology and 
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pathogenic mechanisms underlying IBD. Based on current evidence, impaired 
epithelial barrier function and insufficient innate immune response might result in 
overexposure to commensal bacteria, initiating and/or propagating the uncontrolled 
adaptive immune response observed in IBD. Disease is exacerbated by the 
presence of apoptosis resistant lymphocytes and neutrophils. The upregulation of a 
diverse array of pro-inflammatory cytokines and chemokines chronically activates 
mesenchymal, epithelial and immune cells and continuously attracts new 
leucocytes from the peripheral circulation. Tissue damage is mediated by reactive 
oxygen metabolites, perforin, granzymes, auto-antibodies, activated complement 
and action of serine proteases and MMPs. The MMPs constitute a group of neutral 
endoproteinases and belong to subclan M (also called metzincins) of the 
metalloprotease class and share sequential and structural motifs with ADAMs  
(A Disintegrin And Metalloproteinase) and ADAMTSs (A Disintegrin-like And 
Metalloproteinase with Thrombospondin type 1 motifS). Currently in humans, 23 
different MMPs are recognized divided into collagenases, gelatinases, matrilysins, 
stromelysins, MT (membrane-type)-MMPs and a rest group. The MMPs have 
important functions in physiological and pathological matrix turnover and together 
are capable of cleaving a large array of matrix molecules including but not limited 
to collagen I-XI, proteoglycans, elastin, laminin, vitronectin, tenascin, entactin and 
fibronectin. Individual members are also capable of cleaving various non-structural 
molecules such as IL-8, Transforming Growth Factor-β (TGF-β) and insulin growth 
factor binding protein-3 (IGFBP-3). Pro-inflammatory cytokines, chemokines, 
growth factors and oxidants regulate the expression of MMPs in a wide array of cell 
types, dependent on various intracellular signaling pathways. Expression is also 
determined by DNA and histone modification of the MMP gene and allelic 
distribution at single nucleotide polymorphism (SNP) loci of the MMP promoter. In 
addition, translational and secretion rate are also tightly regulated. Most MMPs 
(except the MT-MMPs) are secreted as inactive zymogens and need to be 
activated by proteinases such as plasmin, thrombin, trypsin and/or (MT-)MMPs. 
Alternatively, substrate-induced conformational change may result in activation of 
the MMP, without loss of the pro-peptide. Active MMPs are inhibited in a 1:1 
stoichiometric complex with a member of the Tissue Inhibitor of Metalloproteinases 
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(TIMP), a group of endogenous inhibitors with their expression tightly regulated, 
similar to MMPs, and besides MMP inhibition probably also involved in cell growth 
and/or apoptosis. MMPs may also be inhibited by a general anti-protease such as 
α2-macroglobulin and are removed from the circulation by lipoprotein related-
receptor protein (LRP)-mediated uptake and degradation in lysosomal vesicles. 
Previous studies have shown an upregulation of several MMPs in inflamed IBD 
tissue and in animal models, inflammation score was significantly decreased by 
administration of MMP inhibitors, suggesting an important role for MMPs in IBD 
pathogenesis.  
 
Expression and regulation of matrix metalloproteinases in 
Inflammatory Bowel Disease 
In chapter 2 a study is presented regarding the expression of gelatinase type 
MMP-2 and MMP-9 in inflamed and non-inflamed IBD. From 16 patients with CD, 
14 patients with UC and 16 normal controls surgically resected mucosa was 
homogenized and used for ELISA measurements. Tissue protein levels of MMP-2 
and MMP-9 were significantly increased in IBD dependent on inflammation status 
without major differences between CD and UC, corroborated by a respective 
increase in mRNA as demonstrated by RT-PCR. The active and pro-enzyme forms 
of both MMPs were increased, as determined by zymography, but in a bio-activity 
assay only MMP-9 activity was upregulated. Immunohistochemistry demonstrated 
MMP-2 expression primarily in the submucosa, whereas MMP-9 was associated 
with polymorphonuclear leucocytes. The results suggest a role for MMP-2 and 




In order to evaluate whether TNF-α-dependent regulatory mechanisms contribute 
to MMP-1, -2, -3, -9 and TIMP-1 and -2 expression in CD and UC an  
ex vivo model was used (chapter 3). A protocol from Autrup et al. 
4
 was modified 
to culture mucosa isolated from surgically resected tissue specimens originating 
from adult human IBD and control patients. The 72 hrs cumulative expression of 
MMP-1, -2, -3 and -9 as determined by ELISA and/or immunocapture bio-activity 
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assay (BIA) in conditioned media was significantly increased in CD and UC 
compared to control intestinal tissue. Addition of infliximab, an anti-TNF-α antibody, 
decreased the production of MMP-1, -3 total and net activity, and of MMP–9 total 
antigen relative to TIMP, while PWM, a T/B cell activator, induced the expression of 
these MMPs, counteracted again by infliximab. Clearly, the expression of these 
MMP members in all examined tissues is partly mediated by TNF-α. Addition of 
PWM reduced the expression of MMP-2 by 50% while infliximab had no effect, 
illustrating a divergent regulatory pathway for this protein. Interestingly, the results 
for MMP-1, -3 and -9 appeared to be related to the allelic composition at selected 
SNP loci, for instance the effects of infliximab and PWM on MMP-9 production 
were much stronger in individuals carrying the CC compared to CT or TT genotype 
at SNP –1562. The results from these chapters point to a protective (MMP-2) and 
detrimental (MMP-1, -3 and -9) effect in tissue degeneration, as also suggested by 
others,
5
 which is disturbed in CD and UC, and may be restored by infliximab. 
Subsequently, the contribution of TNF-α signaling to in vivo gelatinase expression 
in CD was determined (chapter 4). Serum MMP-2 and MMP-9 values were 
monitored in two CD patient cohorts with either fistulas or active disease (n = 38 
and 31, respectively), each group formed by participants from an international trial 
and from an in-house study. Infliximab administration at 0, 2 and 6 weeks was 
paralleled by an increase of serum MMP-2 in CD patients with fistulas and at 10 
weeks a subsequent decline was observed. Opposite to MMP-2, serum MMP-9 
dropped during infliximab administration and gradually increased again after the 
last infusion, although not statistically significant and also observed in placebo 
treated groups. In the patients with active disease similar effects occurred, 
especially at higher infliximab dosage. Interestingly, immunohistochemical staining-
intensity of MMP-9 positive polymorphonuclear leucocytes in intestinal mucosa 
dropped after infliximab infusion. Separate in vitro whole blood culture experiments 
demonstrated a lower MMP-2 level in blood obtained from CD compared to healthy 
volunteers. This level was not affected by LPS stimulation or infliximab treatment, 
presumably as no MMP-2 mRNA could be detected in blood leucocytes. However, 
production/secretion of MMP-9 was higher in CD leucocytes and LPS induced 
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MMP-9 expression in volunteers could be downregulated by infliximab at the 
mRNA but not protein level. 
 
Association of MMPs and TIMPs with IBD susceptibility and 
phenotype 
Chapter 5 describes the evaluation of total protein and activity levels of MMP-1, -2, 
-3, -9, TIMP-1 and TIMP-2 in a large group of tissue samples obtained from 122 
CD, 20 UC and 62 control patients and also the association of these markers with 
CD phenotype. As determined by ELISA and/or BIA with/without prior p-amino-
phenyl-mercuric-acetate (APMA) treatment, all MMPs were found to be 
upregulated in inflamed IBD tissue, especially MMP-3 (18.6 versus control value 
0.0 U/mg total protein, P<0.001). Importantly, MMPs were also increased relative 
to TIMP paralleled by an increase in net MMP activity (for instance MMP-3: 5.7 vs 
0 U/mg, P<0.001). Expression of MMP and TIMP was similar in inflamed CD with 
or without extensive fibrosis and in patients with development of fistulae during 
follow-up and was only slightly downregulated by treatment with immuno-
suppressive corticosteroids and/or azathioprine. 
This study was extended to include the analysis of MMP, TIMP and TNF-α genetic 
variability in relation with IBD susceptibility and CD phenotype, as reported in 
chapter 6. Genomic DNA was isolated from 134 CD and 111 UC patients versus 
248 controls and analyzed by RFLP and tetra primer amplification refractory 
mutational system (ARMS) PCR. The T (in males) and TT (in females) allelic 
constitution at SNP TIMP-1 +372 T/C occurred more frequently in CD patients 
compared to controls. Levels of TIMP-1 protein in inflamed tissue were lower in 
male IBD but not CD patients carrying the T allele. No difference in TIMP-1 level 
was observed between women stratified to TIMP-1 genotype. The C allele at  
TIMP-1 SNP appeared associated with fistulae development during follow-up, but 
only in female CD patients. The 5T5T genotype at MMP-3 –1613 5T/6T was 
associated with reduced risk on colonic involvement at first presentation but 
increased risk on development of strictures during follow-up. The allelic 
composition at MMP-1, -2, -9, TIMP-2 and TNF-α SNPs was not related to CD or 
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UC susceptibility and phenotype, indicating a primary function as mediators/ 
effectors instead of initiators during IBD etiopathogenesis. As the control group 
partly consisted of colorectal carcinoma (CRC) patients donating macroscopically 
normal tissue at least 10 cm away from neoplasia, all analysis were repeated using 
only the healthy volunteers as controls, yielding similar results. 
In the final study (chapter 7) previously determined allelic composition at selected 
MMP, TIMP and TNF-α SNPs and corresponding protein levels were related to 
clinical prognosis of CD.  In a cohort of 87 CD patients, the T allele at TIMP-1 +372 
T/C was found to be associated with a reduced median time lag between resection 
and re-resection (surgical recurrence), i.e., 10.7 versus 19.1 years, this effect was 
borderline non-significant in multivariate analysis using established clinico-
pathological parameters. Low TIMP-1 levels in non-inflamed CD tissue (<2.88 
ng/mg) were associated with increased risk on surgical recurrence, as were low 
levels of TIMP-2 and remarkably, MMP-9. No such effect was found for MMP and 
TIMP levels in inflamed tissue. Although positive smoking status was related to 
diagnostic and surgical recurrence, the results for MMP and TIMP are most likely 
not associated with smoking, since no correlation of these parameters with 
smoking status could be established. The results from chapter 6 and 7 point to 
TIMP-1 SNP + 372 T allele mediated downregulation of TIMP-1 protein levels 
shifting the balance between MMP and TIMP to a more proteolytic phenotype 
leading to enhanced CD susceptibility and worse CD prognosis. 
 
MMP and TIMPs in IBD: disturbed balance? 
As stated in the introduction of this thesis, IBD is considered an exaggerated 
immune response against commensal bacteria in genetically susceptible 
individuals. In this thesis evidence is provided of the pathophysiological importance 
of the presence of a disturbed balance of certain MMPs (e.g., MMP-2 and MMP-9) 
and TIMPs (Fig. 1, next page). 
The chronic ulcers, fissures and fibrosis observed in IBD may reflect and result 
from an impaired mucosal barrier function. The basement membrane underlying 
epithelial and endothelial cells is of crucial importance in maintaining a stable 
tissue border and providing mechanical strength. It is primarily composed of multi- 
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         Defective mucosal barrier +              ◄     ◄ 
Defective wound healing+ 
Defective innate immune response 
▼ 
Exposure to commensal bacteria                      ▲ 
▼ 
Excessive adaptive immune response 
▼ 
Synthesis of excess inflammatory mediators, i.e., 
TNF-α, IL-1, IL-12, IL-23, etc.►  ►    ▲ 
▼ 
Attraction of new leucocytes 
Induction of oxygen radicals, perforin, etc., 
Induction of MMPs relative to TIMPs (chapter 2 and 5). 
Tissue breakdown, dependent on allelic composition at  
TIMP-1 SNP +372 T/C (chapter 6 and 7)►   ►    ▲ 
             ▼ 
Administration of anti-TNF-α infliximab®   
             ▼ 
Downregulation of detrimental MMPs (e.g., MMP-9),  
Upregulation or stabilization of beneficial MMPs  
(e.g., epithelial barrier promoting MMP-2) (chapter 3 and 4) 
             ▼ 
        Improved mucosal wound healing 
             ▼ 
         Improved clinical prognosis 
 
Figure 1. Schematic presentation of the contribution of MMPs and TIMPs in the 
pathogenesis of IBD. Application of anti TNF-α antibody infliximab® restores the 
pivotal MMP versus TIMP balance, promotes restoration of gut barrier function and 
improves clinical outcome of IBD patients. 
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layered collagen IV and laminin sheets, connected through nidogen and heparan 
sulphate proteoglycan perlecan, but may also contain other proteins such as 
anchoring collagen VII fibrils, fibulin, fibronectin, osteonectin, etc.
6
 Basement 
membrane protein constituents are therefore potentially excellent candidates for 
involvement in IBD susceptibility and just recently an association of the “biological 
glue” extracellular matrix protein 1 with UC but not CD was found.
7
 The persistent 
intestinal wounds seen in IBD might also reflect defective wound healing. After 
tissue injury, the fibroblast urokinase-type plasminogen activator receptor (uPAR) 
binds uPA, which cleaves blood-borne plasminogen into active plasmin. Plasmin 
not only cleaves fibrin, but also activates MMPs in close collaboration with other 
proteinases including MT-MMPs, chymotrypsin, etc., resulting in degradation of 
collagen lattices into a gelatin meshwork. Importantly, MMP activity is also tightly 
regulated by TIMPs, auto- and substrate-induced activation, inactivation and 
degradation.
8
 Collagenolytic fragments are removed from the extracellular matrix 
(ECM) by uPAR-associated protein (uPARAP, also called endoprotein 180) 
mediated endocytosis and are degraded in lysosomal vesicles.
9-11
 Epithelial cells 
and fibroblasts synthesize new collagen and other ECM constituents in close 
collaboration to reconstitute the matrix.
12,13
 Also, the MMP-mediated breakdown of 
ECM provides epithelial cells with a mechanism to maintain their directionality 
during reepithelialization
14
 and the cleavage of cell-cell and of cell-matrix 
interactions facilitates in cell migration.
15-19
 In the process of remodeling, stored 
cytokines are released attracting leucocytes which clear the wound of pathogens. 
As stated in the introduction, MMPs are also involved in activating cytokines by 
proteolytic removal of inhibitory sequences. Finally, MMPs, like TIMPs, play a 
significant role in epithelial cell proliferation, differentiation and survival affecting the 
wound healing process as well. For instance, treatment of keratinocytes with  
MMP-2 silencing mRNA decreased proliferation and stimulated apoptosis, while 
silencing of MMP-9 exerted opposite effects, indicating different biological roles for 
these metalloproteinases depending on the cytokine micro-environment.
20-23
 
Several reports have indicated apparent overexpression of MMPs in non-healing 
chronic wounds.
24,25
 Epidermal expression of MMP-1 in transgenic mice was 
associated with delayed wound healing.
26
 Application of an hydro-active dressing 
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containing polyacrylate superabsorber particles removed MMPs from the wound 
bed and was associated with clinical improvement.
27
 Perhaps the best illustration of 
what happens when excess metalloproteinases are present is provided by the 
snake venom metalloproteinases (SVMP). These proteins, closely related to the 
ADAMs (subclan M12) dissociate endothelial cells and dissolute the basement 




The process of fibrosis often seen in CD, may be the consequence of a too low 
MMP over TIMP ratio in combination with upregulated collagen production.
30-32
 
Alternatively, high levels of MMPs may facilitate fibroblast migration and also 
enhance fibrosis. Recently, MMP-3 was found to be involved in epithelial-
mesenchymal cell transition, up-regulating collagen production and promoting the 
fibrotic phenotype.
33
 The role of TIMP in wound healing is also multi-faceted. 
Inhibition of MMPs localizes and fine tunes remodeling of extracellular matrix. 
Production of TIMP-1 by fibroblasts promotes angiogenesis by preventing MMP-9 
mediated release of anti-angiogenic tumstatin from collagen IV fibrils.
34
 Besides the 
inhibition of MMPs, TIMP-2 is involved in the activation of MMP-2 and several 
TIMPs affect cell proliferation, differentiation and apoptosis.
35,36
 Thus, wound 
healing is a subtle process requiring temporal and spatial coordination of collagen, 
MMP and TIMP synthesis. Importantly, both a low and a high MMP level at distinct 
time points may result in persistent non-healing ulcers. Besides the MMPs we 
studied, other MMPs may also be important, such as MMP-7 (matrilysin), MMP-8 
(neutrophil collagenase) and MMP-12 (macrophage metallo-elastase). The ADAMs 
and ADAMTSs also play pivotal roles in matrix remodeling. For instance, ADAMTS 
knock-out mice experience less hepatic fibrosis when treated with carbon tetra-
chloride and ADAM15-mediated T cell adhesion to epithelial cells enhances wound 
repair.
37,38
 Our results show upregulation of selected MMPs relative to TIMP, 
resulting in increased net activity which can be partly restored by infliximab in CD 
and UC. Administration of this anti TNF-α drug to CD patients is associated with 
good clinical response and might be the consequence of downregulation of excess 
MMP-1, -3 and -9. From an MMP point of view, administration of infliximab to UC 
patients may also prove beneficial and indeed several studies in this patient group 
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have yielded promising results.
39
 The concept of blocking MMP action in IBD 
patients by topical administration of selective synthetic MMP inhibitors is therefore 
appealing, but in light of their pleiotropic nature, as described above, should be 
considered with care. Selective MMP inhibition may result in functional substitution 
by other MMPs or ADAMs, considering their overlapping substrate specificity, while 
non-selective MMP inhibition may produce severe side-effects by inhibition of other 
MMPs, ADAMs and ADAMTSs beneficial to the healing process. Our studies on 
the allelic composition at the TIMP-1 SNP locus suggest T allele-mediated 
downregulation of TIMP-1 protein expression enhancing CD susceptibility and 
worsening CD prognosis. These results support the concept of MMP inhibition by 
topical administration of (recombinant) TIMP-1, but as MMP/TIMP levels were not 
related to clinical prognosis, the mechanism behind the C allele protective effect 
remains obscure and should be studied in more detail.  
In summary, the studies described in this thesis provide new insights into the role 
of MMPs and TIMPs in the etiopathogenesis of CD and UC. The association of 
these proteins and the genetic variants with certain IBD phenotypes indicating an 
increased risk should be confirmed in prospective studies. Future work should also 
encompass the expression of other MMPs, ADAM (TS)s and TIMPs in intestinal 
tissue, the distribution of SNPs in corresponding genes and focus on the 
identification of MMP degradation fragments, physiological activation cascade, 
inhibitors and substrate specificity to obtain a detailed mechanistic view of 
metalloproteinase action in IBD. Ultimately, these studies might result in the 
development of novel therapeutic drugs in CD and UC, and perhaps other 
pathologies as well, based on the inhibition or instead activation of one or more 
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Inleiding 
In de periode 1999-2004 is door de onderzoeksgroep waarin ik participeerde een 
aantal studies verricht naar de invloed van matrix metalloproteïnasen (MMP) en 
weefsel inhibitoren van metalloproteïnasen (TIMP) op het verloop van inflammatoir 
darmlijden (Inflammatory Bowel Disease, IBD). Tevens is hierbij de rol onderzocht 
van verhoogde concentraties aan het ontstekingsbevorderende cytokine Tumor 
Necrosis Factor-alpha (TNF-α). Al dit onderzoek  heeft geresulteerd in de 
totstandkoming van het proefschrift dat voor u ligt. Eerst is gekeken naar de 
aanmaak en activiteit van de gelatinasen MMP-2 en MMP-9 in IBD versus 
macroscopisch normaal darmslijmvlies (mucosa). Vervolgens hebben we ex vivo, 
in vivo en/of in vitro de regulatie van MMP-1, -2, -3 en -9, alsmede TIMP-1 en -2, 
door TNF-α bestudeerd, hierbij gebruik makend van het TNF-α neutraliserende 
antilichaam infliximab. Van een groot aantal IBD patiënten is de genetische 
compositie bepaald op vaststaande plekken (loci) in het MMP en TIMP DNA 
(analyse van single nucleotide polymorphisms, SNPs) waarna een associatie werd 
gelegd met de corresponderende eiwit-aanmaak en met IBD susceptibiliteit 
(gevoeligheid), alsmede de uiterlijke verschijningsvorm (fenotype) van de ziekte 
van Crohn (CD). Tenslotte werd in een multivariabele statistische analyse, 
temidden van een aantal geselecteerde klinische parameters, de SNP compositie 
en de expressie van MMP- en TIMP-eiwitten gerelateerd aan de snelheid van het 
optreden van een diagnostisch- en chirurgisch-recidief in patiënten met de ziekte 
van Crohn.  
 
Matrix metalloproteïnasen in IBD 
In hoofdstuk 1 wordt een algemene beschouwing gegeven over IBD en MMPs. 
Binnen IBD worden twee vormen onderscheiden, te weten colitis ulcerosa 
(ulcerative colitis, UC) en de ziekte van Crohn (Crohn’s disease, CD). In patiënten 
met CD worden zieke stukjes darm afgewisseld met gezonde stukken en de 
ontsteking kan zich dwars door de hele darmwand manifesteren (transmuraal). In 
principe kan elk deel van het maag-darmkanaal worden aangetast (“van mond tot 
kont”), in de praktijk blijkt met name de overgang van de dunne in de dikke darm 
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(ileocaecaal gebied) extra gevoelig. Bij patiënten met UC is alleen de dikke darm 
(het colon) aangetast, het ziekteproces is hier meer continu en beperkt zich tot het 
slijmvlies zonder diepere lagen van de darm aan te tasten. Na de Tweede 
Wereldoorlog is het jaarlijkse aantal nieuw gediagnosticeerde patiënten (incidentie) 
toegenomen en bedraagt nu ongeveer 4-9 per 100.000 inwoners in het geval van 
CD en 9-14 voor UC. Daardoor is ook het aantal mensen dat op enig moment één 
van beide ziektes heeft (ofwel: de prevalentie) toegenomen tot 130-175 voor CD 
en 240-275 voor UC per 100.000 inwoners. Een willekeurige IBD patiënt doet 
meestal een groot beroep op de medische zorg in termen van medicijngebruik, 
ziekenhuisopname en operaties (25-60% moet geopereerd worden binnen 10 jaar 
na diagnose). Er is dan ook veel geïnvesteerd om de oorzaken te achterhalen van 
IBD en ook om betere behandelmethoden te vinden. De huidige hypothese luidt 
dat IBD wordt veroorzaakt door een verminderde epitheliale-functie in combinatie 
met een verminderde niet-specifieke immuunfunctie. Dit resulteert in te hoge 
concentraties bacteriën in de darmwand, waardoor ons adaptieve -specifieke- 
immuunsysteem in de darm continu wordt gestimuleerd, met alle gevolgen van 
dien. Het ziekteproces kan hierbij nog verergerd worden omdat is aangetoond dat 
bepaalde immuuncellen in patiënten met IBD, bijvoorbeeld lymfocyten en 
neutrofielen, veel minder gevoelig zijn geworden voor geprogrammeerde celdood 
(apoptose) en aldus langer hun vernietigende werk kunnen blijven doen. De 
geactiveerde immuuncellen scheiden zeer veel cytokines en chemokines af, die 
andere cellen zoals epitheel en fibroblasten eveneens activeren en ervoor zorgen 
dat nieuwe immuuncellen vanuit het bloed in de darmwand terecht komen. De 
bacteriën worden bestreden met reactieve zuurstofradicalen, perforine en 
granzymes (bepaalde celdodende eiwitten), antilichamen, complement en 
proteasen, zoals de serine-proteasen en MMPs. Deze stoffen zijn echter in grote 
hoeveelheden niet alleen schadelijk voor bacteriën, maar zijn dat ook voor het 
eigen darmweefsel. Hierdoor wordt de darmwand nog verder verzwakt, komen nog 
meer bacteriën binnen waardoor een spiraal naar beneden ontstaat die vaak alleen 
nog maar kan worden onderbroken door het chirurgisch verwijderen van het zieke 
stuk darmweefsel.  
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Matrix Metalloproteïnasen (MMPs) knippen andere eiwitten kapot (protease 
functie) en doen dat het best bij een pH van rond de 7. In mensen zijn tot nu 23 
verschillende MMPs gevonden, welke worden onderverdeeld in zogenaamde 
collagenasen, gelatinasen, matrilysinen, stromelysinen, membraan-gebonden 
MMPs en een overige groep. In elk gezond persoon spelen MMPs een belangrijke 
rol in processen waarbij weefsel moet worden vervangen en/of opnieuw 
gemodelleerd, zoals bij de groei van een foetus, de continue vervanging van de 
darmwand en opperhuid, wondheling, etc. Tevens spelen ze een belangrijke rol in 
ziektes, zoals bij diverse vormen van kanker, waar ze de infiltratie en uitzaaiing van 
tumorcellen kunnen versterken of juist tegengaan. Elk MMP heeft zijn eigen 
voorkeur voor welke eiwitten hij het beste knipt (substraatspecificiteit). Gezamenlijk 
zijn de MMPs in staat een groot aantal eiwitten te knippen, zoals collageen I-XI, 
proteoglycanen, elastine, laminine, vitronectine, tenascine, entactine and 
fibronectine. Naast bovengenoemde structuur-eiwitten kunnen bijvoorbeeld ook 
cytokines als Interleukine 8 (IL-8) en Transforming Growth Factor-beta (TGF-β) 
geknipt worden. De door de MMPs bewerkstelligde knip in een eiwit is vaak een 
eerste stap in de afbraak hiervan, maar kan juist ook een eiwit activeren, 
bijvoorbeeld in het geval van IL-8. Gezien hun potentieel gevaarlijke rol wordt de 
aanmaak van MMPs in diverse cellen op verschillende niveaus strikt gereguleerd. 
Cytokines, chemokines, groeifactoren en oxidatie-status kunnen de aanmaak van 
MMPs omhoog of juist naar beneden schroeven, vaak in interactie met elkaar en 
ook nog eens afhankelijk van celtype. Methylering en acetylering van DNA en van 
DNA-bindende histon-eiwitten spelen ook een belangrijke rol, evenals de 
genetische compositie op SNP loci in het DNA gebied met de on/off switch voor 
MMP-productie (promoter gebied). Verder is het MMP messenger-RNA (mRNA) 
vertaalproces streng gereguleerd evenals de uitscheiding (excretie) van MMPs 
door cellen. De meeste MMPs worden bovendien geproduceerd in een inactieve 
vorm en moeten geactiveerd worden door andere proteasen als plasmine, 
thrombine, trypsine of bijvoorbeeld andere MMPs, uiteraard weer op een 
gecoördineerde en gecontroleerde manier. Geactiveerde MMPs zijn nooit lang 
actief, ze binden namelijk al snel aan een lid van de TIMP groep en worden 
hierdoor geremd. Op dit moment zijn in mensen vier verschillende TIMPs 
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gevonden. De aanmaak van deze eiwitten en de controle hierop lijkt wel wat op dat 
van de MMPs, al zijn er individuele verschillen. Naast MMP remming zijn TIMPs 
ook betrokken bij processen als celgroei, -proliferatie en -dood. Andere, meer 
algemene niet-MMP-specifieke proteasen  kunnen ook binden aan MMPs en deze 
remmen. Het lipoproteïne gerelateerde-receptor proteïne (LRP) verwijdert tenslotte 
MMPs uit de circulatie waarna deze intracellulair worden afgebroken in 
zogenaamde lysosomale blaasjes. Voorgaande studies hebben een grote toename 
laten zien in de aanmaak van één of meer MMP-leden in de darmwand van IBD 
patiënten. In muizen- en ratten-IBD-modellen blijkt tevens dat de ontstekingsscore 
naar beneden kan worden gebracht door de toediening van synthetische MMP-
remmers, hetgeen een grote rol voor MMPs in het ziekteproces van IBD 
suggereert. 
 
Aanmaak en regulering van matrix metalloproteïnasen in IBD 
In de eerste studie (hoofdstuk 2) van dit proefschrift is gekeken naar de expressie 
van gelatinase-type MMP-2 en MMP-9 in IBD weefsel. Van 16 patiënten met CD, 
14 met UC en 16 normale controles werd operatief verkregen darmmucosa 
gehomogeniseerd en met behulp van de ELISA techniek geanalyseerd op het 
voorkomen van beide gelatinasen. Zowel MMP-2 als MMP-9 eiwit zijn, afhankelijk 
van de ontstekingsgraad, verhoogd aanwezig in IBD weefsel, en met behulp van 
de RT-PCR techniek kon dit patroon ook op mRNA nivo worden aangetoond. 
Zymografie analyse liet zien dat de actieve- en pro-enzymvormen van beide MMPs 
verhoogd aanwezig zijn, maar in een bio-activiteitsassay was alleen MMP-9 
significant verhoogd. Met behulp van immunohistochemie kon worden aangetoond 
dat MMP-2 voornamelijk in het bindweefsel tussen mucosa en darmspier 
(submucosa) wordt aangemaakt, terwijl de bron van MMP-9 productie de 
polymorfonucleaire leukocyten (PMNL) lijken te zijn. Deze resultaten zijn in 
overeenstemming met eerder gepubliceerde studies en duiden op een rol van 
MMP-2 en MMP-9 in, respectievelijk, het stromale- en inflammatoire-proces. 
In een vervolgstudie werd onderzocht of er een TNF-α-afhankelijkheid in de 
regulatie van MMP-1, -2, -3 en -9 en TIMP-1 en -2 bestaat (hoofdstuk 3). Direct 
na operatie werd restant darmmucosa van volwassen IBD- en controle-patiënten 
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opgeknipt en in kleine stukjes gedurende drie dagen gekweekt onder 
gecontroleerde omstandigheden. De 3-daags cumulatieve productie van alle 
onderzochte MMPs in het kweek medium, bepaald door middel van ELISA en/of 
BIA, was significant groter in IBD-vergeleken met controleweefsel. Het toevoegen 
van het TNF-α-neutraliserende antilichaam infliximab resulteerde in een afname 
van MMP-1 en -3 totale- en netto activiteit, terwijl ook de expressie van MMP-9 
relatief ten opzichte van TIMP een afname liet zien. Toevoeging van Pokeweed 
Mitogen (PWM), een B/T lymfocyt activator, induceerde de expressie van de 
genoemde MMPs, welke voor een deel werd tegengegaan door gelijktijdige 
aanwezigheid van infliximab. Het lijkt er dus op dat in geval van MMP-1, -3 en -9 
de productie gedeeltelijk wordt bepaald door TNF-α, zowel in IBD- als 
controleweefsel. Echter, toevoeging van PWM reduceerde de MMP-2 productie 
met 50%, terwijl infliximab geen enkel effect had, hetgeen erop wijst dat in geval 
van dit gelatinase andere regulatie-mechanismen een grotere rol spelen. De 
regulatie door TNF-α van MMP-1, -3 en -9 lijkt bovendien afhankelijk te zijn van de 
genetische compositie op SNP plekken. De effecten van infliximab en PWM op 
MMP-9 productie waren bijvoorbeeld veel groter in patiënten met het CC 
vergeleken met het CT of TT genotype op SNP MMP-9 –1562 C/T. Deze resultaten 
wijzen op een beschermende rol van MMP-2 en een beschadigende rol van  
MMP-1, -3 en -9 in weefselmodellering, welke balans verstoord is in CD en UC en 
hersteld zou kunnen worden door infliximab. 
Vervolgens  hebben wij in de patiënt zelf (in vivo) gekeken naar het aandeel van 
TNF-α in de regulatie van gelatinase-type MMP-2 en MMP-9, zoals beschreven in 
hoofdstuk 4. De serumwaardes van deze eiwitten werden gemeten in twee CD 
patiëntengroepen. De ene groep werd behandeld voor fistels (buisvormige zweren 
tussen darmen onderling of tussen darm en huid) en de andere groep werd 
behandeld voor ontstekingen in de darm (n =38 en 31, respectievelijk). De 
patiënten met fistels kregen infliximab toegediend op t = 0, 2 en 6 weken. 
Gedurende deze periode nam het serum MMP-2 geleidelijk toe, om daarna weer te 
dalen. In tegenstelling tot MMP-2 nam het serum MMP-9 juist af gedurende de 
eerste 6 weken, om daarna weer toe te nemen. In de patiëntengroep met actieve 
ziekte werden dezelfde effecten geregistreerd, vooral bij hogere infliximab doses. 
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In deze groep bleek ook de intensiteit van immunohistochemische aankleuring van 
MMP-9 positieve PMNLs te verminderen na infliximab infusie. In aparte 
bloedkweek-experimenten bleek de hoeveelheid van MMP-2 in CD lager te liggen 
vergeleken met dat van controles. Deze spiegels konden niet worden beïnvloed 
door toevoeging van het immuno-activerende lipopolysaccharide (LPS) of 
infliximab, waarschijnlijk vanwege het ontbreken van MMP-2 mRNA in de 
bloedleukocyten. De productie van MMP-9 lag echter hoger in het bloed van CD-
patiënten versus dat van controles, kon worden gestimuleerd met LPS en, althans 
op het mRNA nivo, weer naar beneden worden gebracht met infliximab.  
 
Associatie van MMPs en TIMPs met IBD susceptibiliteit en 
fenotype 
Gezien de veranderingen die waren gevonden in de expressie en regulatie van de 
MMPs en TIMPs in IBD was het van belang te onderzoeken of deze werden 
gestuurd door het fenotype van de ziekte en de genetische opmaak van de IBD-
patiënten. Daarom werd eerst een studie uitgevoerd als beschreven in hoofdstuk 
5, waarin de totale hoeveelheid eiwit en activiteit van MMP-1, -2, -3 en, -9 alsmede 
TIMP-1 en -2 is gemeten in darmmucosa van 122 CD, 20 UC en 62 controle 
patiënten in relatie tot ziekte actviteit en bij CD-patiënten in relatie tot het fenotype. 
Alle MMPs bleken verhoogd aanwezig te zijn in ontstoken IBD-weefsel, 
aangetoond met ELISA en/of BIA met voorafgaande p-amino-phenyl-mercuric-
acetate (APMA) activering. De MMPs waren ook verhoogd relatief vergeleken met 
TIMPs, wat gepaard ging met een verhoging van de netto MMP-activiteit 
(aangetoond door middel van BIA zonder voorafgaande APMA behandeling). Zo 
was bijvoorbeeld de totale MMP-3 hoeveelheid 18,6 Units (U)/mg en de netto 
MMP-3 activiteit 5,7 U/mg in ontstoken IBD-weefsel, terwijl in controle-weefsel 
MMP-3 niet eens gemeten kon worden (0,0 U/mg, P<0,001). In ontstoken CD-
weefsel was de mate van bindweefselvorming (fibrosering) niet van belang voor de 
expressie van MMPs en TIMPs. Evenmin was de aanmaak van deze eiwitten niet 
geassocieerd met het wel of niet optreden van fistels gedurende de follow-up. 
Tenslotte bleek de expressie van alle MMPs en TIMPs slechts gedeeltelijk naar 
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beneden gebracht te kunnen worden door middel van behandeling van de patiënt 
met immunosuppresieve medicatie als corticosteroïden of azathioprine. Vervolgens 
hebben we gekeken of wellicht genetische variabiliteit in MMP, TIMP of TNF-α een 
invloed zou kunnen hebben op eiwit-expressie en op IBD susceptibiliteit en CD 
fenotype (hoofdstuk 6). Genomisch DNA werd gewonnen uit het bloed en/of 
operatie weefsel van 134 CD en 111 UC patiënten versus 248 controles, waarna 
het werd geanalyseerd met behulp van de restriction fragment length 
polymorphism (RFLP)-techniek en met tetra primer amplification refractory 
mutational system (ARMS)-PCR. Het T-(mannen) en TT-(vrouwen)genotype op 
SNP TIMP-1 +372 T/C bleek vaker voor te komen in CD patiënten vergeleken met 
controles. De TIMP-1 eiwit expressie was lager in het ontstoken weefsel van 
mannelijke IBD patiënten met het TIMP-1 T allel vergeleken met patiënten die 
drager zijn van het C allel, maar dit kon voor CD patiënten niet worden aangetoond 
en evenmin voor vrouwen. Het TIMP-1 C allel lijkt geassocieerd met de (latere) 
ontwikkeling van fistels in vrouwelijke CD patiënten. Het 5T5T genotype van SNP 
MMP-3 –1613 5T/6T is geassocieerd met een lagere kans op aanwezigheid van 
het CD ziekteproces in het colon tijdens de eerste diagnose, maar ook met een 
verhoogde kans op de ontwikkeling van stricturen gedurende follow-up. De 
genetische variabiliteit op geselecteerde SNP loci van MMP-1, -2, -9, TIMP-2 en 
TNF-α  was niet geassocieerd met CD of UC susceptibiliteit of fenotype, hetgeen 
een primaire rol voor deze eiwitten verderop in het IBD ziekteproces in plaats van 
aan het begin ervan veronderstelt. De controle-groep bestond voor een deel uit 
colorectale carcinoompatiënten, waarvan uit het operatiepreparaat wat normaal 
darmmucosa op ongeveer 10 cm van het kankergezwel was genomen. Aangezien 
dit van invloed had kunnen zijn op de genetische resultaten werden alle analyses 
herhaald met alleen de gezonde vrijwilligers in de controle-groep, wat dezelfde 
uitkomsten gaf. In de afsluitende studie (hoofdstuk 7) zijn de resultaten van de 
genetische variabiliteit op bovengenoemde MMP, TIMP en TNF-SNPs alsmede 
eiwitniveaus gekoppeld aan de klinische prognose van CD. Patiënten met het  
T-allel op SNP TIMP-1 +372 T/C bleken na operatie sneller (10,7 jaren) wederom 
onder het mes te moeten vergeleken met patiënten zonder deze SNP variant (19,1 
jaren). Het effect verloor maar net zijn significantie in een multivariate analyse 
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gebruik makend van geselecteerde klinisch-pathologische kenmerken als geslacht, 
leeftijd bij operatie, etc. Verder bleek een lage TIMP-1 expressie (<2,88 ng/mg) in 
niet-ontstoken CD-weefsel geassocieerd met een verhoogde kans op operatieve 
resectie. Dit werd tevens gevonden voor TIMP-2, en merkwaardig genoeg, ook 
voor MMP-9. Het MMP of TIMP nivo in ontstoken weefsel was in dit opzicht niet 
van belang. In onze analyses bleek het roken van sigaretten een belangrijke 
prognostische variabele voor een diagnostisch- en chirurgisch- recidief. Onze MMP 
en TIMP resultaten hebben echter waarschijnlijk niets te maken met het roken, 
omdat geen enkele relatie tussen MMPs, TIMPs en rookgedrag kon worden 
aangetoond, ook niet in de multivariate analyses. Een belangrijke conclusie die 
getrokken kan worden uit hoofdstukken 6 en 7 is dat het TIMP-1 SNP +372 T allel 
mogelijk de expressie van TIMP-1 negatief beïnvloedt, waardoor de balans tussen 
MMP en TIMP verschuift naar een meer proteolytisch fenotype wat de 
susceptibiliteit voor CD verhoogt en tevens leidt tot een slechtere prognose van 
CD. 
 
MMPs  en TIMPs in IBD: een verstoord evenwicht? 
De huidige hypothese luidt dat IBD veroorzaakt wordt door een overdreven 
immuunreactie tegen commensale bacteriën in genetisch vatbare personen. In dit 
proefschrift is aangetoond dat een verstoord evenwicht tussen MMPs en TIMPs 
betrokken is in de pathogenese van IBD, zie figuur 1, volgende bladzijde. De 
chronische zweren, fistels, insnoeringen (fissuren) en fibrosering, zoals die kunnen 
voorkomen in de darm van IBD patiënten, kunnen het gevolg zijn van een 
verminderde mucosale barrière. De zogenaamde basaalmembraan onder epitheel- 
en endotheelcellen verleent steun, flexibele mechanische weerstand en scheidt 
weefselcompartimenten. Het bestaat uit meerdere lagen collageen IV en laminine, 
met elkaar verbonden door nidogeen en heparansulfaat-proteoglycaan perlecan, 
maar bevat ook andere eiwitten als collageen VII fibrillen, fibuline, fibronectine, 
osteonectine, enz. Basaalmembraan-eiwitten zouden heel goed betrokken kunnen 
zijn bij IBD susceptibiliteit en in lijn hiermee is recent een genetische associatie van 
extracellulaire matrixproteïne-1 (een biologische “lijm”) met UC maar niet met CD 
gevonden. 
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Onvoldoende mucosale barrière +         ◄              ◄ 
Onvoldoende wondheling + 
Onvoldoende aangeboren immuun respons 
▼ 
Blootstelling aan commensale bacteriën                  ▲ 
▼ 
Overdreven adaptieve immuun respons 
▼ 
Synthese van overmaat inflammatoire stoffen, 
TNF-α, IL-1, IL-12, IL-23 etc.  ►  ►         ▲ 
▼ 
Invasie van nieuwe leukocyten 
Inductie van zuurstofradicalen, perforine, etc., 
Inductie van MMPs relatief tov TIMPs (hoofdstuk 2 en 5).  
Weefsel afbraak, afhankelijk van genetische compositie op       ▲   
  TIMP-1 SNP +372 T/C (hoofdstuk 6 en 7)  ►       ► 
▼ 
Toediening van anti-TNF-α infliximab®    
▼ 
Verminderde aanmaak van schadelijke MMPs (bv. MMP-9),  
Verhoogde expressie of stabilisering van “goede” MMPs (bv. 
epitheliale barrière stimulerende MMP-2) (hoofdstuk 3 en 4) 
      ▼ 
Verbeterde mucosale wondheling 
      ▼ 
    Verbeterde klinische prognose 
 
Figuur 1. Schematische presentatie van MMPs en TIMPs in de pathogenese van 
IBD. Toediening van het anti TNF-α antilichaam infliximab® herstelt de cruciale 
MMP versus TIMP balans, stimuleert herstel van de darm barrière functie en 
verbetert de klinische prognose van IBD patiënten. 
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De chronische wonden in IBD patiënten zouden ook het gevolg kunnen zijn van 
niet-adequate wondheling. Verwonding resulteert in eerste instantie in de snelle 
vorming van het welbekende bloedkorstje, waarna het langzamere weefselherstel 
kan beginnen. Als eerste stap hiertoe bindt de urokinase-type plasminogen 
activator-receptor (uPAR) het uPA, welke vervolgens plasminogeen knipt tot actief 
plasmine. Dit laatste eiwit knipt niet alleen het fibrine (wat het tijdelijk bloed korstje 
vormt) maar activeert, in nauwe samenwerking met andere proteïnasen als 
membraan-gebonden MMPs en chymotrypsine, ook verschillende leden van de 
MMP familie waardoor beschadigd collageen matrix afgebroken kan worden tot 
een gelatine “soep”. Dit proces verloopt normaal gesproken onder strenge controle: 
de MMP activiteit wordt gereguleerd door TIMPs, auto- en substraat geïnduceerde-
activering, inactivering en degradatie. De collageen fragmenten worden uit de 
extracellulaire matrix verwijderd door uPAR-geassocieerde-proteïne (uPARAP) 
gemedieerde endocytose en worden vervolgens vernietigd in lysosomale blaasjes. 
Tegelijkertijd maken epitheliale cellen en fibroblasten nieuw collageen en andere 
matrixcomponenten, wat uiteindelijk mede het nieuwe weefsel vormt en het 
bloedkorstje vervangt. De MMPs spelen niet alleen een belangrijke en direkte rol in 
weefsel-hermodellering, maar zijn ook van belang in het faciliteren van epitheliale 
proliferatie, differentiatie, apoptose en daarmee in het proces van epitheliale 
wondsluiting. Hierbij kunnen diverse MMPs een verschillende rol spelen. Zo 
stimuleert MMP-2 epiheliale cellen en helpt ze overleven, terwijl voor MMP-9 juist 
een tegenovergestelde rol is weggelegd. Verder is het zo dat door het 
hermodelleren van weefsel de in matrix opgeslagen cytokines vrijkomen, die na 
activering door MMPs nieuwe leukocyten naar de wondplek lokken. Verschillende 
studies hebben aangetoond dat chronische niet-helende wonden een overmaat 
aan MMPs hebben. Kunstmatige overexpressie van MMP-1 in transgene muizen 
was geassocieerd met een vertraagde wondheling. Applicatie van een 
hydroactieve dressing met superabsorberende polyacrylaat-deeltjes verwijderde 
MMPs uit de wond en was geassocieerd met een verbeterde genezing. Wellicht de 
beste illustratie van wat er kan gebeuren in geval van een overmaat aan MMPs 
wordt gegeven door de snake venom (slangengif) metalloproteïnasen. Deze 
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eiwitten, aanwezig in slangengif, knippen endotheelcellen van mekaar en lossen 
de basaalmembraan op, met ernstige bloeduitstortingen tot gevolg.  
 
Fibrose, vaak gezien in CD, zou het gevolg kunnen zijn van te weinig MMP in 
verhouding tot TIMP, in combinatie met een verhoogde collageenproductie. Een 
alternatieve verklaring zou kunnen zijn dat hoge niveaus van MMPs de migratie 
van fibroblasten zouden kunnen faciliteren en op die manier fibrose juist zouden 
kunnen stimuleren. Recent heeft een groep auteurs aangetoond dat MMP-3 
epitheliale cellen in cellen met mesenchymale eigenschappen kan transformeren, 
waardoor hun collageenproductie werd verhoogd en het fibrotische fenotype werd 
gestimuleerd. De rol van TIMPs kent eveneens vele gezichten. Het remmen van 
MMPs is belangrijk voor het fine tunen van de weefselmodellering. Aan de andere 
kant is TIMP-2 noodzakelijk voor de activatie van MMP-2 en van verscheidene 
TIMPs is aangetoond dat ze een rol spelen bij celdifferentiatie, proliferatie en 
apoptose. Het moge duidelijk zijn dat wondheling een subtiel proces is, waarbij een 
gecoördineerde aanmaak van MMPs, TIMPs en collageen een belangrijk vereiste 
is: zowel te weinig als teveel MMPs op verschillende tijdstippen kan resulteren in 
chronische zweren. Andere MMPs, zoals MMP-7 (matrilysine), MMP-8 (neutrofiel 
collagenase) en MMP-12 (macrofaag metallo-elastase) spelen mogelijk ook een 
belangrijke rol, evenals aan MMP-gerelateerde eiwitten als ADAMs (A Disintegrin 
And Metalloproteïnase) en ADAMTSs (A Disintegrin-like And Metalloproteïnase 
with Thrombospondin type 1 motifS).  
Onze resultaten wijzen op een overmaat aan MMP productie ten opzichte van 
TIMPs, resulterend in een verhoogde netto-activiteit en beschadiging van het 
darmweefsel, wat kan worden tegen gegaan door toediening van infliximab in 
zowel CD als UC patiënten. De goede klinische respons die patiënten geven na 
infliximab behandeling kan het gevolg zijn van een verminderde aanmaak van 
MMP-1, -3 en -9. Van hieruit bezien zou behandeling van UC patiënten met 
infliximab ook een goede optie zijn, en de resultaten van verschillende pilot-studies 
wijzen hier ook op. Het is verleidelijk om synthetische MMP-remmers aan IBD 
patiënten te geven, maar gezien de veelzijdigheid van deze eiwitten is 
voorzichtigheid op zijn plaats. Selectieve MMP-remming zou kunnen resulteren in 
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functionele substitutie door andere MMPs of ADAM(TS)s, gezien hun 
overlappende substraatspecificiteit. Niet-specifieke remming zou daarentegen 
kunnen leiden tot ernstige bijwerkingen door remming van MMPs en ADAM(TS)s 
welke juist bevorderlijk zijn voor het genezingsproces, zoals MMP-2. Onze 
resultaten voor wat betreft de genetische compositie op het TIMP-1 SNP +372 T/C 
suggereren een T allel veroorzaakte daling van TIMP-1 eiwitproductie, zodat 
MMPs meer vrij spel krijgen, waardoor de susceptibiliteit voor CD wordt verhoogd 
en de prognose negatief wordt beïnvloed. Remming van de overmaat MMPs met 
recombinant TIMP is daarom wellicht een interessant alternatief. Echter, omdat de 
MMP/TIMP ratios niet gerelateerd zijn aan de klinische prognose, is het niet 
duidelijk waar het positieve effect van het C allel vandaan komt, dit zal dus eerst 
bestudeerd moeten worden.  
Samenvattend: het in dit proefschrift beschreven onderzoek geeft nieuwe inzichten 
in de rol van MMPs en TIMPs in de etiopathogenese van IBD. Toekomstige studies 
moeten onderzoek omvatten naar de expressie van andere MMPs, ADAM(TS)s en 
TIMPs in darmweefsel, alsmede de genetische compositie op corresponderende 
relevante SNPs. Daarnaast moet er een focus gelegd worden op de identificatie 
van MMP degradatie-fragmenten, de fysiologische activeringscascade, remmers 
en substraatspecificiteit om een gedetailleerd mechanistisch inzicht te verkrijgen in 
metalloproteïnase-activiteit in IBD. Uiteindelijk kunnen deze studies resulteren in 
het ontwikkelen van nieuwe medicijnen voor CD en UC, en wellicht andere 
immunopathologiën, gebaseerd op de remming dan wel activering van één of meer 
leden van de veelzijdige matrix metalloproteïnasen familie. 
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Nawoord 
Dit proefschrift is tot stand gekomen met de hulp van velen. Ik wil op deze plaats 
als eerste de wetenschappelijk medewerkers van het laboratorium Maag-, Darm- 
en Leverziekten (Hein, Izäk, Qiang, Wim, Marij, Annie, Jan-Paul (†), Kees, Marlies, 
Johan en Eveline) bedanken voor hun steun en inzet. Daarnaast ben ik de afdeling 
Pathologie zeer erkentelijk voor het beschikbaar stellen van resectieweefsel, TNO 
(Roeland en Jan) voor het faciliteren van de MMP ELISAs en BIAs, het personeel 
van het medisch archief voor hun assistentie bij het doorzoeken van de talrijke 
medische dossiers en de artsen in opleiding (Tomas, Eduard) voor de stimulerende 
discussies. Tenslotte gaat mijn dank uit naar mijn familie (pap, mam en Helma), 
schoonfamilie en vrienden voor hun morele en motiverende steun gedurende het 
hele traject en natuurlijk naar mijn partner Pascale niet alleen voor haar rol als 
steun en toeverlaat maar ook voor het vele redactionele werk en het ontwerp van 
de kaft. 
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Curriculum vitae 
De auteur van dit proefschrift werd op 29 september 1974 geboren in Amsterdam. 
In 1993 werd het VWO diploma behaald aan het Augustinus College in Groningen 
waarna aansluitend werd gestart met de opleiding biologie aan de Landbouw 
Universiteit Wageningen. Gedurende het afstudeervak onder begeleiding van  
ing. A.H. Westphal en Dr. A. de Kok werd onderzoek gedaan aan het  
Neisseria meningitides lipoamidedehydrogenase, onderdeel van het 
pyruvaatdehydrogenase-complex van deze bacterie. Tijdens de afsluitende stage 
in het St Radboud Ziekenhuis te Nijmegen onder begeleiding van Dr. M.R. Bernsen 
en Dr. G.N. van Muijen is onderzoek verricht ten behoeve van de moleculaire 
karakterisatie van melanoom infiltrerende T-lymfocyten. Na het behalen van het 
doctoraal diploma in 1998 met afstudeerrichting celbiologie werd in 1999 op de 
afdeling Maag-, Darm- en Leverziekten van het Leids Universitair Medisch 
Centrum aangevangen met het door de Maag Lever Darm Stichting 
gesubsidieerde promotie-onderzoek naar de rol van matrix metalloproteinases bij 
chronisch inflammatoir darmlijden onder begeleiding van Dr. ir. H.W. Verspaget en 
Prof. dr. C.B.H.W. Lamers, hetgeen heeft geresulteerd in een aantal publicaties en 
de totstandkoming van dit proefschrift. Tegenwoordig is de auteur als junior 
medewerker in dienst bij Domenica en verricht pensioen-specialistische 
werkzaamheden voor diverse verzekeraars. 
 

 
  
 
 
